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ABSTRACT
B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia
in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However,
approximately 50% of these patients will progress to advanced, symptomatic disease and require
therapy. Current treatment options are limited due to progressive drug resistance and severe
drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities.
Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic
CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in
patients who require therapy would be clinically beneficial.
In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options
for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell
culture model. The primary objective of the initial study was to determine whether consumption
of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients
diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate
whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the
chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemiaderived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro.
Our initial study indicated that consumption of an EPA + DHA containing n-3
supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early
stage CLL, 2) increased molar concentrations of n-3 in the plasma, 3) increased the chemosensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of
32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL.
Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic
xviii

disease where therapy is required. However, a definitive clinical trial will be needed to determine
if n-3 can slow the progression of CLL.
The aim of the second study was to expanding upon the chemo-sensitization capabilities
of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a
measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen
species (ROS) generation) were performed to explore potential mechanism(s) through which
enhanced chemo-sensitivity was achieved.
Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines
EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and
with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner;
3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in
MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased
generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS
generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA.
N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity
to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant
cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of
the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to
increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities.
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CHAPTER 1: INTRODUCTION
CHRONIC LYMPHOCYTIC LEUKEMIA
EPIDEMIOLOGY, CHARACTERIZATION
B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia
in the western world (Gaidano, Foa, & Dalla-Favera, 2012) and accounts for 30% of all mature
B-cell malignancies (Linet et al., 2007). CLL involves progression toward malignant disease
with most cases of CLL being preceded by monoclonal B-cell lymphocytosis (MBL), an indolent
B-cell expansion defined by less than 5 x 103 MBL/µL in the peripheral blood (Gaidano et al.,
2012). The incidence of CLL in the United States is approximately 100,000 individuals with an
estimated 15,000 new diagnoses per year (Shanafelt & Call, 2004). CLL is typically diagnosed in
the asymptomatic stages incidentally during a complete blood cell count (CBC) for unrelated
indications (Shanafelt & Call, 2004). However, approximately 50% of these patients experience
rapid progressive disease, require therapy and have a significantly shortened lifespan (Shanafelt
& Call, 2004). It is approximated that 4,500 individuals will die of CLL or CLL-related
complications in the United States per year (Lanasa, 2010; Shanafelt & Call, 2004). The life
expectancy of an individual with CLL is highly variable with a medium survival from diagnosis
varying between 18 months to >10 years (Eichhorst, Dreyling, Robak, Montserrat, & Hallek,
2011; Gaidano et al., 2012; Shanafelt & Call, 2004), a trait largely attributed to the marked
clinical heterogeneity of the disease.
CLL is considered to be a disease of the elderly with a median age range of 60-68 years
(Shanafelt & Call, 2004). According to the NCI SEER (Surveillance Epidemiology and End
Results) study, which enrolled 20,000 CLL and small lymphocytic lymphoma (SLL) patients in
1

the United States from 1987 to 2004, the incidence of CLL increased with age and showed a 7090% higher propensity in males than females when adjusting for age (Linet et al., 2007).
Compared to Caucasians, the incidence in African-Americans and Asian/Pacific Islanders was
found to be 25-28% and 69-80% lower, respectively (Linet et al., 2007). While the exact origin
of CLL remains unknown, immunogenetic studies and gene expression profiling analyses have
provided insight into the putative CLL progenitor and suggest that the origin of CLL is derived
from antigen-experienced B cells (including both memory B cells and marginal zone Bcells)(Gaidano et al., 2012).
Historically, CLL is viewed as a tumor caused by the accumulation of long-lived but
mainly indolent lymphocytes (Gaidano et al., 2012). However, studies have shown that a small
fraction of CLL cells have proliferative capacity resulting in approximately 2% new CLLs being
produced per day (Messmer et al., 2005). While lymphocytes in the peripheral blood are in a
predominantly resting, non-proliferative state, specific structures known as proliferation centers
(bone marrow and lymph nodes) replenish the CLL population and aid to the accumulation of
CLL cells (Gaidano et al., 2012).
Although designated as a single entity, CLL is characterized by biological, clinical and
cytogenetic heterogeneity with a characteristic immunophenotype of IgM weak, CD5+, CD19+,
CD20weak, CD22weak, CD79a+, CD23+, CD43+, CD11cweak, CD10negative, and cyclin D1 negative
(Linet et al., 2007).

CLASSIFICATION AND STAGING
Chronic lymphocytic leukemia has been recognized as a distinct clinical entity for nearly
100 years (Linet et al., 2007). However, disease classification systems did not systematically
distinguish „chronic‟ from „acute‟ forms of leukemia until the late 1960s with the adoption of the
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International Classification of Disease (ICD) (Linet et al., 2007). The absence of standardized
disease definitions, staging schemes and markers of behavior hampered clinical trials and
epidemiological studies until the mid-1970s (Linet et al., 2007). It was during this time that
proposals for staging systems by Rai et al. and Binet et al. (1977) were accepted. Clinical trial
guidelines from the International Workshop of CLL, Binet et al. and Cheson et al. were
subsequently implemented in the 1980s and 1990s. The staging system and clinical trial
guidelines were instrumental to advances in the treatment and understanding of CLL biology
(Linet et al., 2007; Shanafelt & Call, 2004). The improved knowledge of normal B- and T-cell
differentiation and genetic changes led to the revised European and American Lymphoma
classification in the mid-1990s, followed by the World Health Organization (WHO)
classification of all hematopoietic and lymphoproliferative disorders and set the basis for modern
classification and staging of CLL (Linet et al., 2007).
Before the advent of automated instruments for performing blood cell counts, CLL was
typically diagnosed when patients exhibited symptoms such as lymphadenopathy, cytopenias,
frequent infections, and abnormal morphology of peripheral blood lymphocytes (Shanafelt &
Call, 2004). At this point in time, CLL was thought to be an indolent disease of the elderly
(Shanafelt & Call, 2004). Clinical management of CLL was predominately mediated by
“watchful waiting” and most clinicians often counseled patients that they would likely die of
causes unrelated to CLL before they would require therapy (Shanafelt & Call, 2004). The
infectious complications associated with CLL, increased risk of autoimmune disorders, and
increased risk of secondary malignancies were less defined and clinically underappreciated with
treatment being reserved for patients with advanced-stage disease (Shanafelt & Call, 2004).
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Nearly all of these paradigms have changed with the advent of automated instruments,
immunophenotyping, flow cytometry, and cytogenetic evaluations (Shanafelt & Call, 2004).
Currently, CLL should be considered anytime a patient presents an absolute lymphocyte
count (ALC) > 5 x 109/L without clear etiology over a duration of at least 3 months (Eichhorst et
al., 2011; Shanafelt & Call, 2004). Furthermore, according to the WHO classification, SLL and
CLL are considered the same entity. SLL requires the presence of lymphadenopathy and/or
splenomegaly, with the number of B-lymphocytes in the peripheral blood not exceeding 5 x
109/L and must be excluded during the diagnosis of CLL (Eichhorst et al., 2011). Similarly,
reactive causes of lymphocytosis and leukemic phase of other lymphoproliferative disorders,
particularly mantle cell lymphoma, must be excluded before diagnosis of CLL (Eichhorst et al.,
2011; Shanafelt & Call, 2004). Diagnostic criteria for CLL are described in Table 1.1.
Upon diagnosis of CLL, patients staging is determined according to the clinical “staging”
criteria outline by Rai et al.(Rai & Jain, 2011) which separates patients into different prognostic
“risk” groups based on the presence of lymphadenopathy, splenomegaly, hepatomegaly, and
cytopenias (Shanafelt & Call, 2004). The three stage system categorizes patients as having low
risk (original Rai stage 0), intermediate risk (Rai stage I-II), or high risk (Rai stage III-IV)
disease (Shanafelt & Call, 2004). Staging criteria are described in Table 1.2. Additional
cytogenetic and phenotypic tests are performed to assist with predicting diagnosis and guide
treatment (Shanafelt & Call, 2004) (outlined in next section).
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Table 1. 1. Diagnostic Criteria for CLL
Diagnostic Criteria
1. ALC, >5.0 x 109/L
2. Clonal B-cell proliferation

3. Rule out leukemic phase of other
lymphoproliferative disorders
(especially mantle cell lymphoma)

Typical Method of Testing
Automated blood counter
Exclusively or light chain use on flow
cytometry
Immunophenotype consistent with CLL:
CD5+, CD19+, CD20dim, dim surface
immunoglobulin
Mantle cell lymphoma:
Flow cytometry*: CD23dim or absent, CD5+, bright
CD20+
FISH**: t(11:14)
Cyclin D1 positive
Nodal marginal zone lymphoma:
Flow cytometry*: CD5-, bright CD20+
Hairy cell lymphoma:
Flow cytometry*: CD5-, bright CD11c/CD22+,
CD19+, bright CD20+, CD103+
TRAP positive
Lymphoplasmacytic lymphoma:
Flow cytometry*: CD5+/-, CD19+, CD20+
SPEP-associated monoclonal protein (>2.5g/dL)
Follicular lymphoma (leukemic phase):
Flow Cytometry*: CD5-, CD19+, CD20+,
CD10+/FISH**: t(14:18)
Material obtained from (Shanafelt & Call, 2004)

Table 1.1 Diagnostic Criteria for Chronic Lymphocytic Leukemia. Abbrev: ALC- absolute lymphocyte
count; CLL- chronic lymphocytic leukemia; FISH- fluorescence in situ hybridization; SPEP- serum protein
electrophoresis; TRAP- tartrate-resistance acid phosphatase; *Flow cytometric results must be correlated with
careful pathologic assessment of morphologic features; **FISH- translocation of indicated chromosome.
Material was obtained from (Shanafelt & Call, 2004).
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Table 1. 2. Rai Staging Criteria
Rai
Stage

ALC
>5.0 x 109/L

0
I
II
III
IV

+
+
+
+
+

Physical Examination
Enlarged
Enlarged
nodes
liver/spleen

+
+/+/+/-

Hemoglobin
<10.5 g/dL

Platelets
<100 x 109/L

Median
Survival
(months)
*
150
101
+
71
+/+
19
+/+/+
19
Material obtained from (Shanafelt & Call, 2004)

Table 1.2. Rai Staging Criteria. Abbrev: ALC- absolute lymphocyte count; +: present, -: absent; +/-: may be
present or absent; *: according to original series by Rai et al. Material was obtained from (Shanafelt & Call,
2004).

SYMPTOMS, RISK ASSESSMENT, PROGNOSTICS
Clinical manifestations associated with CLL often include fever, night sweats, weight
loss defined as >10% of body weight, fatigue, frequent infections, splenomegaly, hepatomegaly,
lymphadenopathy, autoimmune complications and cytopenias (Shanafelt & Call, 2004).
Given the heterogeneity of CLL, various prognostic indicators have been established to
aid in predicting prognosis and guiding treatment. The staging criteria outlined by Rai et al. (Rai
& Jain, 2011) provided a useful tool for grouping patients into low-, intermediate- or high-risk
groups and has been shown to correlate with prognosis of disease (Table 1.2). The lymphocyte
doubling time (LDT) also provided insight into the kinetics of CLL. The LDT is a clinical
measurement that addresses the kinetics of cell growth by calculating the number of months the
ALC takes to double. Since patients with advanced disease (Rai stages III and IV) typically
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require therapy, the prognostic utility of LDT is most important for patients with early stage
disease (Rai stages 0, I and II) (Shanafelt & Call, 2004). Studies have found that patients with
CLL exhibiting a LDT of less than 12 months had shortened survival time as compared to those
patients with a LDT greater than 12 months (Montserrat, Sanchez-Bisono, Vinolas, & Rozman,
1986). While historically clinical stage and LDT have been the most accurate and widely used
prognostic tools for counseling patients with CLL, both are imprecise. Clinical staging can
underappreciate the prognosis of patients due to marked heterogeneity in the clinical progression
of disease in patients at similar age (Shanafelt & Call, 2004). Similarly, the LDT can be
confounded by factors that cause fluctuations in the ALC (Shanafelt & Call, 2004). As such,
other diagnostic tools such as flow cytometry, gene expression profiling, chromosomal analysis
and fluorescence in situ hybridization (FISH) have been established to aid in risk assessment and
prognosis of CLL.
Extensive molecular investigations of the B-Cell Receptor (BCR) indicated that 60-65%
of CLL harbor somatic hypermutations in the immunoglobulin heavy variable chain (IgVH)
genes. In 1999, Damle et al. (Damle et al., 1999) and Hamblin et al. (Hamblin, Davis, Gardiner,
Oscier, & Stevenson, 1999) reported the prognostic significance of somatic mutations in the
IgVH genes in CLL. When patients with early stage CLL were stratified as IgVH-mutated or
IgVH-nonmutated, significant differences in survival times were observed (Damle et al., 1999;
Hamblin et al., 1999). Median survival time for early-stage patients with nonmutated IgVH
genes was less than 95 months (8 years) whereas early-stage patients with a mutated IgVH had a
median survival time greater than 293 months (24 years) (Damle et al., 1999; Hamblin et al.,
1999). Whereas tests for IgVH mutational status are not typically performed in the United States
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(Shanafelt & Call, 2004), its utilization as a prognostic marker is beneficial for patients with
CLL.
Phenotypic evaluations of CLL cells have indicated the presence of surface protein
marker CD38 in subsets of CLL. Numerous reports have substantiated the prognostic
significance of CD38 expression (Del Poeta et al., 2001; Lekovic et al., 2011; Shanafelt & Call,
2004). Del Poeta et al. reported an 8-year survival of 92% for patients who were CD38 negative
but only 50% for patients who were CD38 positive (Del Poeta et al., 2001). However, the
consistency of CD38 expression on CLL cells has been controversial because many groups
reported changes in the CD38 status in as many as 10-25% of patients with CLL (Shanafelt &
Call, 2004). Despite the controversy of CD38 expression, it appears to be correlated with poor
prognosis (Lekovic et al., 2011).
Gene expression profiles have also aided to the identification of prognostic markers for
CLL. Gene expression profile analyses (GEPA) have identified a restricted set of genes that
helped discriminate between mutated- and unmutated-IgVH clones in patients with CLL
(Shanafelt & Call, 2004). Of particular interest was the tyrosine kinase gene, zeta-associated
protein 70 (ZAP-70). Under normal conditions, ZAP-70 is involved with T-cell signaling;
however, it has been shown to be differentially expressed by patients with unmutated IgVH CLL
clones (Shanafelt & Call, 2004). Subsequent studies have shown that ZAP-70 positive CLL cells
correctly predict the mutational status (unmutated) in approximately 78-90% of patients (Crespo
et al., 2003; Wiestner et al., 2003). More importantly, ZAP-70 expression was also a prognostic
marker for time to treatment (TT) and overall survival (OS) (Crespo et al., 2003). Crespo et al.
reported that patients who had at least 20% ZAP-70-positive CLL cells had more rapid
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progression and poorer survival than those with less than 20% ZAP-70-positive CLL cells
(Crespo et al., 2003).
Similarly, GEPA have identified other markers thought to aid in prognosis including
notch homolog 1 (NOTCH1), splicing factor 3B subunit 1 (SF3B1) and baculoviral IAP repeatcontaining protein 3 (BIRC3) (Gaidano et al., 2012). Descriptions of these genes and their
influence on prognosis are provided in Table 1.3.

Table 1. 3. GEPA Identified Prognostic Markers for Chronic Lymphocytic
Leukemia
Gene

Description

NOTCH1 (Notch Homolog
1)

Encodes a ligand-activated
10%
Poor Prognosis
transcription factor that regulates
several downstream pathways involved
in cell growth. Mutations in NOTCH1
impair NOTCH1 degradation leading to
increased intensity and duration of
NOTCH1 activity.
Critical component of splicesome.
5-10%
Associated with
Thought to control cell cycle
shortened survival
progression and apoptosis.
time.
Negative regulator of MAP3K14.
4%
Poor Prognosis
Mutations in BIRC3 disrupts
proteosomal degradation of MAP3K14
and leads to constitutive activation of
non-cannonical NF B.
Material obtained from (Gaidano et al., 2012)

SF3B1 (Splicing Factor 3B
Subunit 1)
BIRC3 (Baculoviral IAP
Repeat-containing Protein 3)

Frequency

Prognostic
Indication

Chromosomal analysis and the development of FISH aided the detection of chromosomal
abnormalities and provided numerous prognostic markers for CLL (Shanafelt & Call, 2004).
Studies have demonstrated that over 80% of all CLL patients have chromosomal abnormalities
(Rodriguez-Vicente, Diaz, & Hernandez-Rivas, 2013). Descriptions of the most common
chromosomal abnormalities and their influence on prognosis are illustrated in Table 1.4.
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In summary, CLL, although designated as a single entity, is a highly variable disease. While
clinical staging remains the foundation for determining the prognosis of patients, it fails to
recognize a substantial subset of patients who are likely to experience rapid progression to
advanced stage disease. The use of LDT and identification of various prognostic markers
outlined above have aided the identification of patients with early-stage CLL who are at risk of
early progression. All of these tools are vital for guiding clinical treatment of CLL and
identifying at risk patients who may benefit from shorter follow-up intervals.

Table 1. 4. Prognosis by FISH Results for Patients with CLL
Chromosomal Abnormality

Description

Frequency

None
Del13q14

Contains the DLEU-1/2 genes
which encode for miR-15a and
miR-16a. MiR-15a/16a
regulates a variety of genes
including anti-apoptotic Bcl-2
gene, cyclins CCND1/3 and
CDK6.
Thought to alter dosage of one
or more proto-oncogenes.
Affects the ATM gene.
Deficiency in ATM causes
genomic instability.
Disrupts the TP53 tumor
suppressor gene.

50-60%

Median Survival
(years)
9.0
11.0

15%

9.0

unknown

6.6

5-10%

2.5

Trisomy 12 positive
Del11q22-23

Del17p13

Table 1.4. Prognosis by FISH Results for Patients with CLL. Del13q14: deletion of chromosomal region
13q14; Del11q22-23: deletion of chromosomal region 11q22-23; Del17p13: deletion of chromosomal region
17p13; DLEU-1/2: deleted in leukemia-1/2; miR: microRNA; Bcl-2: B-cell lymphoma 2; CCND1/3: cyclins;
CDK6: cyclin-dependent kinase 6; ATM: ataxia telangiectasia; TP53: tumor suppressor protein p53. Data
obtained from (Gaidano et al., 2012).

TREATMENT
Currently, no curative therapy exists for CLL with the exception of allogeneic
transplantation (Dreger, 2009). Historically, the goal of treatment was to alleviate symptoms and
prolong survival (Shanafelt & Call, 2004). Additionally, chemotherapy for all (non-selected)
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patients has been found to be ineffective for patients with early-stage disease. Treatment of
early-stage CLL has been associated with severe toxicity and no increase in survival (Shanafelt
& Call, 2004). As such, treatment for early-stage CLL is not recommended outside of clinical
trials (Shanafelt & Call, 2004). Watchful waiting with active support care measures remains the
standard of care for early-stage (asymptomatic) patients (Shanafelt & Call, 2004).
However, approximately 50% of patients with early-stage CLL will progress to
aggressive symptomatic disease and require therapy (Shanafelt & Call, 2004). Criteria for
treatment, according to the National Cancer Institute, are outlined in Table 1.5. Treatment
options are largely dependent on the performance status of the patient (ECOG-Eastern
Cooperative Oncology Group), prior treatment, duration of remission, co-morbidities, and
adverse effects associated with prior treatment (Shanafelt & Call, 2004). Current therapies for
CLL include alkylating agents, purine analogues, monoclonal antibodies, combinatorial
treatments, and allogeneic transplantation (Shanafelt & Call, 2004). Descriptions of the various
treatment options and their mechanism(s) of action are in Table 1.6.
Although numerous treatment options exist for the treatment of CLL, most of them are
undermined due to progressive drug resistance and the severe toxicities associated with
treatments which are often too toxic for the elderly and those with co-morbidities. Similarly,
certain prognostic indicators, such as del17p13, have been shown to contribute to
chemorefractoriness further limiting the application of certain drugs (Gaidano et al., 2012).
Given the age group of individuals diagnosed with CLL, a non-toxic therapeutic intervention that
could 1) have cytotoxic effects against malignant cells, 2) increase the sensitivity of CLL cells to
chemotherapy or 3) reduce anti-cancer drug-induced toxicities would be highly desirable and
clinically beneficial. Increased chemo-sensitivity would be expected to increase drug efficacy,
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and potentially reduce drug dosage resulting in reduced drug-induced toxicities. Similarly, a
reduction in drug-induced toxicities would allow for potential increases in the number of
chemotherapy cycles an individual can receive, thereby, increasing the likelihood of achieving a
response.

Table 1. 5. Clinical Treatment of CLL Criteria
Indication for Treatment
Exception
Worsening Anemia (hemoglobin, <10.5g/dL),
Rule out autoimmune hemolytic anemia,
Thrombocytopenia (platelets, <100 x 109/L) due pure red blood cell aplasia, or ITP as etiology
to marrow failure
of cytopenias
>50% increase in ALC in <2 months or
Exclude acute infection or transient reactive
anticipated doubling lymphocyte doubling time
etiology as cause of increase in ALC
of <6 months
Progressive or massive splenomegaly (>6 cm
Consider Richter transformation if rapid
below costal margin)
enlargement
Progressive or massive lymphadenopathy (>10
Consider Richter transformation if rapid
cm in longest dimension)
enlargement
Constitutional Symptoms:
Exclude infection as the etiology of
Weight loss >10% body weight in < 6 months
constitutional symptoms
Fever >38oC for > 2 weeks without infection
Night sweats without evidence of infection
Extreme Fatigue (unable to work or perform
usual activities)
Autoimmune anemia or ITP poorly responsive to
other therapies
Material obtained from (Shanafelt & Call, 2004)

Table 1.5. Clinical Treatment of CLL Criteria. Abbrev. ALC: absolute lymphocyte count; ITP: Idiopathic
thrombocytopenic purpura. Material was obtained from (Shanafelt & Call, 2004).
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Table 1. 6. Treatment Regimes for Chronic Lymphocytic Leukemia
Type
Allogeneic
Transplantation

Therapies
Transplantation

Chlorambucil
Cyclosphosphamide
Bendamustine (Bifunctional)
Purine Nucleoside Fludarabine*
Cladrine
Analogs
Pentostatin
Bendamustine (Bifunctional)
Alkylating Agents

Immunotherapies

Rituximab (Anti-CD20)
Alemtuzumab (Anti-CD52)

Combinatorial
Therapies

CHOP, CAP, FCR**, OFAR
CFAR

Mechanism of Action
The anti-leukemic principle of
allogeneic transplantation is thought
to be through the immune-mediated
anti-host activities conferred with
the graft (graft-versus-leukemia
effect (GVL)). Only curative
therapy. Limited in use due to
compatibility issues and chronic
graft-versus-host complications.
Irreversible DNA cross-linking
ultimately leading to cell death.
Purine analog, inhibits DNA
synthesis by inhibiting DNA
polymerase, DNA primase, DNA
ligase and accessory protein that
synthesizes an RNA primer
ultimately leading to cell death.
Exert cytotoxic effects by inducing
complement-mediated cytotoxicity
and antibody-dependent cellmediated cytotoxicity.
Multi-factorial.

Table 1.6. Treatment Regimes for Chronic Lymphocytic Leukemia. CHOP: cyclophosphamide,
doxorubicin, vincristine, prednisone; CAP: cyclophosphamide, doxorubicin, prednisone; FCR: fludarabine,
cyclophosphamide, rituximab; OFAR: oxaliplatin, fludarabine, alemtuzumab, rituximab; CFAR:
cyclophosphamide, fludarabine, alemtuzumab, rituximab. *: Standard of Care as Monotherapy; **: Standard of
Care
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NUCLEAR FACTOR KAPPA B
BACKGROUND
Nuclear factor kappa B (NF B) is a multi-protein complex transcriptional regulator that
is made up of different protein dimers (Karin et al., 2002). The NF B family of transcription
factors is composed of homo- and hetero-dimers derived from five distinct subunits: Rel A (p65),
c-Rel, RelB, p50 (NF B1) and p52 (NF B2) (Lawrence, 2009; F. Li & Sethi, 2010). All family
members share a highly conserved Rel homology domain and interactions with inhibitors of
kappa B (I Bs), the intracellular inhibitors of NF B (F. Li & Sethi, 2010). NF B proteins bind
B sites as either as homo- or hetero-dimers, and can exert both positive and negative effects on
target gene transcription (Hayden & Ghosh, 2012). NF B proteins are characterized by the
presence of an N-terminal Rel homology domain (RHD) which comes into contact with DNA
and supports dimerization of NF B subunits (Hayden & Ghosh, 2012). Only Rel A, c-Rel, and
RelB possess C-terminal transactivation domains (TADs) that confer the ability to initiate
transcription (Hayden & Ghosh, 2012). Despite p50 and p52 lacking TADs, they can positively
regulate transcription through heterodimerization with TAD-containing NF B subunits or
through interaction with non-Rel proteins that have transactivating capability (Hayden & Ghosh,
2012). Inversely, p50 and p52 homodimers can negatively regulate transcription by competing
with TAD-containing dimers for binding B sites. Similarly, p50 and p52 dimers may also
constitutively occupy some B sites thereby enforcing an activation threshold for certain NF B
target genes (Hayden & Ghosh, 2012).
A hallmark of the NF B pathway is its regulation by I B proteins. I B proteins I Bα,
I Bß, I B , I B Bcl-3 (B-cell lymphoma 3) and I Bns and the precursor proteins p100
(NF B2) and p105 (NF B1) are defined by the presence of multiple ankyrin repeats (Hayden &
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Ghosh, 2012). Activation of NF B is achieved through phosphorylation of I Bs on conserved
serine residues inducing polyubiquitination of the nuclear export signal, which, under normal
conditions keeps a steady-state cytoplasmic localization of NF B dimers, thus preventing DNA
binding (Hayden & Ghosh, 2012). Proteosomal degradation of I B from the NF B complex
allows NF B dimers to accumulate in the nucleus and bind DNA B sites (Hayden & Ghosh,
2012). The degenerative nature of the B site sequence, ability of individual NF B subunits to
form homo- or hetero-dimers, heterotypic interactions with other transcription factors, and the
regulation of transcriptional activity by post-translational modifications (PTMs) targeting NF B
subunits allow for both positive and negative regulation of transcription of a wide variety of
target genes (Hayden & Ghosh, 2012). The termination of transcription response depends on
both resynthesis of typical I B proteins and removal of active NF B dimers from the DNA
(Hayden & Ghosh, 2012).
Collectively, the regulation and activity of NF B are intricate in nature and can be
influenced by a variety of factors. The following sections are to explore the signaling pathways
which lead to NF B activation, its physiological role and its implications in cancer.

ACTIVATION OF NF B
NF B is activated by many divergent stimuli, including pro-inflammatory cytokines (e.g.
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1)), T- and B-cell mitogens, bacteria,
lipopolysaccharide (LPS), viruses, viral proteins, double-stranded RNA, physical and chemical
stresses and cellular stresses such as ionizing radiation and chemo-therapeutic agents (F. Li &
Sethi, 2010). Activation of NF B can be broadly classified into two types of pathways: canonical
and non-canonical (Hayden & Ghosh, 2012; F. Li & Sethi, 2010).
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The canonical pathway is triggered by microbial products and pro-inflammatory
cytokines such as TNF-α and IL-1 (Hayden & Ghosh, 2012; F. Li & Sethi, 2010). Upon
recognition of ligand, cytokine receptors such as TNF receptor (TNFR), IL-1 receptor (IL-1R) or
toll-like receptor 4 (TLR4) trigger signaling cascades that culminate in activation of inhibitor of
I B kinase-ß (IKKß) .IKKß exists in a complex with IKKα and the regulatory protein NEMO
(IKK ) (Hayden & Ghosh, 2012; Karin et al., 2002). Activation of IKKß phosphorylates I B
proteins such as IkBα resulting in IkBα‟s polyubiquitination and proteosomal degradation,
thereby allowing the NF B complex to translocate into the nucleus and bind B sites (Figure
1.1) (Hayden & Ghosh, 2012; Karin et al., 2002). It should also be noted that IKKα and IKKß
can mediate cross-talk with additional signaling pathways, including p53, MAP kinase (MAPK)
and IFN regulatory factor (IRF) pathways, and directly regulate aspects of transcriptional
responses (Hayden & Ghosh, 2012).
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Figure 1. 1. Canonical NF B Pathway.
Upstream ligand activated cytokine receptors, such as TNFR and IL-1R, activate the IKKß subunit of the
NEMO/IKKα/IKKß complex. Activated IKKß phosphorylates the I B proteins (bound to the NF B heterodimers).
Phosphorylation of I B leads to polyubiquitination of I B and ubiquitin-dependent degradation of I B by the 26s
proteasome, resulting in the nuclear translocation of RelA/p50 (or c-Rel/p50) heterodimers and subsequent binding to B
sites and transcriptional activation of target genes. Figure is redrawn from (Karin, Cao, Greten, & Li, 2002; Lawrence,
2009).
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The non-canonical, or alternative, pathway is triggered by specific members of the TNF
cytokine family, such as CD40 ligand, receptor activator of NF B ligand (RANKL) and B-cell
activating factor (BAFF) (Hayden & Ghosh, 2012; Sun, 2011). In contrast to the canonical
pathway, the non-canonical pathway depends on IKKα and is independent of NEMO (Hayden &
Ghosh, 2012; Lawrence, 2009). These cytokines (CD40L/BAFF/RANKL) activate NF Binducing kinase (NIK) which, in turn, activates IKKα (Lawrence, 2009). Activation of IKKα
leads to phosphorylation of p100 and the generation of p52/RelB complexes and regulates genes
involved in lympho-organogenesis and B-cell activation (Figure 1.2) (Hagemann, Biswas,
Lawrence, Sica, & Lewis, 2009; Hayden & Ghosh, 2012).
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Figure 1. 2. Non-canonical NF B Pathway.
Upstream activation by TNF cytokine family members, such as CD40L and BAFF, activates the kinase, NIK. NIK in turn
activates IKKα which phosphorylates the p100 subunit of the p100/RelB complexs. Phosphorylation of p100 leads to its
polyubiquitination and triggering the ubiquitin-dependent degradation of the carboxyl terminal half of p100, releasing its
amino acid half, the p52 polypeptide, which together with its heterodimer partner, RelB, translocates into the nucleus to
activate transcription. Figure is redrawn from (Karin et al., 2002; Lawrence, 2009).

19

Although various stimuli can activate NF B, most are mediated through either the
canonical or non-canonical (alternative) pathways to regulate a wide variety of genes. Although
each NF B dimer is likely to have distinct regulatory functions, many of the target genes are
conserved to several, if not all NF B proteins (Karin et al., 2002). These genes fall into four
major categories: immunoregulatory and inflammatory genes, anti-apoptotic genes, genes that
positively regulate cell proliferation, and genes that encode for negative regulators of NF B
(Karin et al., 2002). Collectively, the transcriptional programs regulated by NF B are essential
for the development and maintenance of immune systems, skeletal systems, and epithelium
(Hayden & Ghosh, 2012). In these settings, the NF B pathways contributes to control of cell
survival, differentiation and proliferation (Hayden & Ghosh, 2012). While NF B aids in various
processes necessary for normal functioning cells, the same processes can be performed in a
variety of diseases in which aberrant activation of NF B has been associated, including cancer
(Hayden & Ghosh, 2012). In this context, the initiation of tumorigenesis requires six essential
alterations to normal cell physiology: self-sufficiency in growth signals, insensitivity to contact
inhibition, evasion of apoptosis, immortalization, sustained angiogenesis and tissue invasion and
metastasis (Karin et al., 2002). NF B is known to induce several of these cellular alterations
(Karin et al., 2002). Thus, the likelihood that NF B is involved in cancer is high, a notion which
will be explored in the following section.

NF B AND CANCER
Increased constitutively active NF B has been observed in various solid tumors as well
as hematological malignancies (Braun et al., 2006; Darnell, 2002; Ditsworth & Zong, 2004).
Several mechanisms have indicated how NF B transcription factors bypass their normal modes
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of regulation. For example, the avian REV-T oncovirus produces a constitutively active v-Rel
oncoprotein which can induce constitutive NF B activation and causes rapidly progressing
lymphomas and leukemias (Gilmore, 1999). Chromosomal abnormalities can also disrupt genes
which encode NF B and I B proteins, thereby uncoupling NF B factors from their regulators
and causing constitutive NF B activation. Finally, autocrine and paracrine production of proinflammatory cytokines, oncogenic activation of upstream signaling molecules can persistently
stimulate IKK activity leading to constitutive NF B activation (Karin et al., 2002). Together,
constitutively active NF B activation can promote various aspects of tumorigenesis including
promoting cancer-cell proliferation, inhibition of apoptosis and increasing tumor‟s angiogenic
and metastatic potential (Karin et al., 2002).
NF B can contribute to cell-proliferation by activating genes such as IL-2, granulocytemacrophage colony-stimulating factor (GM-CSF) and CD40L which encode for various growth
factors that stimulate the proliferation of lymphoid and myeloid cells. The continuous production
of these cytokines can induce a chronic stimulation of cell proliferation through an autocrine or
paracrine fashion. Additionally, NF B has also been shown to stimulate production of cyclin D1,
thereby promoting cell-cycle progression (Guttridge, Albanese, Reuther, Pestell, & Baldwin,
1999; Hinz et al., 1999).
NF B can also inhibit apoptosis by promoting transcription of anti-apoptotic genes
(Karin et al., 2002). These factors include inhibitors of apoptosis (cIAPs), caspase-8/FADD
(FAS-associated death domain)-like IL-1ß converting enzyme (FLICE) inhibitory protein (cFLIP) and members of the Bcl-2 family (Karin & Lin, 2002). Furthermore, NF B can also
attenuate the apoptotic response of genotoxic anti-cancer therapies and ionizing radiation thereby
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contributing to chemo-resistance (F. Li & Sethi, 2010; C. Y. Wang, Cusack, Liu, & Baldwin,
1999; C. Y. Wang, Mayo, & Baldwin, 1996).
In addition to the ability of NF B to promote cell proliferation and inhibit apoptosis,
NF B can also increase angiogenesis and metastatic potential. This is achieved by NF Btargeted transcription of various chemokines, such as IL-8, which increase the migratory and
invasive capacity (Guo et al., 2011; Kim, Choi, Park, & Kim, 2012) and by transcription of the
stimulator of angiogenesis- vascular endothelial growth factor (VEGF) (Huang, Robinson,
Deguzman, Bucana, & Fidler, 2000; Tanaka et al., 2012). NF B has also been shown to induce
transcription of several metalloproteinases- proteolytic enzymes that promote tumor invasion of
surrounding tissues (J. Li et al., 2012; Qin et al., 2012).
Consistent with the notions that NF B can promote oncogenesis, various studies have
demonstrated that NF B activation is positively associated with disease progression. Studies by
Tang et al. found that high levels of immunohistochemical expression of NF B p65 were
detected in lung cancers (X. Tang et al., 2006). Interestingly, the NF B p65 expression in lung
adenocarcinomas was significantly higher in advanced TNM (tumor, lymph nodes, metastasis)
stages (III-IV) than in earlier stages (I-II), suggesting that NF B is associated with disease
progression (X. Tang et al., 2006). These findings are further supported by Zhang et al. who
found that expression of NF B/Rel A was higher in non-small cell lung cancer (NSCLC) tissue
as compared to normal adjacent tissue and normal lung tissue (Zhang et al., 2007). Additionally,
there was a positive correlation between NF B activation (nuclear translocation of Rel A) and
tumor clinicopathological features such as tumor grade and TNM staging, supporting the
findings by Tang et al (Zhang et al., 2007). Zhang et al. also demonstrated that nuclear Rel A
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binding and cytoplasmic phosphorylated-inhibitor of kappa-B-alpha (pI B-α) were positively
associated with poor prognosis (Zhang et al., 2007).
Although the involvement of NF B activation in various malignancies has been
evaluated, the activation of NF B in CLL remains of primary interest in this dissertation.
Targeting NF B activation has also come into light as a promising candidate for intervention for
the treatment of CLL. (F. Li & Sethi, 2010). Increased constitutive activation of NF B has been
observed in primary CLL cells (Hewamana, Alghazal, et al., 2008; Hewamana, Lin, et al., 2008;
Hewamana et al., 2009). It has also been found that increased binding of Rel A, a subunit of
NF B which contains the transactivation domain, was positively correlated with white blood cell
count, a measure of tumor burden, and lymphocyte doubling time, a measure of tumor kinetics
(Hewamana, Alghazal, et al., 2008). Furthermore, it has been shown that Rel A DNA binding
was strongly associated with Binet staging, predictive of time to initial treatment and subsequent
treatment, and predictive of overall survival (Hewamana et al., 2009). Rel A DNA binding has
also been shown to be negatively correlated with induction of spontaneous apoptosis in vitro
suggesting that NF B is an important mediator of survival (Hewamana, Alghazal, et al., 2008).
This is supported by the fact that inhibition of NF B activation, through the use of an
irreversible-IKK inhibitor (LC-1), induced dose-responsive increases in apoptosis (Hewamana,
Lin, et al., 2008). The addition of LC-1 was also able to overcome the cytoprotective effects of
CD40L and IL-4, upstream agonists of NF B activation, providing further support of the
importance of NF B in CLL (Hewamana, Lin, et al., 2008). Additionally, studies by Pepper et
al. indicated that the cytotoxic effects of aspirin and its analogues were mediated by both COX-2
inhibition as well as inhibition of Rel A DNA (Pepper et al., 2011). It is also important to note
that in the studies by Hewamana et al., inhibition of NF B activation by LC-1 exhibited strong
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synergy with fludarabine, a commonly used first-line treatment in CLL (Riches, Ramsay, &
Gribben, 2011; Silber et al., 1994), in both good prognostic CLL patients who were fludarabinesensitive and poor prognostic CLL patients who displayed chemorefractoriness toward
fludarabine (Hewamana, Lin, et al., 2008). Given the ability of NF B to promote survival of
CLL cells in vitro and aid in various biological processes such as proliferation, migration,
inhibition of apoptosis and chemo-resistance, therapeutic interventions which target NF B
would be of considerable interest and clinically relevant.
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OMEGA-3 FATTY ACIDS
BACKGROUND
Omega-3 (n-3) and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) are essential fatty
acids (EFAs). These fats are referred to as essential because humans, like all mammals, are
unable to synthesize them and thereby must obtain them from the diet. The n-6 EFA is
represented by linoleic acid (LA; 18:2n-6) and n-3 EFA is represented by alpha-linolenic acid
(ALA; 18:3n-3) (Figure 1.1). LA is primarily found in seeds of most plants, whereas, ALA is
primarily found in green leafy vegetables, flax seed, and walnuts (Simopoulos, 2008). The
distinction of these two essential fatty acids (FAs) is based on the location of the first double
bond from the methyl (omega) end of the FA molecule located between carbon 6-7 (n-6) or 3-4
(n-3) (Figure 1.1) (Simopoulos, 1991, 2000, 2002, 2008).
Both EFAs are capable of being metabolized in humans to their longer chain 20-carbon
and 22-carbon derivatives. LA is metabolized to 20-carbon arachidonic acid (AA; 20:3n-6) and
ALA is metabolized to the 20-carbon eicosapaentaenoic acid (EPA; 20:5n-3) and 22-carbon
docosahexaenoic acid (DHA; 22:6n-3). This is achieved by increasing the carbon chain length
and degree of unsaturation through addition of extra carbons to the carboxyl end of the fatty acid
chain (Figure 1.1) and then desaturating a bond. While AA can be metabolized from its precursor, LA, it can also be obtain from meats of animals that consume LA and then store AA in
their meat. Similarly, EPA and DHA can be obtained from fish or fish oils (Simopoulos, 1991,
2000, 2002, 2008).
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Figure 1. 3. Chemical Structures of Omega-3 and Omega-6 Fatty Acids.
Picture modified from the European Food Information Council. Abbrev. X:Y- X denotes number of carbon atoms; Y
denotes number of unsaturations; n-3: omega-3; n-6: omega-6. Picture modified from the European Food
Information Council.

EFAs are important components of cellular membranes and are selectively found
amongst lipid classes. ALA and LA are mostly found in triglycerides, cholesterol esters with a
relatively small abundance found in phospholipids. AA and EPA are found in triglycerides,
cholesterol esters and phospholipids. Unlike the other n-3 FAs, DHA is predominantly found in
phospholipids (Simopoulos, 2008). Furthermore, n-6 and n-3 FA compete with each other for
incorporation into the cell and are substrates for the same metabolizing enzymes (reviewed in the
following section). As such, consumption of n-3 such as EPA or DHA can partially displace n-6,
especially AA, in the membranes of cells (Simopoulos, 1991, 2000, 2002, 2008).
Currently, the western diet is heavily favored toward the n-6 FA with little to no n-3 FA
intake. The average ratio of n-6 to n-3 in the western diet is 15-20 to 1 (Simopoulos, 2008)
whereas the ideal ratio of n-6 to n-3 is 4-1:1 (Patterson, Wall, Fitzgerald, Ross, & Stanton, 2012).
Furthermore, mammalians lack the ability to convert n-6 to n-3 as they lack the necessary
converting enzyme, omega-3 desaturase (Simopoulos, 2008). This is an important consideration;
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both n-6 and n-3 are integral parts of cellular membranes and are structurally similar. Yet these
two classes of EFA are not interconvertible, and are metabolically and functionally distinct, often
having important opposing physiological functions (Simopoulos, 2008). As such, this imbalance
toward n-6 can lead to increased risk of various diseases. In support of this notion, various
studies have illustrated that a high intake of n-6 and a high n-6/n-3 ratio can promote
pathogenesis of many diseases including cardiovascular, autoimmune, cancer, and inflammatory
disease (Simopoulos, 2008). Inversely, consumption of n-3 has been shown to have beneficial
health effects and often has suppressive effects on pathogenesis (Simopoulos, 2008).
Beneficial health effects of n-3, particularly EPA and DHA, were described first in
Greenland Eskimos who consumed high quantities of fish and displayed lower rates of coronary
heart disease, asthma, type 1 diabetes mellitus, and multiple sclerosis (Simopoulos, 2008) than
populations that consumed less fish. Since then, beneficial effects of n-3 have been extended to
include cancer, inflammatory bowel disease, rheumatoid arthritis and psoriasis (Simopoulos,
2008).
The application of n-3 as potential therapeutic options for CLL is of great interest and the
principle focus of this thesis. The metabolism of PUFAs and their physiological role in humans
as well as their implications on CLL will be discussed in the following sections.

METABOLISM
As introduced above, both LA and ALA are able to be metabolized to their longer 20carbon and 22-carbon derivatives. This is achieved through a series of elongation and
desaturation reactions mediated by specific elongase and desaturase enzymes illustrated in
Figure 1.2 with delta-6 desaturase being the rate limiting enzyme (Patterson et al., 2012;
Simopoulos, 2008). Since both n-3 and n-6 FA utilize the same enzymes their conversion to their

27

longer derivatives can be influenced if there is a high intake of one type of EFA. For instance, a
high intake of ALA can interfere with the elongation and desaturation of LA. This concept has
been demonstrated in human studies which illustrated that a constant consumption of ALA with
a decreasing consumption of LA led to increases in EPA in the plasma phospholipids (Liou,
King, Zibrik, & Innis, 2007). Additionally, the elongation and desaturation of n-3 and n-6 FA
can also be hindered by the present of trans-fats, which inhibit the delta-6 desaturase (Patterson
et al., 2012; Simopoulos, 2008). As such, the propensity of PUFAs to undergo elongations and
desaturations is largely dependent on the type of fat intake of the individual.
The elongation and desaturation of LA and ALA is an important process as the
bioactivity of these EFAs is thought to be predominately mediated through their longer chain
metabolites. Of the various n-6 and n-3 derivatives, AA and EPA are especially important as
these FAs are precursors for eicosanoid production (Haeggstrom, Rinaldo-Matthis, Wheelock, &
Wetterholm, 2010; Serhan & Petasis, 2011). Eicosanoids are biologically active, 20-carbon lipids
which are important mediators of acute inflammation, and have been implicated in several
specific diseases such as thrombosis, cancer, atherosclerosis, asthma and rhinitis (Haeggstrom et
al., 2010; Patterson et al., 2012). These AA-derived and EPA-derived eicosanoids are produced
by three major pathways: the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450
(CYP) pathways (Haeggstrom et al., 2010; Luo & Wang, 2011; Patterson et al., 2012).
Collectively, eicosanoids consist of prostaglandins (PGs), thromboxanes (TXs), leukotrienes
(LTs), hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EET),
epoxyeicosatetraenoic acids (EETeTrs) and hydroxyeicosapentaenoic acids (HEPE) (Arnold,
Konkel, Fischer, & Schunck, 2010; Luo & Wang, 2011; Patterson et al., 2012). The synthesis of
the various eicosanoids is illustrated in Figure 1.3.
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Linoleic Acid (LA: 18:2n-6)

Alpha-Linolenic Acid (ALA: 18:3n-3)

Delta-6-Desaturase
Gamma-Linolenic Acid (GLA: 18:3n-6)

Stearidonic Acid (SA: 18:4n-3)

Elongase
Dihomogamma-Linolenic Acid (DGLA: 20:3n-6) Eicosatetraenoic Acid (EA: 20:4n-3)

Delta-5-Desaturase
Arachidonic Acid (AA: 20:4n-6)

Eicosapentaenoic Acid (EPA: 20:5n-3)

Elongase
(22:4n-6 Intermediate)

Docosapentaenoic Acid (DPA: 22:5n-3)

Delta-4-Desaturase
Docosapentaenoic Acid (DPA:22:5n-6)

Docosahexaenoic Acid (DHA: 22:6n-3)

Figure 1. 4. Metabolism of Linoleic Acid and Alpha-Linolenic Acid to their longer-chain derivatives.
Abbrev. X:Y- X denotes number of carbon atoms; Y denotes number of unsaturations; n-3: omega 3; n-6: omega 6.
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Whereas PUFA are able to undergo enzymatic metabolism, they are also able to undergo
non-enzymatic degradation. Non-enzymatic degradation of PUFA is mediated by various
reactive oxygen and nitrogen species (ROS/RNS) which oxidize lipids, collectively referred to as
lipid peroxidation, and yield a diverse array of products (Niki, 2009). The degree of lipid
peroxidation is dependent on the number of unsaturations possessed by the FA molecule. As
such, the higher the degree of unsaturation the FA molecule possesses the greater the amount of
lipid peroxidation that can ensue (Niki, 2009).
Lipid peroxidation can be mediated by free radical-mediated oxidation or free radicalindependent non-enzymatic oxidation (Niki, 2009). Free radical-mediated lipid peroxidation is
achieved by a chain mechanism in which one initiating free radical can oxidize many molecules
of lipids (Niki, 2009). The type of free radical which oxidizes the lipid molecules is dependent
on the condition of the cell (Niki, 2009). Free radical-independent non-enzymatic oxidation is
mediated by singlet oxygen and ozone (Niki, 2009). Singlet oxygen oxidizes unsaturated lipids
mainly by the ene-reaction to give hydroperoxide with concomitant double-bond migration, with
minor side reactions such as 1,4 addition to give 1,4-endoperoxide and 1,2 addition to give
dioxetane, which readily decomposes to yield carbonyl compounds (Niki, 2009).
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Membrane Phospholipid
Phospholipase-A2
5-Lipoxygenase

Cyt. P450

Arachidonic Acid

5-HETE
LTA Synthase
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5,6-EET
8,9-EET
11,12-EET
14,15-EET

Cyclo-Oxygenase-1
(COX-1: Constitutively Active)

4-series Leukotrienes (LTs)

Cyclo-Oxygenase-2
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Biological Effect
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Biological Effect

Membrane Phospholipid
Phospholipase-A2
5-Lipoxygenase
5-HEPE
LTA Synthase
5-series Leukotrienes (LTs)

Cyt. P450

Eicosapentaenoic Acid
Cyclo-Oxygenase-1
(COX-1: Constitutively Active)
Cyclo-Oxygenase-2
(COX-2: Inducible)

EETeTrs
19- and 20-HEPEs

Biological Effect

Biological Effect
PGH3
Tissue-Specific Isomerases
(PGE Synthase, TXA Synthase, PGI
Synthase)

PGE3 TXA3 PGI3

PGD3 PGF3a

Biological Effect

Figure 1. 5. Schematic of Eicosanoid Production.
Within a cell, AA and EPA is released from the membrane phospholipids by the enzyme phospholipase-A2 (PLA2)
where after they will be metabolized by the cyclo-oxygenase enzymes (COX-1, a constitutive enzyme, or COX-2, an
inducible enzyme), 5-lipoxygenase (LOX) or cytochrome p450 (CYP). AA COX-derived eicosanoid PGH2 is
subsequently metabolized by a series of specific prostaglandin synthase enzymes leading to the production of the 2-series
prostaglandins: PGE2, PGI2, PGD2, and PGF2α and thromboxanes A2 and B2. AA LOX-derived eicosanoid 5hydroperoxyeicosatetraenoic acid (5-HPETE) is subsequently metabolized by Leukotriene Synthase to produce the 4series of leukotrienes: LTA4, LTB4, LTC4, LTD4 and LTE4. Metabolism of AA by CYP produces the 16- to 20-HETEs
and 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs). In contrast, EPA can also act as a substrate for COX,
LOX and CYP enzymes and give rise to an entirely different set of eicosanoids. These are the 3-series prostaglandins and
thromboxanes and the 5-series leukotrienes and epoxyeicosatetraenoic acids (EETeTrs) and 19- and 20hydroxyeicosapentaenoic acids (HEPE).
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Collectively, PUFA are substrates for a variety of enzymatic and non-enzymatic
reactions. The type of PUFA, degree of unsaturation and intake all influence the rate and type of
by-products that are produced aiding to the complexity of PUFA metabolism and the versatility
of their actions.

MECHANISMS OF ACTION
The mechanisms through which PUFA exert their actions are diverse and multifaceted, a
trait aided by the diversity of their by-products. However, one of the most prominent roles of
PUFA is their involvement with inflammation.
Inflammation is an important physiological host defense mechanism that protects the host
from infection and other insults. Inflammation initiates pathogen killing and tissue repair
processes as well as restoration of homeostasis at an infected or damaged site (Niki, 2009).
Under normal conditions, inflammation is tightly regulated to prevent excessive damage to the
host. Regulation is often mediated through negative feedback mechanisms such as antiinflammatory cytokines, inhibition of pro-inflammatory cascades, shedding of receptors for
inflammatory mediators and through activation of regulatory cells (Niki, 2009). As such,
controlled, regulated inflammatory responses are essential to remain healthy and maintain body
homeostasis. However, a loss of tolerance and/or regulation of inflammatory processes can lead
to excessive, irreparable damage to the host tissue leading to various pathologies, including
cancer (Niki, 2009).
Eicosanoids are key mediators and regulators of inflammation (Calder, 2009;
Haeggstrom et al., 2010; Serhan & Petasis, 2011). As previously mentioned, the eicosanoids
produced by AA are comprised of the 2-series PGs and TXs and the 4-series LTs. PGE2 and the
4-series LTs are particularly important as these eicosanoids modulate both the intensity and
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duration of the inflammatory response (Calder, 2009). However, eicosanoid production is not
solely derived from AA, but can also be derived from EPA. The eicosanoids produced from
EPA, which includes the 3-series PGs/TXs and 5-series LTs, are functionally different from their
AA-derived counterparts and often times have antagonistic actions on inflammation (Table 1.7)
(Calder, 2009).
Prostaglandins and thromboxanes, collectively referred to as prostanoids, exert their
biological effects by binding to cell-surface prostanoid receptors belonging to the family of Gprotein-coupled rhodopsin receptors (GPCRs) or nuclear receptors such as the peroxisome
proliferator-activated receptors (PPARs) (Cathcart, Lysaght, & Pidgeon, 2011; Ricciotti &
FitzGerald, 2011). The prostanoid receptor family is composed of 8 members: E prostanoid
receptor (EP 1-4); D prostanoid receptor (DP1); F prostanoid receptor (FP); I prostanoid receptor
(IP); and thromboxane receptor (TP) (Ricciotti & FitzGerald, 2011). These prostanoid receptors
are coupled to a range of intracellular signaling pathways summarized in Table 1.8.
Of particular interest are the EP receptors and PGE2 as PGE2 is one of the most abundant
eicosanoids produced in the body (Ricciotti & FitzGerald, 2011). EP2 and EP4 activate adenylyl
cyclase to generate cyclic adenosine monophosphate (cAMP) leading to activation of protein
kinase A (PKA) (Alfranca et al., 2006; Ricciotti & FitzGerald, 2011). PKA can, in turn, inhibit
glycogen synthase kinase 3 alpha (GSK3α), thereby promoting transcription of T-cell factor
(Tcf)-dependent genes such as COX-2. Additionally, EP4 specifically activates the
phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt) pathway which, in some cell types,
augments extracellular signal-regulated kinase (ERK) activity and mediates expression of early
growth response protein 1 (EGR-1) and subsequent transcription of genes such as prostaglandin
E synthase-1 (mPGES-1) (Alfranca et al., 2006). PGE2 has also been shown to activate nuclear
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factor kappa B (NF B), a key mediator of the inflammatory processes(Ditsworth & Zong, 2004),
and hypoxia inducible factor-1 alpha (HIF-1α) (Alfranca et al., 2006). Additionally, PGE2 has
been shown to transactivate the epidermal growth factor receptor (EGFR) via activation of
proto-oncogene tyrosine-protein kinase Src (c-Src), which activates EGFR directly or indirectly
by inducing metalloproteinase activity that releases membrane bound transforming growth
factor-alpha (TGFα) (Buchanan, Wang, Bargiacchi, & DuBois, 2003; Pai et al., 2002).
Collectively, the bioactivity of PGE2 is diverse and cell-type specific. However, PGE2 is
typically associated with promotion of increased states of inflammation and has been implicated
in various tumorigenic processes (Reader, Holt, & Fulton, 2011).
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Table 1. 7. Pro-inflammatory Effects of N-6 Fatty Acid-derived Eicosanoids
and Anti-inflammatory Effects of N-3 Fatty Acid-derived Eicosanoids

Prostaglandins

Thromboxanes

Leukotrienes

Prostaglandins
Thromboxanes
Leukotrienes
Resolvins

Neuroprotectin

Pro-inflammatory effects of the n-6 fatty-acid-derived eicosanoids
Arachidonic Acid (n-6)
Physiological Effect
Organ or Cells
Derived Eicosanoids
PGD2
Bronchoconstriction
Bronchi
Pro-inflammatory
Activation of Eosinophils
Pro-arrhythmic
Vessels
PGE2
Induces Fever
Nociceptor Sensory
Causes Pain
Neurons
Increases Production of
IL-6
PGF2
Bronchoconstriction
Bronchi
Pro-arrhythmic
Vessels
PGI2
Causes Pain
Nociceptor Sensory
Neurons
TXA2/TXB2
Pro-aggregation
Platelets
Vasoconstriction
Vessels
Bronchoconstriction
Bronchi
LTA4/LTB4/LTC4/LTD4/LTE4 Pro-inflammatory
Leukocytes
Chemotaxis
Leukocytes
Release of ROS
Granulocytes
Anti-inflammatory effects of the n-3 fatty-acid-derived eicosanoids
Eicosapentaenoic Acid and
Physiological Effect
Organ or Cells
Docosahexaenoic Aicd (n-3)
Derived Eicosanoids
PGD3/PGE3/PGF3/PGI3
Anti-arrhythmic
Vessels
TXA3/TXB3
Anti-aggregation
Platelets
LTA5/LTB5/LTC5/LTD5/LTE5
Anti-inflammatory
Leukocytes
RVE1
Anti-aggregation
Platelets
Anti-inflammatory
Dendritic Cells
RVD
Anti-inflammatory
Dendritic Cells
NPD1
Anti-inflammatory
Retina (photoreceptor cells)
Anti-apoptotic
and Brain
Decreases Oxidative
Stress
Material obtained from (Calder, 2009).
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Table 1. 8. Signal Transduction of AA-derived Prostanoids
Class
PGE2

PGD2
PGF2α
PGI2
TxA2

Subtype
EP1
EP2
EP3
EP4
DP
CRTH2
FPA, FPB
IP-IP
IP-TPα
TPα, TPß

G-Protein Coupled
Second Messenger(s)
Gq
IP3
Gs
cAMP
Gi, G12, GRho
cAMP, Ca2+
Gs
cAMP
Gs
cAMP
Gi
cAMP, Ca2+
Gq, GRho
IP3
Gs, Gq, Gi
IP3 ,
cAMP
Gs
cAMP
Gq, Gs (α), Gi (ß), Gh,
IP3 ,
cAMP
G12/13
Ca2+
Material obtained from (Alfranca et al., 2006).

Table 1.8. Signal Transduction of AA-derived Prostanoids. Abrrev.: PGE2: prostaglandin E2;
EP:prostaglandin E2 receptor; IP3: inositol triphosphate; cAMP: cyclic adenosine monophosphate; PGD2:
prostaglandin D2; DP: prostaglandin D2 receptor; CRTH2: chemoattractant receptor-homologous molecule
expressed on Th2 cells; PGF2α: prostaglandin F2α; FP: prostaglandin F receptor; PGI2: prostacyclin 2; IP:
prostacyclin receptor; TP: thromboxane receptor; TxA2: thromboxane A2. Data obtained from (Alfranca,
Iniguez, Fresno, & Redondo, 2006).

Whereas eicosanoids are primary mediators of inflammation, products of lipid
peroxidation can also contribute to an inflammatory state. While the mechanisms, dynamics and
products of lipid peroxidation are still under investigation, it has been shown that lipid
peroxidation induces: 1) disturbances of fine structures, 2) alterations in integrity, fluidity and
permeability of cell membranes leading to functional loss, 3) modifies low-density lipoproteins
to pro-atherogenic and pro-inflammatory forms, and 4) can generate potentially toxic products
(Greenberg et al., 2008; Niki, 2009). Despite the potential mutagenic and genotoxic effects that
lipid peroxides can elicit, it has also become evident that lipid peroxidation products exert
various biological functions in vivo such as regulation of gene expression, signaling messengers,
activators of receptors and nuclear transcription factors, and inducers of adaptive responses
(Niki, 2009). Recent studies have provided evidence that many products of lipid peroxidation
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exert opposite dual effects, depending on conditions, such as cytotoxic or cytoprotective effects,
pro- and anti-atherogenic effects, pro- and anti-apoptotic effects and pro- and anti-inflammatory
effects (Parthasarathy, Santanam, Ramachandran, & Meilhac, 2000; Zmijewski et al., 2005).
Thus, the contribution of lipid peroxides to a pro-inflammatory state is complex and context
dependent.
The mechanisms of action exerted by n-6 and n-3 are diverse and multi-faceted.
Typically, n-6 FAs are considered to be pro-inflammatory; whereas n-3 FAs are considered to be
anti-inflammatory. States of chronic inflammation are an underlying cause for various
pathologies including cancer (Balkwill & Coussens, 2004; Clevers, 2004). A diet rich in n-6 will
shift the balance toward a pro-inflammatory and pro-thrombotic state and can, thereby, promote
tumor promotion and progression. Inversely, the addition of n-3 can antagonize the proinflammatory effects of n-6 thereby providing a potential therapy for the treatment of cancer, the
focal point of this thesis.

OMEGA-3 FATTY ACIDS AND CANCER
Recently, numerous studies have supported the notion that AA and its metabolites have a
significant role in tumor promotion (Hyde & Missailidis, 2009). Although the role of AA and its
metabolites on tumor promotion is intricate and multi-faceted, much attention has been placed on
COX-2 and PGE2. It is clear that overexpression of COX-2 is implicated in various forms of
human cancers including lung (Krysan et al., 2004), breast (Barnes, Haywood, Flint, Knox, &
Bundred, 2006), colorectal (Chan, Ogino, & Fuchs, 2007), prostate (Lee, Pan, Cheng, Chi, &
Liu, 2001), head and neck (D. W. Tang et al., 2003), and chronic lymphocytic leukemia (Ryan et
al., 2006; Secchiero et al., 2005). In conjunction, AA-COX derived eicosanoid, PGE2, is the most
abundantly formed prostaglandin (Ricciotti & FitzGerald, 2011) and has been implicated in
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various aspects of tumorigenesis via induction of cell proliferation, anti-apoptosis, angiogenesis,
invasion, and metastasis (Greenhough et al., 2009). In addition, PGE2 has also been linked to
upregulation of B-cell CLL/lymphoma 2 (Bcl-2), an anti-apoptotic protein, and induction of
NF B (D. Wang & Dubois, 2010).
Nuclear factor kappa B belongs to a family of transcription factors that play a pivotal role
in inflammatory and stress responses as well as in tumor cell resistance to apoptosis (Balkwill &
Coussens, 2004; Darnell, 2002). NF B controls various cytokines (e.g. IL-1, IL-2, IL-6, IL-12,
TNF-α), chemokines (e.g. IL-8, MIP-1α, MCP1), adhesion molecules (e.g. ICAM, VCAM and
E-selectin) and inducible effector enzymes such as inducible nitric oxide synthase (iNOS) and
COX-2 (Schmitz & Ecker, 2008). Several studies have demonstrated that NF B can promote
oncogenesis by virtue of its ability to regulate the expression of a wide array of genes that
modulate apoptosis, proliferation, inflammation, tumor metastasis, and angiogenesis (Clevers,
2004). Increased constitutively active NF B has been observed in various solid tumors as well as
hematological malignancies (Braun et al., 2006; Darnell, 2002; Ditsworth & Zong, 2004).
Activation of NF B has been linked to aggressive tumor growth and resistance to both
chemotherapy and radiotherapy (F. Li & Sethi, 2010). NF B regulates COX-2 (Schmitz &
Ecker, 2008). COX-2 increases production of PGE2 (Calder, 2009). PGE2 in turn can stimulate
various pathways associated with tumorigenesis including activation of NF B (Ditsworth &
Zong, 2004; D. Wang & Dubois, 2010). Thus, the relationship between NF B, COX-2 and PGE2
is inherently intertwined and potentially self-propagating.
N-3 and n-6 compete with each other for incorporation and metabolism. The effects of n3 derived metabolites are antagonistic of n-6 derived metabolites. Given the involvement of AA
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and its metabolites in tumor promotion, the use of n-3, particularly EPA and DHA, as therapeutic
options for various malignancies presents a promising avenue of research.
Consistent with this thought, n-3 fatty acids have consistently been shown to slow the
growth and increase the chemo-sensitivity of various malignancies in vitro and in animal models
(Das & Madhavi, 2011; Das, Madhavi, Sravan Kumar, Padma, & Sangeetha, 1998; Dekoj et al.,
2007; Hardman, Avula, Fernandes, & Cameron, 2001). However, the capacity of n-3 to translate
into clinical benefit is of primary interest. Clinical studies utilizing n-3 in breast and lung cancer
have demonstrated promising results. Studies by Bougnoux et al. indicated that response to
therapy was positively correlated with n-3 levels in breast adipose tissue in patients with
localized breast carcinoma given a therapy of mitoxantrone, vindesine, cyclophosphamide, and
5-fluorouracil (Bougnoux et al., 1999). Notably, increased DHA especially stood out as a
positive predictor of chemo-sensitivity (Bougnoux et al., 1999). In line with these observations,
studies by Bougnoux et al. also illustrated that supplementation with 1.8 g/daily of DHA
improved the efficacy of anthracycline-based therapy against the progression of visceral
metastases (Bougnoux et al., 2009). In this study, significant increases in time to progression
and median overall survival were achieved in patients with the highest plasma DHA levels as
compared to the lowest plasma DHA levels ( 8.7 months versus 3.5 months and 34 months
versus 22 months; respectively) (Bougnoux et al., 2009). Importantly, it was also found that
supplementation with DHA did not induce any additional adverse effects. It should be noted that
this was a small study (n= 25) and the relationship between DHA content and metastatic cancer
outcome subsequent to chemotherapy does not ensure a causality (Bougnoux et al., 2009).
Similarly, studies by Murphy et al. indicated that supplementation with fish oil increased the
first-line chemotherapy efficacy in patients with advanced non-small cell lung cancer (NSCLC)
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(Murphy et al., 2011b). In this study, patients with clinical diagnosis of stage IIIB or IV NSCLC
who were chemotherapy-naïve were either supplemented with fish oil (2.5g of EPA + DHA/day;
n=15) or no fish oil (standard of care group (SOC); n=31) in conjunction with first-line platinumbased doublet chemotherapy of palliative intent consisting of either carboplatin with vinorelbine
or carboplatin with gemcitabine (Murphy et al., 2011b). Primary endpoints of this study were
response rates, defined as complete response plus partial response, and clinical benefit, defined
as the sum of complete response, partial response and stable disease divided by the number of
patients (Murphy et al., 2011b). Collectively, results from Murphy et al. illustrated that patients
in the fish oil group had increased response rates and greater clinical benefit compared to the
SOC group (60.0% versus 25.8%, p-value: 0.008 and 80.0% versus 41.9%, p-value: 0.02,
respectively) (Murphy et al., 2011b). It should also be noted that patients in the fish oil group had
greater 1-year survival rates as compared to the SOC group (60.0% versus 38.7%), although this
was not statistically significant (Murphy et al., 2011b). Furthermore, patients in the fish oil group
did not display any additional toxicities associated with treatment as compared to the SOC
group. Inversely, as compared to the SOC group, patients in the fish oil received a significantly
higher number of chemotherapy cycles (number of chemotherapy cycles received ± SD: 3.9 ±
0.9 versus 3.0 ± 1.4, p-value: 0.02) and longer, almost significant, time on chemotherapy (time
on chemotherapy (days) ± SD: 78.9 ± 23.5 versus 60.3 ± 31.1, p-value: 0.05) (Murphy et al.,
2011b).
N-3 may also be able to reduce the side effects of treatments. In support of this notion,
Ghoreishi et al. illustrated that a daily dose of 630 mg n-3 partially prevented paclitaxel induced
peripheral neuropathy (PIPN), a dose-limiting side effect of paclitaxel therapy (Ghoreishi et al.,
2012). Additionally, Heller et al. indicated that the addition of 0.2g/kg/daily fish oil increased
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liver and pancreas function while reducing weight loss in patients recovering from major elective
abdominal surgery (Heller et al., 2004). Studies by van der Meij et al. indicated that patients with
stage III NSCLC who consumed oral n-3 supplements (2.02g EPA + 0.92g DHA) during
multimodality treatment had significantly greater quality of life parameters, physical and
cognitive function, global health status and social function, and higher physical activity as
compared to the placebo group (van der Meij et al., 2012). Similarly, Murphy et al. also found
that patients with NSCLC who consumed fish oil (2.2g of EPA/day) retained weight and either
gained or maintained muscle mass as compared to the non-intervention group during first-line
therapy (Murphy et al., 2011a).
Collectively, these findings highlight the application of n-3 at both the basic research
level as well as in a clinical setting. However, the primary purpose of this research was to
evaluate the potential of n-3 as therapeutic interventions for the treatment of CLL. Although
limited, in vitro and in vivo studies on B-leukemic cells have provided insight into the
application of n-3 as potential therapeutic options for the treatment of B-cell malignancies (such
as CLL). Studies by Cha et al. indicated that supplementation of mice bearing L1210 B-leukemia
with a DHA containing diet, as compared to a chow diet, in combination with arabinosylcytosine
(AraC) chemotherapy displayed improved survival (Cha, Meckling, & Stewart, 2002). In this
study, compared to the chow diet, the 1.5% DHA-containing diet (average intake of 1.8 g of
DHA/kg/day) prolonged the life span (33 ± 3.4 days, p: <0.01) of L1210-bearing mice following
AraC treatment with no incidence of death due to drug toxicity(Cha et al., 2002). However, it
should be noted that a high intake of DHA (4.5 g of DHA/kg/day) in combination with AraC did
not shown benefit. Inversely, the high DHA-containing diet was associated with a shorter
survival time (26.5 ± 2.0 days), increased circulating tumor cell burden, and lowered red blood
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cell concentrations (Cha et al., 2002). Studies by Guffy et al. illustrated that in vitro treatment of
L1210 lymphoblastic leukemia cells with DHA increased the sensitivity of cells to the anticancer drug Adriamycin in a dose-responsive manner as compared to cells treated with oleic acid
(Guffy, North, & Burns, 1984). Additionally, increased DHA content indicate dose-responsive
decreases in viability at a fixed concentration of Adriamycin (Guffy et al., 1984). Petersen et al.
indicated that treatment of L1210 cells with DHA increased the sensitivity of cells to the
thioether lipid BM 41.400 as compared to cells treated with oleic acid (Petersen, Kelley, Modest,
& Burns, 1992). Whereas the use of n-3 has actively been explored in various malignancies,
including B-cell malignancies, it has not been demonstrated whether or not n-3 can provide
benefit to patients diagnosed with CLL in clinical settings.
It should be reminded that CLL is the most common form of adult leukemia in the
western world (Riches et al., 2011). CLL is primarily a disease of the elderly with two thirds of
patients being 65 years of age at the time of diagnosis (Riches et al., 2011). CLL is often initially
diagnosed in the asymptomatic stages where watchful waiting is the primary course of treatment
(Riches et al., 2011). However, approximately 50% of these patients will progress to advanced,
symptomatic stages (Shanafelt & Call, 2004). Progression to symptomatic stages is associated
with shortened survival and need for therapy (Shanafelt & Call, 2004). Despite the success of
current treatment options, such as FCR (fludarabine, cyclophosphamide and rituximab), many
patients develop drug resistance and disease relapse (Riches et al., 2011; Shanafelt & Call, 2004;
Silber et al., 1994). Additionally, clinical treatment of CLL in patients who require aggressive
treatment is limited due to significant side-effect profiles which are often too toxic for the elderly
or those with co-morbidities (Riches et al., 2011). As such, clinical treatment of CLL is often
hindered by progressive drug resistance and drug-induced toxicities (Riches et al., 2011).
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Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic
CLL to symptomatic CLL or enhance the effects of actively used chemotherapeutic drugs in
patients who require therapy would be clinically beneficial. Thus, the application of n-3 as a
novel therapeutic option for CLL is of considerable interest. In the following chapters, the
application of n-3 fatty acids, particularly EPA and DHA, as therapeutic options for CLL will be
explored through both in vitro studies as well as clinical studies with the aim of providing
scientific insight into the potential use of n-3 as therapeutic options for the treatment of CLL.

43

REFERENCES
Alfranca, A., Iniguez, M. A., Fresno, M., & Redondo, J. M. (2006). Prostanoid signal
transduction and gene expression in the endothelium: role in cardiovascular diseases.
Cardiovasc Res, 70(3), 446-456. doi: 10.1016/j.cardiores.2005.12.020
Arnold, C., Konkel, A., Fischer, R., & Schunck, W. H. (2010). Cytochrome P450-dependent
metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol
Rep, 62(3), 536-547.
Balkwill, F., & Coussens, L. M. (2004). Cancer: an inflammatory link. Nature, 431(7007), 405406. doi: 10.1038/431405a
Barnes, N., Haywood, P., Flint, P., Knox, W. F., & Bundred, N. J. (2006). Survivin expression in
in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J
Cancer, 94(2), 253-258. doi: 10.1038/sj.bjc.6602932
Bougnoux, P., Germain, E., Chajes, V., Hubert, B., Lhuillery, C., Le Floch, O., . . . Calais, G.
(1999). Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid
level in locally advanced breast carcinoma. Br J Cancer, 79(11-12), 1765-1769. doi:
10.1038/sj.bjc.6690281
Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., Couet, C., & Le Floch, O. (2009).
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic
acid: a phase II trial. Br J Cancer, 101(12), 1978-1985. doi: 10.1038/sj.bjc.6605441
Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P., & Kroemer, G. (2006). Targeting
NF-kappaB in hematologic malignancies. Cell Death Differ, 13(5), 748-758. doi:
10.1038/sj.cdd.4401874

44

Buchanan, F. G., Wang, D., Bargiacchi, F., & DuBois, R. N. (2003). Prostaglandin E2 regulates
cell migration via the intracellular activation of the epidermal growth factor receptor. J
Biol Chem, 278(37), 35451-35457. doi: 10.1074/jbc.M302474200
Calder, P. C. (2009). Polyunsaturated fatty acids and inflammatory processes: New twists in an
old tale. Biochimie, 91(6), 791-795. doi: 10.1016/j.biochi.2009.01.008
Cathcart, M. C., Lysaght, J., & Pidgeon, G. P. (2011). Eicosanoid signalling pathways in the
development and progression of colorectal cancer: novel approaches for
prevention/intervention. Cancer Metastasis Rev, 30(3-4), 363-385. doi: 10.1007/s10555011-9324-x
Cha, M. C., Meckling, K. A., & Stewart, C. (2002). Dietary docosahexaenoic acid levels
influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr
Cancer, 44(2), 176-181. doi: 10.1207/s15327914nc4402_09
Chan, A. T., Ogino, S., & Fuchs, C. S. (2007). Aspirin and the risk of colorectal cancer in
relation to the expression of COX-2. N Engl J Med, 356(21), 2131-2142. doi:
10.1056/NEJMoa067208
Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell, 118(6), 671-674. doi:
10.1016/j.cell.2004.09.005
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., . . . Montserrat, E.
(2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations
in chronic lymphocytic leukemia. N Engl J Med, 348(18), 1764-1775. doi:
10.1056/NEJMoa023143

45

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., . . . Chiorazzi, N. (1999).
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic
lymphocytic leukemia. Blood, 94(6), 1840-1847.
Darnell, J. E., Jr. (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer,
2(10), 740-749. doi: 10.1038/nrc906
Das, U. N., & Madhavi, N. (2011). Effect of polyunsaturated fatty acids on drug-sensitive and
resistant tumor cells in vitro. Lipids Health Dis, 10, 159. doi: 10.1186/1476-511X-10-159
1476-511X-10-159 [pii]
Das, U. N., Madhavi, N., Sravan Kumar, G., Padma, M., & Sangeetha, P. (1998). Can tumour
cell drug resistance be reversed by essential fatty acids and their metabolites?
Prostaglandins Leukot Essent Fatty Acids, 58(1), 39-54.
Dekoj, T., Lee, S., Desai, S., Trevino, J., Babcock, T. A., Helton, W. S., & Espat, N. J. (2007).
G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. J
Surg Res, 139(1), 106-112. doi: S0022-4804(06)00559-2 [pii]
10.1016/j.jss.2006.10.024
Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A. M., Capelli, G., . . .
Amadori, S. (2001). Clinical significance of CD38 expression in chronic lymphocytic
leukemia. Blood, 98(9), 2633-2639.
Ditsworth, D., & Zong, W. X. (2004). NF-kappaB: key mediator of inflammation-associated
cancer. Cancer Biol Ther, 3(12), 1214-1216.
Dreger, P. (2009). Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc
Hematol Educ Program, 602-609. doi: 10.1182/asheducation-2009.1.602

46

Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E., & Hallek, M. (2011). Chronic
lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol, 22 Suppl 6, vi50-54. doi: 10.1093/annonc/mdr377
Gaidano, G., Foa, R., & Dalla-Favera, R. (2012). Molecular pathogenesis of chronic lymphocytic
leukemia. J Clin Invest, 122(10), 3432-3438. doi: 10.1172/JCI64101
64101 [pii]
Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., . . . Darabi,
M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral
neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer, 12, 355.
doi: 10.1186/1471-2407-12-355
Gilmore, T. D. (1999). Multiple mutations contribute to the oncogenicity of the retroviral
oncoprotein v-Rel. Oncogene, 18(49), 6925-6937. doi: 10.1038/sj.onc.1203222
Greenberg, M. E., Li, X. M., Gugiu, B. G., Gu, X., Qin, J., Salomon, R. G., & Hazen, S. L.
(2008). The lipid whisker model of the structure of oxidized cell membranes. J Biol
Chem, 283(4), 2385-2396. doi: 10.1074/jbc.M707348200
Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., &
Kaidi, A. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and
adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377-386. doi:
10.1093/carcin/bgp014
Guffy, M. M., North, J. A., & Burns, C. P. (1984). Effect of cellular fatty acid alteration on
adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res, 44(5), 18631866.

47

Guo, D. L., Zhou, H., Wu, Y., Zhou, F., Zhang, X. M., Xu, G. Y., & Wen, H. P. (2011). [Role of
NF-kappaB in factor VIIa-induced proliferation and migration of colon cancer cell line
SW620 cells]. Zhonghua Zhong Liu Za Zhi, 33(9), 649-653.
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S., Jr. (1999). NFkappaB controls cell growth and differentiation through transcriptional regulation of
cyclin D1. Mol Cell Biol, 19(8), 5785-5799.
Haeggstrom, J. Z., Rinaldo-Matthis, A., Wheelock, C. E., & Wetterholm, A. (2010). Advances in
eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun,
396(1), 135-139. doi: 10.1016/j.bbrc.2010.03.140
Hagemann, T., Biswas, S. K., Lawrence, T., Sica, A., & Lewis, C. E. (2009). Regulation of
macrophage function in tumors: the multifaceted role of NF-kappaB. Blood, 113(14),
3139-3146. doi: 10.1182/blood-2008-12-172825
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999). Unmutated Ig
V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood, 94(6), 1848-1854.
Hardman, W. E., Avula, C. P., Fernandes, G., & Cameron, I. L. (2001). Three percent dietary
fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast
cancer xenografts. Clin Cancer Res, 7(7), 2041-2049.
Hayden, M. S., & Ghosh, S. (2012). NF-kappaB, the first quarter-century: remarkable progress
and outstanding questions. Genes Dev, 26(3), 203-234. doi: 10.1101/gad.183434.111
Heller, A. R., Rossel, T., Gottschlich, B., Tiebel, O., Menschikowski, M., Litz, R. J., . . . Koch,
T. (2004). Omega-3 fatty acids improve liver and pancreas function in postoperative
cancer patients. Int J Cancer, 111(4), 611-616. doi: 10.1002/ijc.20291

48

Hewamana, S., Alghazal, S., Lin, T. T., Clement, M., Jenkins, C., Guzman, M. L., . . . Pepper, C.
(2008). The NF-kappaB subunit Rel A is associated with in vitro survival and clinical
disease progression in chronic lymphocytic leukemia and represents a promising
therapeutic target. Blood, 111(9), 4681-4689. doi: 10.1182/blood-2007-11-125278
Hewamana, S., Lin, T. T., Jenkins, C., Burnett, A. K., Jordan, C. T., Fegan, C., . . . Pepper, C.
(2008). The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic
subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Clin Cancer Res, 14(24), 8102-8111. doi: 10.1158/1078-0432.ccr-08-1673
Hewamana, S., Lin, T. T., Rowntree, C., Karunanithi, K., Pratt, G., Hills, R., . . . Pepper, C.
(2009). Rel a is an independent biomarker of clinical outcome in chronic lymphocytic
leukemia. J Clin Oncol, 27(5), 763-769. doi: 10.1200/jco.2008.19.1114
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M. (1999). NFkappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-Sphase transition. Mol Cell Biol, 19(4), 2690-2698.
Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D., & Fidler, I. J. (2000). Blockade of
nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human
ovarian cancer cells by suppressing expression of vascular endothelial growth factor and
interleukin 8. Cancer Res, 60(19), 5334-5339.
Hyde, C. A., & Missailidis, S. (2009). Inhibition of arachidonic acid metabolism and its
implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol, 9(6),
701-715. doi: 10.1016/j.intimp.2009.02.003
Karin, M., Cao, Y., Greten, F. R., & Li, Z. W. (2002). NF-kappaB in cancer: from innocent
bystander to major culprit. Nat Rev Cancer, 2(4), 301-310. doi: 10.1038/nrc780

49

Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nat Immunol, 3(3),
221-227. doi: 10.1038/ni0302-221
Kim, H., Choi, J. A., Park, G. S., & Kim, J. H. (2012). BLT2 up-regulates interleukin-8
production and promotes the invasiveness of breast cancer cells. PLoS One, 7(11),
e49186. doi: 10.1371/journal.pone.0049186
Krysan, K., Dohadwala, M., Luo, J., Lin, Y., Zhu, L., Heuze-Vourc'h, N., . . . Dubinett, S.
(2004). Cyclooxygenase-2-dependent expression of survivin in non-small cell lung
cancer. Chest, 125(5 Suppl), 140S.
Lanasa, M. C. (2010). Novel insights into the biology of CLL. Hematology Am Soc Hematol
Educ Program, 2010, 70-76. doi: 10.1182/asheducation-2010.1.70
Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb
Perspect Biol, 1(6), a001651. doi: 10.1101/cshperspect.a001651
Lee, L. M., Pan, C. C., Cheng, C. J., Chi, C. W., & Liu, T. Y. (2001). Expression of
cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Anticancer Res, 21(2B), 1291-1294.
Lekovic, D., Mihaljevic, B., Kraguljac-Kurtovic, N., Peruncic-Jovanovic, M., Bogdanovic, A.,
Colovic, M., & Gotic, M. (2011). [Prognostic significance of new biological markers in
chronic lymphocytic leukaemia]. Srp Arh Celok Lek, 139(11-12), 753-758.
Li, F., & Sethi, G. (2010). Targeting transcription factor NF-kappaB to overcome
chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta, 1805(2),
167-180. doi: 10.1016/j.bbcan.2010.01.002
Li, J., Lau, G., Chen, L., Yuan, Y. F., Huang, J., Luk, J. M., . . . Guan, X. Y. (2012). Interleukin
23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix

50

metalloproteinase 9 expression. PLoS One, 7(9), e46264. doi:
10.1371/journal.pone.0046264
Linet, M. S., Schubauer-Berigan, M. K., Weisenburger, D. D., Richardson, D. B., Landgren, O.,
Blair, A., . . . Dores, G. M. (2007). Chronic lymphocytic leukaemia: an overview of
aetiology in light of recent developments in classification and pathogenesis. Br J
Haematol, 139(5), 672-686. doi: 10.1111/j.1365-2141.2007.06847.x
Liou, Y. A., King, D. J., Zibrik, D., & Innis, S. M. (2007). Decreasing linoleic acid with constant
alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma
phospholipids in healthy men. J Nutr, 137(4), 945-952.
Luo, P., & Wang, M. H. (2011). Eicosanoids, beta-cell function, and diabetes. Prostaglandins
Other Lipid Mediat, 95(1-4), 1-10. doi: 10.1016/j.prostaglandins.2011.06.001
Messmer, B. T., Messmer, D., Allen, S. L., Kolitz, J. E., Kudalkar, P., Cesar, D., . . . Chiorazzi,
N. (2005). In vivo measurements document the dynamic cellular kinetics of chronic
lymphocytic leukemia B cells. J Clin Invest, 115(3), 755-764. doi: 10.1172/jci23409
Montserrat, E., Sanchez-Bisono, J., Vinolas, N., & Rozman, C. (1986). Lymphocyte doubling
time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J
Haematol, 62(3), 567-575.
Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., Reiman, T., & Mazurak, V. C.
(2011a). Nutritional intervention with fish oil provides a benefit over standard of care for
weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving
chemotherapy. Cancer, 117(8), 1775-1782. doi: 10.1002/cncr.25709
Murphy, R. A., Mourtzakis, M., Chu, Q. S., Baracos, V. E., Reiman, T., & Mazurak, V. C.
(2011b). Supplementation with fish oil increases first-line chemotherapy efficacy in

51

patients with advanced nonsmall cell lung cancer. Cancer, 117(16), 3774-3780. doi:
10.1002/cncr.25933
Niki, E. (2009). Lipid peroxidation: physiological levels and dual biological effects. Free Radic
Biol Med, 47(5), 469-484. doi: 10.1016/j.freeradbiomed.2009.05.032
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002).
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon
cancer growth and gastrointestinal hypertrophy. Nat Med, 8(3), 289-293. doi:
10.1038/nm0302-289
Parthasarathy, S., Santanam, N., Ramachandran, S., & Meilhac, O. (2000). Potential role of
oxidized lipids and lipoproteins in antioxidant defense. Free Radic Res, 33(3), 197-215.
Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P., & Stanton, C. (2012). Health implications
of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab, 2012, 539426. doi:
10.1155/2012/539426
Pepper, C., Mahdi, J. G., Buggins, A. G., Hewamana, S., Walsby, E., Mahdi, E., . . . Fegan, C.
(2011). Two novel aspirin analogues show selective cytotoxicity in primary chronic
lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.
Cell Prolif, 44(4), 380-390. doi: 10.1111/j.1365-2184.2011.00760.x
Petersen, E. S., Kelley, E. E., Modest, E. J., & Burns, C. P. (1992). Membrane lipid modification
and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res,
52(22), 6263-6269.
Qin, J., Wang, Y., Bai, Y., Yang, K., Mao, Q., Lin, Y., . . . Xie, L. (2012). Epigallocatechin-3gallate inhibits bladder cancer cell invasion via suppression of NF-kappaBmediated

52

matrix metalloproteinase-9 expression. Mol Med Rep, 6(5), 1040-1044. doi:
10.3892/mmr.2012.1054
Rai, K. R., & Jain, P. (2011). Advances in the clinical staging of chronic lymphocytic leukemia.
Clin Chem, 57(12), 1771-1772. doi: 10.1373/clinchem.2010.159004
Reader, J., Holt, D., & Fulton, A. (2011). Prostaglandin E2 EP receptors as therapeutic targets in
breast cancer. Cancer Metastasis Rev, 30(3-4), 449-463. doi: 10.1007/s10555-011-93032
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arterioscler Thromb
Vasc Biol, 31(5), 986-1000. doi: 10.1161/atvbaha.110.207449
Riches, J. C., Ramsay, A. G., & Gribben, J. G. (2011). Chronic lymphocytic leukemia: an update
on biology and treatment. Curr Oncol Rep, 13(5), 379-385. doi: 10.1007/s11912-0110188-6
Rodriguez-Vicente, A. E., Diaz, M. G., & Hernandez-Rivas, J. M. (2013). Chronic lymphocytic
leukemia: a clinical and molecular heterogenous disease. Cancer Genet, 206(3), 49-62.
doi: 10.1016/j.cancergen.2013.01.003
Ryan, E. P., Pollock, S. J., Kaur, K., Felgar, R. E., Bernstein, S. H., Chiorazzi, N., & Phipps, R.
P. (2006). Constitutive and activation-inducible cyclooxygenase-2 expression enhances
survival of chronic lymphocytic leukemia B cells. Clin Immunol, 120(1), 76-90. doi:
10.1016/j.clim.2005.12.012
Schmitz, G., & Ecker, J. (2008). The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res,
47(2), 147-155. doi: 10.1016/j.plipres.2007.12.004
Secchiero, P., Barbarotto, E., Gonelli, A., Tiribelli, M., Zerbinati, C., Celeghini, C., . . . Zauli, G.
(2005). Potential pathogenetic implications of cyclooxygenase-2 overexpression in B

53

chronic lymphoid leukemia cells. Am J Pathol, 167(6), 1599-1607. doi: 10.1016/s00029440(10)61244-8
Serhan, C. N., & Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution.
Chem Rev, 111(10), 5922-5943. doi: 10.1021/cr100396c
Shanafelt, T. D., & Call, T. G. (2004). Current approach to diagnosis and management of chronic
lymphocytic leukemia. Mayo Clin Proc, 79(3), 388-398. doi: 10.4065/79.3.388
Silber, R., Degar, B., Costin, D., Newcomb, E. W., Mani, M., Rosenberg, C. R., . . . Potmesil, M.
(1994). Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic
leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood, 84(10), 34403446.
Simopoulos, A. P. (1991). Omega-3 fatty acids in health and disease and in growth and
development. Am J Clin Nutr, 54(3), 438-463.
Simopoulos, A. P. (2000). Human requirement for N-3 polyunsaturated fatty acids. Poult Sci,
79(7), 961-970.
Simopoulos, A. P. (2002). The importance of the ratio of omega-6/omega-3 essential fatty acids.
Biomed Pharmacother, 56(8), 365-379.
Simopoulos, A. P. (2008). The importance of the omega-6/omega-3 fatty acid ratio in
cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood), 233(6),
674-688. doi: 10.3181/0711-mr-311
Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res, 21(1), 71-85. doi:
10.1038/cr.2010.177
Tanaka, T., Nakayama, H., Yoshitake, Y., Irie, A., Nagata, M., Kawahara, K., . . . Shinohara, M.
(2012). Selective inhibition of nuclear factor-kappaB by nuclear factor-kappaB essential

54

modulator-binding domain peptide suppresses the metastasis of highly metastatic oral
squamous cell carcinoma. Cancer Sci, 103(3), 455-463. doi: 10.1111/j.13497006.2011.02174.x
Tang, D. W., Lin, S. C., Chang, K. W., Chi, C. W., Chang, C. S., & Liu, T. Y. (2003). Elevated
expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for
COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med,
32(9), 522-529.
Tang, X., Liu, D., Shishodia, S., Ozburn, N., Behrens, C., Lee, J. J., . . . Wistuba, II. (2006).
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and
preneoplastic lesions. Cancer, 107(11), 2637-2646. doi: 10.1002/cncr.22315
van der Meij, B. S., Langius, J. A., Spreeuwenberg, M. D., Slootmaker, S. M., Paul, M. A., Smit,
E. F., & van Leeuwen, P. A. (2012). Oral nutritional supplements containing n-3
polyunsaturated fatty acids affect quality of life and functional status in lung cancer
patients during multimodality treatment: an RCT. Eur J Clin Nutr, 66(3), 399-404. doi:
10.1038/ejcn.2011.214
Wang, C. Y., Cusack, J. C., Jr., Liu, R., & Baldwin, A. S., Jr. (1999). Control of inducible
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition
of NF-kappaB. Nat Med, 5(4), 412-417. doi: 10.1038/7410
Wang, C. Y., Mayo, M. W., & Baldwin, A. S., Jr. (1996). TNF- and cancer therapy-induced
apoptosis: potentiation by inhibition of NF-kappaB. Science, 274(5288), 784-787.
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nat Rev Cancer, 10(3), 181-193.
doi: 10.1038/nrc2809

55

Wiestner, A., Rosenwald, A., Barry, T. S., Wright, G., Davis, R. E., Henrickson, S. E., . . .
Staudt, L. M. (2003). ZAP-70 expression identifies a chronic lymphocytic leukemia
subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct
gene expression profile. Blood, 101(12), 4944-4951. doi: 10.1182/blood-2002-10-3306
Zhang, D., Jin, X., Wang, F., Wang, S., Deng, C., Gao, Z., & Guo, C. (2007). Combined
prognostic value of both RelA and IkappaB-alpha expression in human non-small cell
lung cancer. Ann Surg Oncol, 14(12), 3581-3592. doi: 10.1245/s10434-007-9560-z
Zmijewski, J. W., Landar, A., Watanabe, N., Dickinson, D. A., Noguchi, N., & Darley-Usmar,
V. M. (2005). Cell signalling by oxidized lipids and the role of reactive oxygen species in
the endothelium. Biochem Soc Trans, 33(Pt 6), 1385-1389. doi: 10.1042/bst20051385

56

CHAPTER 2: INHIBITION OF NUCLEAR FACTOR
KAPPA B ACTIVATION IN EARLY-STAGE CHRONIC
LYMPHOCYTIC LEUKEMIA BY OMEGA-3 FATTY
ACIDS
The information in this chapter has been published in Cancer Investigations (2013) 31:24-38.
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ABSTRACT
Targeting the nuclear factor kappa B (NF B) pathway is proposed as a therapy for
chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3)
supplement would suppress NF B activation in lymphocytes of Rai Stage 0-1 CLL patients. The
initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: (1)
plasma n-3 increased; (2) NF B activation was suppressed in lymphocytes; (3) in vitro
sensitivity of lymphocytes to doxorubicin was increased; and (4) expression of 32 genes in
lymphocytes was significantly decreased.
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INTRODUCTION
Chronic lymphocytic leukemia is a B-cell leukemia. During the early stages (Rai Stage 01) of CLL patients, no therapy is required (Robak, 2007). However, about 50% of these patients
will progress to more advanced stages (Shanafelt & Call, 2004). Progression to later stages (Rai
Stage 2-4) disease is associated with shortened survival and the need for chemotherapy
(Shanafelt & Call, 2004). Therefore, early identification of progression potential and a
therapeutic intervention that could prevent or delay disease progression without undesirable side
effects would be clinically beneficial.
Nuclear factor kappa B (NF B) belongs to a family of transcription factors that plays a
key role in inflammatory and stress responses as well as in tumor cell resistance to apoptosis
(Balkwill & Coussens, 2004; Darnell, 2002). Several studies suggest that NF B family members
are involved in cancer development (Clevers, 2004; Munzert et al., 2002). NF B can promote
oncogenesis by virtue of its capacity to regulate the expression of a large number of genes that
modulate apoptosis, proliferation, inflammation, tumor metastasis and angiogenesis (Clevers,
2004). Increased, constitutive activity of NF B is observed in various solid tumors and in
hematological malignancies (Cilloni, Martinelli, Messa, Baccarani, & Saglio, 2007; Darnell,
2002; Ditsworth & Zong, 2004).
There is increasing evidence that NF B may play a key role in controlling apoptosis and
disease progression in hematologic malignancies (Cilloni et al., 2007). Previous studies have
demonstrated that CLL cells have elevated NF B DNA-binding activity compared to normal B
cells (Braun et al., 2006; Endo et al., 2007) and that inhibition of NF B activation in vitro
resulted in apoptosis of the malignant cells (Braun et al., 2006; Endo et al., 2007). NF B is
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currently considered an important target for the development of novel drugs for the treatment of
hematological malignancies, especially CLL, and of solid tumors (Braun et al., 2006; Cilloni et
al., 2007; Cilloni et al., 2006; Darnell, 2002; Hewamana et al., 2008; Hewamana et al., 2009).
Omega-3 and omega-6 polyunsaturated fatty acids are essential fatty acids which must be
obtained from diet. The ratio of omega-3 to omega-6 in the average western diet is heavily
weighted in favor of omega-6 (Simopoulos, 2000, 2002). Long chain omega-3 fatty acids
(eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) are primarily found in fish oils
(Simopoulos, 1991). However, the 18 carbon n-3 FA, alpha linolenic acid (ALA), is also found
in plant derived foods, especially canola or flax oil and walnuts. Omega-3 fatty acids have
consistently been shown in vitro and in vivo to slow growth of cancer of various types and to
increase the efficacy of chemotherapy (Bougnoux et al., 1999; Hardman, 2002). The omega-6
fatty acid, linoleic acid (LA), is found in corn and soybean oils. The elongated, desaturated
product of LA, arachidonic acid (AA), is found in the meat of animals that consumed corn or
soybeans and can be synthesized by humans. Growing evidence supports the notion that AA and
its metabolites have a significant role in tumor promotion (Hyde & Missailidis, 2009).
Our preliminary work and that of others (Narayanan, Narayanan, & Reddy, 2005; Ross,
Maingay, Fearon, Sangster, & Powell, 2003) indicates that supplementation with omega-3 fatty
acids (n-3) inhibits NF B activity of many cancer types in vitro and in mouse models. We did
not know if this inhibitory effect would translate to humans. The primary objective of this study
was to determine if consumption of an n-3 supplement would suppress the activation of NF B in
the lymphocytes of patients with early stage (Rai Stage 0-1) CLL. We hypothesized that dietary
omega-3 supplementation would decrease the activation of NF B in malignant lymphocytes
from patients with CLL in early stages. In this pilot study, we assayed NF B activity in
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lymphocytes from patients with early stage (Rai Stage 0-1) CLL before and after up to 12
months of oral omega-3 supplementation. Secondary objectives were to evaluate the effects of n3 supplementation on 1) fatty acid composition of lymphocytes, 2) concentration of fatty acids in
the plasma before and after consumption of n-3, 3) the in vitro sensitivity of the patients‟
lymphocytes to doxorubicin and 4) changes in lymphocyte gene expression.
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METHODS
IRB and informed consent
The Marshall University Institutional Review Board reviewed and approved the protocol
for this study under a Federal Wide Assurance (FWA #00002704) with the Office of Human
Research Protections. The trial was listed at www.clinicaltrials.gov/, number NCT00899353.
The purpose of the study and possible risks and benefits were explained prior to obtaining signed
informed consent from all research participants. Whenever possible, specimens were obtained at
the same time as blood was being obtained for routine clinical tests.

Subject Population
Subjects participating in this pilot study had been diagnosed with chronic lymphocytic
leukemia in the early stages (Rai stage 0-1) at the time of entry according to standard clinical
practice, and did not require therapy. General eligibilities were that participants had to be older
than 18 years of age with no maximum age limit, free of co-morbid conditions with a life
expectancy of more than 12 months, patients who have taken omega-3 or other fish oil
containing nutritional supplements prior to study accrual, discontinued their use for minimum of
2 months before enrollment, and patients should have an ECOG (Eastern Cooperative Oncology
Group) performance score of 0, 1 or 2.
After obtaining informed consent, two 7 ml tubes of Ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood were obtained (time 0) as a baseline and at each subsequent
monthly visit. One month after the initial specimen, each patient started n-3 consumption with a
dose of 3 capsules (2.4g of n-3) per day (1 capsule/meal). Dosage was increased to 6 capsules
(4.8g of n-3) and then to 9 capsules (7.2g of n-3) per day (up to 3/meal) at monthly intervals A
schematic of dosing scheme is provided in Appendix, Supplementary Figure 2.1). If a patient did
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not want to consume the increased dosages, he/she was allowed to continue in the study at a
lower dose. Results of fatty acid composition in lymphocytes and plasma, NF B activity,
doxorubicin sensitivity, and mRNA expression of the lymphocytes up to consumption of 7.2 g
per day for three months are reported. No placebo was used, rather after-consumption data were
compared to baseline data.

Normal participants
Five normal healthy volunteers were recruited. These volunteers did not receive omega-3
supplementation and served to establish normal values for NF B activation in lymphocytes.

Description of omega 3 supplement
The supplement was a commercially available (Res-Q 1250, N3 Oceanic, Palm, PA) fish
oil concentrate prepared by molecular distillation. It was free from pollutants, PCB‟s, pesticides
and mercury. Each capsule contained about 400mg of EPA, 300mg of DHA and 100-150 mg of
other omega 3 fatty acids. Thus, consumption of 3, 6, or 9 capsules/day yielded 2.4 g, 4.8 g, or
7.2 g/day of n-3, respectively. These amounts are all below the maximum tolerated dose of 13.1
g/day EPA + DHA reported by Burns et al. (Burns et al., 1999). Potential dose limiting events
were diarrhea, stomach upset or dislike of taking the capsules.

Platelet function
Tests of platelet function were performed in the clinical laboratory at Cabell Huntington
Hospital. For these tests, anticoagulated fresh, whole blood is rapidly passed through a small
hole in a membrane coated with either collagen and adenosine diphosphate (ADP)
(Collagen/ADP) or collagen and epinephrine (Collagen/EPI). Platelets adhere to and gradually
block the small hole in the center of each membrane. The time, in seconds, for blood to close the
hole is the Closure Time (CT).
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Molecular Testing
Tests for cytogenetic alterations were performed using standard tests (culture and
banding) at Cabell Huntington Hospital. Interphase fluorescence in situ hybridization (FISH) was
performed using a multiprobe panel (Vysis, Abbot Molecular, Abbott Park, IL, USA.) targeting
five prognosis related CLL anomalies according to routine techniques at the Laboratory
Corporation of America.

Lymphocyte Isolation
EDTA anticoagulated blood specimens (7 ml x 2) were placed on ice until retrieved by
research laboratory personnel (within 2 hours of collection). The sample was centrifuged at 400
x g for 10 minutes and about 2 ml of plasma was removed, divided to 0.5 ml aliquots and stored
at -80°C for future assay. The buffy coat, some plasma and adjacent red blood cells were
removed. A Ficoll-Paque (GE Healthcare, Piscataway, NJ) gradient was used to isolate
lymphocytes, according to manufacturer‟s protocol. Following Ficoll-Paque separation, greater
than 95% of cells were lymphocytes (Silber et al., 1994). Since there was not 100% lymphocyte
isolation, samples were referred to as WBCs. WBCs were washed twice with a glucose
containing balanced salt solution, counted and divided into appropriate aliquots for NF B
activity assay, doxorubicin sensitivity, mRNA assay and for gas chromatography analysis.

White and red blood cell fatty acid composition
The fatty acid compositions of WBCs or RBCs were assessed using gas chromatography
of samples collected prior to initiation of the omega 3 supplement (baseline, time 0) and after
consumption of each dose of the supplement for 1 month. The assay was performed as
previously published (Witte, Salazar, Ballester, & Hardman, 2010).
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Plasma Fatty Acid Concentrations
The concentrations of 10 analyzed fatty acids in plasma were assessed using gas
chromatography, according to our routine techniques, prior to initiation of the omega-3
supplement (baseline, time 0) and after consumption of each dose of the supplement for 1 month.
Two hundred forty microliters to 400 µL of plasma was added to distilled water with 0.1% BHT
for a final volume of 700 µL to prevent fatty acid oxidation. One hundred microliters of 1mM
nervonic acid was added to each sample. Nervonic acid served as the internal standard as
previously published (Shantha & Ackman, 1990). Lipids were extracted with
chloroform/methanol, then methylated. Methylated lipids were separated and identified using gas
chromatography as previously published (Witte et al., 2010). Fatty acid methyl ester standards
(Nu-Chek-Prep, Elysian, MN) were used for peak identification. Respective fatty acids were
corrected for FID response and carbon response as previously described by others (Huang Yieru,
1990; William, 1989) and initial plasma volume used (see Equation 1). We were especially
interested in total omega 6 fatty acids, LA, gamma linolenic acid (GLA), 20:3n-6, and AA, and
total omega-3 fatty acids, ALA, EPA, docosapentaenoic acid (DPA) and DHA.

Equation 1: [Fatty Acid]
[Fatty Acid] = AUC of fatty acid x [Nervonic acid] x FID Response Factor x Carbon Response Factor x Final Volume of Fatty Acid
AUC of Nervonic Acid
Initial Volume of Fatty Acid

Protein extraction
Protein extraction from lymphocytes was performed using Thermo Scientific Mammalian
Protein Extraction Reagent (M-PER) according to manufacturer‟s protocol. Total protein
concentration was determined using Pierce Coomassie (Bradford) Protein Assay Kit protocol.
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A standard curve was used to determine the protein concentration of each unknown
sample.

NF B Activity Assay
NF B activities in patient specimens, positive and negative controls were evaluated using
a Thermo Scientific Transcription Factor kit for NF B p50, according to manufacturer‟s
protocol. The kit contains streptavidin-coated 96-well plates and an NF B biotinylatedconsensus sequence. Only the active form of NF B will bind to the DNA consensus sequence.
Protein extracts containing 1-15µg of protein/well were added in triplicates to appropriate
microplate wells. Luminescence resulting from a reaction with bound NF B was detected using
a Berthold Centro LB960 Luminometer and analyzed with MikroWin 2000 ver. 1.08. NF B
activity was normalized by luminescence units/µg of protein per well.

Doxorubicin sensitivity assay
About 5 x 105 lymphocytes were diluted into 500 µl of RPMI/15% fetal bovine serum,
100 units/mL penicillin, and 0.1 mg/mL streptomycin media. Cells were aliquoted in triplicates
in microtubes and treated with 0, 0.5, 1, 1.5, 2, or 2.5 µM doxorubicin (DOX) for 20 hours at
37°C. Lymphocytes were centrifuged at 600 x g for 10 minutes then DOX/media was removed.
A standard colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay was used to determine remaining live cells compared to the untreated sample. MTT is a
yellow tetrazolium dye that is reduced to a purple formazan dye in living cells by reductase
enzymes. The relative number of viable cells can be assessed by spectrophotometric
measurement of formazan production relative to control specimens.
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mRNA extraction, microarray and statistical analyses
Expression profiling was performed on mRNA from 5 patients characterized with higher
initial NF B activity and 4 patients with lower initial NF B activity. Remaining patients were
not assayed due to limited samples or to insufficient n-3 consumption time points.
About 1 million WBCs from each patient were homogenized in Tri-Reagent LS (Sigma)
following the manufacturer‟s protocol to isolate mRNA. RNA concentration and purity was
determined using a Nanodrop ND-1000 spectrophotometer. Total RNA quality was determined
using an Agilent BioAnalyzer (Agilent, Santa Clara, CA). All samples had RNA Integrity
Numbers higher than 7.
RNA expression profiles were obtained using a universal reference microarray design.
Total RNA, 250 ng, was labeled using QuickAmp labeling kit (Agilent) and Cy3-CTP and Cy5CTP from Perkin Elmer (Waltham, MA) according to previously described methods (Syed &
Threadgill, 2006). The RNA samples isolated from patient‟s peripheral blood were labeled using
Cy3-CTP and the universal human reference RNA was labeled with Cy5-CTP. Following
purification of labeled cRNA, 825 ng of Cy3- and Cy5-labeled samples were combined and
hybridized for 17 hours at 65oC onto Whole Human Genome 4x44k microarrays (Agilent).
Arrays were scanned and lowest-normalized data extracted to tab-delimited text files using
Agilent Feature Extraction software (version 10.5.1.1).
The log ratio of expression of the sample to that of universal reference RNA was
computed, with values removed for control spots, spots identified as not well above background
on both channels, and spots identified as non-uniform or saturated on either channel. Values
from all arrays were compiled into a single table. Spots for which more than 50% of the samples
had missing values were removed from further analysis. The Agilent array platform contains a
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number of probes that are spotted multiple times on the array; for these probes the average across
replicate spots was computed. Missing values were then imputed using the K nearest neighbor
algorithm as implemented by the R/Bioconductor (www.r-project.org, www.bioconductor.org)
impute.knn function in the "impute" package. A two-class Significance Analysis of Microarrays
(Tusher, Tibshirani, & Chu, 2001), using the SAM function in the R/Bioconductor package
"siggenes", was performed between the baseline mRNA expressions and the mRNA expressions
after consumption of highest amount of omega-3 on: 1) samples with higher initial NF B
activity (patients 1 to 5, n= 5 patients) or 2) with lower initial NF B activity (patients 6 to 9, n=
4 patients). A threshold delta value was chosen using the findDelta function from the same
package to give a false discovery rate of 10%. The resulting list of probes was filtered for a
minimum fold change of 1.5. For any genes represented by multiple probes in this list of
significantly differentially expressed genes, the maximum fold change among those probes was
reported. These analyses follow the method detailed in Tusher VG, et al. (Tusher et al., 2001).
Microarray data are available in MIAME-complaint form at the NCBI GEO repository,
accession number GSE29678.

Statistical Analysis, other data
SPSS (IBM SPSS Statistics) Version 14.0 was used for statistical analysis of other
numeric data by Multiple Comparison using Games-Howell Post-Hoc Test. Correlation
coefficients were calculated from least squares linear regression plots. Prism© software
(Graphpad, Inc., La Jolla, CA) was used for preparation of graphs.
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RESULTS
Subject characteristics
Fifteen CLL and 5 normal participants were recruited for this pilot study. All available
data from these patients is reported. Individual characteristics are indicated in Table 2.1.
Graphic display of NF B data seemed to indicate 2 populations of patients. Thus, patient
characteristics were analyzed on the basis of subjects which fell below the median NF B
activation (< 21.4 x 105 NF B luminescence units/µg of protein) or above the median NF B
activation ( > 21.4 x 105 NF B luminescence units/µg of protein ). Subject characteristics, with
subjects divided into higher and lower initial NF B activation groups are shown in Table 2.2.
There were no significant differences in mean age or gender of the groups. Data indicated that
the „lower initial activation‟ patients had significantly lower absolute lymphocyte counts (Mean
± SEM: 11.9 ± 3.2 x 103 lymphocytes/µl vs 28.8 ± 4.0 x 103 lymphocytes/µl; p: 0.009) and
tended to be at lower Rai stage (stage 0, 84% vs 58%, not statistically different by Fisher exact
test) than patients exhibiting „higher initial activation‟ of NF B at baseline.
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Table 2. 1. Individual Patient Characteristics
Patient

Age/Gender

RAI Stage
(0-1)

Duration of N3
Consumption
(Months)

Baseline
ALC
(103/µL)

ALC post n-3
consumption
(103/µL)

Fold
Change
in ALC

T(14;19)

Del.13q

Trisomy
12

Del. 17p

CD38

ß2M
(mg/L)

0

Time
From
Diagnosis
to N-3
Initiation
(Months)
16

1

63/M

12

25.4

41.3

1.62

-

-

+

-

-

1.7

2

70/F

0

8

12

30.5

52.1

1.71

+

-

-

-

-

1.4

3

64/F

0

39

12

15.2

11.9

0.78

-

+

-

-

Unknown

1.6

4

59/F

1

133a

12

26.3

25.2

0.96

-

+

-

-

-

2.1

5

58/M

1

2

5

20.7

27.3

1.32

-

Unknown

-

-

+

1.3

6

77/M

0

157

12

35.5

38.2

1.08

-

+

-

-

-

unknown

7

68/M

1

2

12

5.7

5.7

1.00

-

+

-

-

-

1.4

8

65/F

0

5

12

20.3

18.9

0.92

-

+

-

-

-

3.5

9

72/M

0

5

12

5.7

8.5

1.49

-

-

+

-

-

1.8

10

63/F

0

28

12

7.5

7.9

1.05

-

-

-

Unknown

-

1.9

11

72/F

0

35

12

8.5

9.9

1.16

-

-

-

-

-

1.8

12

62/F

Unknown

79

8

Unknown

2.5

N/A

-

Unknown

-

-

unknown

Unknown

13

63/M

1

61

8

48.1

49.7

1.03

-

-

-

-

-

1.5

14

82/F

0

11

5

7.9

9.6

1.22

-

-

-

-

-

2.4

15

73/M

0

14

1

23.6

Unknown

N/A

-

-

+

-

+

3.8

Table 2.1. Individual Patient Characteristics. Individual patient‟s age, gender, staging, time from diagnosis to n-3 initiation, duration of n-3 consumption,
absolute lymphocyte counts (ALC) before and after n-3 consumption, fold change in ALC as compared to baseline, cytogenetics and phenotype is shown.
Prognostics were done on samples at diagnosis of CLL. Tests for IGVH status were not performed at this institution. Prognosis - translocation between
chromosome 14 and chromosome 19 [ t(14;19)]; and deletion of long arm of chromosome 13 (Del.13q), are associated with good prognosis; trisomy 12 is
associated with intermediate prognosis; deletion of short arm of chromosome 17 (Del.17p), CD38 positive, and high levels of ß2-microglublin (ß2M mg/L) >
2 are associated with poor prognosis; a patient referral, exact time of diagnosis unknown.
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Table 2. 2. Patient Lymphocyte Count, Cytogenetics, Phenotype and NF B
Activity
Total Population

Patients (n)
Age
( Mean ± SEM )
Rai Stage (Stage 0/1)
Absolute Lymphocyte Count
(103/µl)
( Mean ± SEM )
# with T (14;19)
# with Del. 13q
# with Trisomy 12
# CD38 +/ß2M mg/L
( Mean± SEM )
NF B Activity
( Mean ± SEM )

Baseline
NF B
Activity >
Median
7
64.9 ± 2.5

Baseline NF B
Activity <
Median

4/3

5/1

20.07; 5.7 – 48.1
(median; range)
1
5
3

28.8 ± 4.0

11.9 ± 3.2

1
3
1

0
2
2

2/10
1.8; 1.3 - 3.8
(median; range)

1/5
1.60 ± 0.12

1/5
2.37 ± 0.41

21.4 x 105;
0.945 x 105 – 231 x 105
(median; range)

127. x 105
± 27.7 x 105

7.75 x 105
± 2.67 x 105

15
66; 63 - 82
(median; range)
11/4

6
69.2 ± 1.6

P-value

0.192

0.009

0.134

0.005

Table 2.2. Patient Characteristics and NF B Activity. Median and Range of patient‟s age, staging, median
and range of absolute lymphocyte counts, cytogenetics, phenotype and median and range of NF B activity for
all patients are shown. Mean ± SEM patient age, staging, mean ± SEM absolute lymphocyte count, cytogenetics,
phenotype and mean ± SEM NF B activity on the basis of whether patients fell above or below the median
initial NF B activity are shown. NF B values were done on entry into the study and after n-3 consumption.
NF B activity is presented in NF B luminescence units/µg protein. Subjects were divided into two groups based
on whether initial NF B activation fell below or above the median (21.4 x 105 NF B luminescence units/ µg
protein) NF B activation in lymphocytes from all but 2 patients. Three (3) patients were excluded as baseline
NF B Activity was not determined.
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Omega-3 fatty acid supplementation did not have detrimental effects on
platelet function
Consumption of omega 3 fatty acids is known to slightly slow blood clotting. To assess
the impact of omega 3 fatty acids on platelet function, standard clinical tests, collagen/ADP and
collagen/EPI (epinephrine), were performed at baseline and after 6 months of omega-3
consumption (dosage up to 7.2 g of n-3/day).
There was no difference between either collagen/ADP or collagen/EPI times at baseline
and after omega-3 consumption. Omega-3 consumption slightly increased collagen/EPI time but
this increase was neither statistically nor clinically significant and remained within normal
parameters (Appendix, Supplementary Figure 2.1).

Omega-3 consumption had minimal side effects
Known side effects associated with omega-3 consumption are diarrhea, nausea, fishy
odors, bloating and slowed blood coagulation. Side effects experienced by participants were
most commonly associated with mild diarrhea (grade 1 and 2, n=4 and 1, respectively) or nausea
(n=2). As a result of associated side effects, patients 3, 4, 8, 10 and 14 reduced intakes to 4.8,
2.4, 4.8, 2.4, and 4.8 g of n-3/day, respectively.

Omega-3 fatty acid fraction in RBCs and WBCs increased upon fish oil
consumption
The content of fatty acids in tissue membranes is generally indicative of consumption of
those fats and can be used as a measure of compliance with the supplement. There was a
statistically significant reduction of AA and there were significant increases in EPA, DPA, and
DHA in red blood cells following omega-3 consumption (data not shown, previously published

72

(Witte et al., 2010)). Differences in the levels of omega-6 and omega-3 fatty acids in white blood
cells showed a trend similar to that of red cells but were not mathematically significant.

Consumption of n-3 increased n-3 fatty acid content in plasma
Mean ± SEM baseline (prior to n-3 supplementation) plasma concentrations of 10 fatty
acids analyzed from 6 patients with early-stage CLL are shown in Table 2.3. Mean baseline
[µM] of analyzed fatty acids were in agreement with previously published results (Harper,
Edwards, DeFilippis, & Jacobson, 2006). Only 6 patients were analyzed as these were the only
patients who consumed all three proposed doses of n-3 (2.4g, 4.8g and 7.2 g of n-3/day).
Mean ± SEM fatty acid plasma concentrations of 10 fatty acids analyzed from 6 subjects
at baseline (0 g supplement), 2.4, 4.8, and 7.2 g of n-3 consumption per day and discontinued n-3
consumption (n=2) are shown in Figure 2.1 and Table 2.3. Graphs are provided for visual
comparison (Fig. 2.1) and Table 2.3 provides means ± SEM molar concentrations for use in
future comparisons.
Figure 2.1A shows the mean [µM] ± SEM of stearic acid (SA) and oleic acid (OA) with
increasing n-3 consumption and discontinued n-3 consumption. Plasma OA was significantly
decreased following consumption of 2.4 g of n-3 per day (p-value: 0.033 (Table 2.3)). No
differences were observed in SA during the course of n-3 consumption.
Figure 2.1B shows the mean [µM] ± SEM of n-6 fatty acids: LA, GLA, homogamma
linolenic acid (HLA) and AA following increasing doses of n-3 or discontinued consumption of
n-3. Compared to baseline, there were significant decreases in LA at 2.4 g, and GLA at 4.8 and
7.2 g of n-3 per day (p-value: 0.007, 0.037, and 0.03, respectively (Table 2.3)). Dose-responsive
reductions in AA were observed at 4.8 g and 7.2 g of n-3 per day (p-value: 0.045 and 0.005,
respectively) compared to baseline (Table 2.3).
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Figure 2.1C shows the mean [µM] ± SEM of n-3 fatty acids: ALA, EPA, DPA and DHA
following increasing doses of n-3 consumption and discontinued consumption of n-3. DPA was
significantly increased at 7.2 g of n-3 per day (p-value: 0.042) compared to baseline (Table 2.3).
There were dose-responsive increases in EPA and DHA at 2.4 g, 4.8 g and 7.2 g of n-3 per day
(p-value: all <0.001) compared to baseline (Table 2.3). Interestingly, significantly higher plasma
levels of DHA remained 3 months after discontinuation of n-3 consumption (p-value: <0.001)
compared to baseline (Table 2.3).
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Table 2. 3. Plasma Concentrations of 10 Fatty Acids Analyzed from Subjects Before and
Following N-3 Consumption.
Fatty acid

Baseline

Following

0 g of n-3
per day

2.4 g of

4.8 g of

n-3 per day

n-3 per day

n-3 per day

[µM] ± SEM

[µM] ± SEM

[µM] ± SEM]

[µM] ± SEM

SA

P-values

Following

P-values

7.2 g of

P-values

3 Months Off
supplement

Pvalues

0g of n-3 per
day
[µM] ± SEM

967.6 ± 55.10

717.0 ± 62.14

0.051

862.3 ± 55.35

0.666

819.6 ± 68.23

0.462

798.4 ± 35.85

0.138

3142.2 ±
203.36

2209.0 ± 205.72

*0.033

2491.4 ±
257.87

0.310

2358.8 ±
249.98

0.144

2690.4 ±
130.98

0.383

3411.7 ±
212.53

2359.3 ± 146.28

*0.007

2840.8 ±
163.76

0.252

2726.6 ±
177.10

0.137

3305.1 ±
329.59

0.998

64.4 ± 8.09

40.7 ± 4.39

0.129

34.9 ± 3.67

*0.037

32.8 ± 4.88

*0.030

45.0 ± 4.72

0.292

104.0 ± 22.51

52.4 ± 8.86

0.270

67.9 ± 11.44

0.620

76.8 ± 8.70

0.791

75.4 ± 2.72

0.719

139.2 ± 13.13

114.2 ± 13.77

0.685

110.0 ± 9.63

0.408

95.7 ± 11.43

0.131

154.8 ± 14.77

0.927

825.4 ± 53.24

649.4 ± 58.01

0.212

629.9 ± 32.37

*0.045

536.8 ± 47.71

*0.005

711.0 ± 56.19

0.600

79.1 ± 7.17

154.0 ± 11.04

*<0.001

302.5 ± 14.95

*<0.001

352.0 ± 15.98

*<0.001

91.4 ± 12.55

0.904

65.7 ± 7.17

69.0 ± 5.58

0.996

90.5 ± 5.72

0.093

93.3 ± 5.17

*0.042

71.4 ± 4.02

0.954

69.4 ± 9.41

138.3 ± 8.08

*<0.001

205.2 ± 13.34

*<0.001

202.2 ± 14.43

*<0.001

149.2 ± 6.54

*<0.001

b

(18:0)
OA

(18:1n-9)
LA
(18:2n-6)
GLA
(18:3n-6)
ALA
(18:3n-3)
HLA
(18:3n-6)
AA
(20:4n-6)
EPA
(20:5n-3)
DPA
(22:5n-3)
DHA
(22:6n-3)

Table 2.3. Plasma Concentrations of 10 Fatty Acids Analyzed from Subjects Before and Following N-3
Consumption.
Mean fatty acid plasma concentrations [µM] ± SEM over the course of n-3 supplementation (n=6) and
discontinued n-3 consumption (n=2) from subjects are shown. Omega-3 supplementation was compared against
baseline. Statistical significance was determined by Games-Howell Multiple Comparison Test. Abbreviations:
SA: Stearic Acid; OA: Oleic Acid; LA: Linoleic Acid; GLA: Gamma-Linolenic Acid; HLA: HomogammaLinolenic Acid; AA: Arachidonic Acid; ALA: Alpha-Linolenic Acid; EPA: Eicosapentaenoic Acid; DPA:
Docosapentaenoic Acid; DHA: Docosahexaenoic Acid.n-9: omega-9 fatty acid; n-6: omega-6 fatty acid; n-3:
omega-3 fatty acid.* indicates significance, α = 0.05. b A:B; A denotes carbon number, B denotes number of
unsaturations.
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Figure 2.1. Human Plasma Concentrations of 10 Fatty Acids Analyzed Before and Following N-3
Consumption.
Mean fatty acid plasma concentrations [µM] ± SEM from subjects over the course of n-3 supplementation (n=6)
and after discontinued n-3 consumption (n=2) are shown. Figure A illustrates mean [µM] ± SEM concentrations
of SA and OA with increasing n-3 doses and discontinued n-3 consumption. Figure B illustrates mean [µM] ±
SEM concentrations of omega 6 fatty acids LA, GLA, HLA and AA with increasing n-3 doses and discontinued
n-3 consumption. Figure C illustrates mean [µM] ± SEM concentrations of n-3 fatty acids ALA, EPA, DPA and
DHA with increasing n-3 doses and discontinued n-3 consumption. Statistical significance was determined by
Games-Howell Multiple Comparison Test. Abbreviations: SA: Stearic Acid; OA: Oleic Acid; LA: Linoleic
Acid; GLA: Gamma-Linolenic Acid; HLA: Homogamma-Linolenic Acid; AA: Arachidonic Acid; ALA: AlphaLinolenic Acid; EPA: Eicosapentaenoic Acid; DPA: Docosapentaenoic Acid; DHA: Docosahexaenoic
Acid.(A:Bn-9): A denotes carbon number, B denotes number of unsaturations; n-9: omega-9 fatty acid; n-6:
omega-6 fatty acid; n-3: omega-3 fatty acid. α= 0.05, * <0.05, ** <0.01
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Omega-3 consumption reduced NF B activation
Figure 2.2 shows the NF B activity ± SD of 15 early (Rai Stage 0-1) stage CLL patients
during omega-3 intervention and the mean of 5 healthy controls. In the 7 patients with higher
(greater than the median) baseline NF B activity (patients 1-6, 13), NF B activity was decreased
by the n-3 in a dose responsive manner. Furthermore, 7.2 g of n-3/day returned NF B activity to
levels comparable to that observed in control patients (mean ± SD: 87,138 ± 79,040 NF B
luminescence units/ µg protein). Lower (less than the median) initial activation of NF B activity
was observed in 6 patients (patients 7-10, 11, 15) at baseline and 7.2 g of n-3/day decreased
NF B activity to near normal levels. Patients 12 and 14 could not be categorized as either higher
initial NF B activity or lower initial NF B activity as baseline NF B activity was not
determined. NF B activity increased in patients 1, 2, 6 and 8 by three months after they
discontinued consumption of omega-3. It is interesting that 2.4 or 4.8 g of n-3 per day, taken for
long terms (patient 3, 4 and 10) decreased to or maintained NF B activity at a near normal level.
Figure 2.3A illustrates NF B activity (mean ± SEM) during n-3 consumption for all 15
patients. The greatest apparent decrease in NF B activity was following 7.2g of n-3 per day
compared to baseline NF B activity but across all patients this decrease was not quite significant
(p: 0.079).
Figure 2.3B illustrates mean NF B activity ± SEM during the course of n-3 consumption
for patients (# 1-6, 13, n=7) with higher (> median) initial NF B activity. Compared to baseline,
there were statistically significant decreases in NF B activity following consumption of 7.2g of
n-3/day (p: 0.027) and at 3 months after n-3 was discontinued (p: 0.040).
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Figure 2.3C illustrates mean NF B activity ± SEM during the course of n-3 for patients
(# 7-10, 11, 15, n=5) with lower initial NF B activity. There was no significant change in NF B
activity during consumption of n-3. This might be expected since these patients did not initially
have NF B activity significantly different from normal levels.
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Figure 2.2. Effects of Omega-3 Consumption on NF B Activity.
The NF B activities of 15 patients diagnosed with CLL (Rai stage 0-1) before and after consumption of omega3 and of 5 normal control patients (mean + SD) are shown. NF B activity was normalized to NF B
luminescence units/ µg protein. All Y-axis are the same as for the patient # 1. The X-axis shows the time each
sample was collected beginning with month 0. The number above each column indicates the amount of n-3
(grams) being consumed at each time point. All assays were performed in triplicate. Error bars that are not
visible are so small they are concealed by the top of the column.
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Figure 2.3. NF B Activity.
NF B Activity across time is shown. Games-Howell test was performed to determine statistical significance. (A)
Mean ± SEM NF B activity for all patients following n-3 consumption is shown. Across all patients, the
decrease in NF B activity following consumption of 7.2 g of n-3/day compared to baseline was not quite
significant (p: 0.079). (B) Mean ± SEM NF B activity for patients whose baseline NF B activity was above the
median (>2.14 X 106) and called “Higher activation” is shown. NF B activity was significantly less than
baseline after 7.2 g of n-3/day and after 3 months off supplement (p: 0.027 and 0.040; respectively). (C) Mean ±
SEM NF B activity for patients whose baseline NF B activity was below the median (<2.14 X 10 6) and called
“Lower activation” is shown. NF B activity was not significantly different from the normal subjects and no
significant changes were seen over the course of n-3 supplementation. All Y-axis are the same as for figure
2.3A. The X-axis shows the n-3 consumption across time.
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Omega-3 consumption increases in vitro chemo-sensitivity of lymphocytes to
doxorubicin
We evaluated the effects of omega-3 consumption on the chemo-sensitivity of malignant
lymphocytes to doxorubicin, a therapeutic agent that has been used in treating CLL (Keating,
2010). Figure 2.4 shows the in vitro sensitivity to doxorubicin for 12 patients over the course of
omega-3 supplementation. Due to inadequate sample required for chemo-sensitivity assays and
limited number of data points, data from patients 11, 12 and 13 are not shown. In vitro results
demonstrate that consumption of omega-3 fatty acids increased the sensitivity (i.e. increased cell
death at lower doses of doxorubicin) of malignant lymphocytes to doxorubicin in most patients.
Discontinuing omega-3 consumption was associated with decreased sensitivity to doxorubicin,
as observed in patients 4, 6, 7 and 8.
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Figure 2.4. Chemo-sensitivity of Lymphocytes to Doxorubicin During Omega-3 Intervention.
The chemo-sensitivity (fraction of cells [compared to No doxorubicin] alive after each dose of doxorubicin
treatment) of malignant lymphocytes to doxorubicin of 12 patients on omega-3 supplementation are shown.
Consumption of omega-3 increased sensitivity of lymphocytes of most patients with higher NF B activity (1, 3,
4, 5) to doxorubicin in vitro. Discontinued omega-3 consumption decreased doxorubicin sensitivity of the
lymphocytes in vitro as seen in patients 4, 6, 7 and 8. All Y-axis are the same as for patient # 1.
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mRNA expression in lymphocytes
Since omega-3 altered activation of NF B, sensitivity to doxorubicin and potentially
slowed cancer progression, there should be changes in gene expression in the patient
lymphocytes following consumption of omega-3. Expression profiling of mRNA from
lymphocytes collected at baseline and following consumption of the highest level of omega-3
indicated:
1. In patients with lower initial NF B activation, consumption of omega-3 did not
significantly change NF B activation and did not significantly change mRNA abundance of any
genes (data not shown).
2. In patients with higher initial NF B activation, consumption of omega-3 significantly
decreased NF B activation and significantly decreased mRNA abundance of 31 identified genes.
Genes down-regulated by omega-3 are shown in Table 2.4. Only the sixteen genes with known
function are illustrated. Three of these genes are known to be NF B responsive genes.
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Table 2. 4. Differential mRNA Expression in Lymphocytes in Patients with
Higher Initial NF B Activation
Number

Gene

Description

1

JMJD1C jumonji domain
containing 1C [Homo
sapiens ]

Probable JmjC domain-containing histone demethylation protein 2C. Known target
of NF B.

RIF1

2

ZNF644

3

4

CHD9
TPR

5

OSBPL8 (Oxysterol
binding protein-like 8)

6

KIAA1109

7

BRWD1 (Bromodomain
and WD repeat domain
containing 1)

8

MKL (myocardin-like
protein 2)

9

Fold
Change

Included in pluripotency of stem cells, response to double-strand breaks, and breast
cancer development. Inhibition of RIF1 has been shown to sensitize cancer cells to
camptothecin or staurosporine treatment.
Metal ion binding, regulation of transcription. Known target of NF B.

Chromatin remodeling transcriptional regulation of mesenchymal cells.
Directly binds Mad1 and Mad2. Important for the Mad1-Mad2-mediated spindle
checkpoint. Translocated promotor region (to activated MET oncogene).
Encodes a member of the oxysterol-binding protein (OSBP) family, a group of
intracellular lipid receptors.

0.2762535

Chromosomal aberrations involving this gene are associated with papillary thyroid
carcinomas and a variety of hematological malignancies.

0.2854771

0.3021278

ASH1L

Mammalian ASH1L is a histone methyltransferase that occupies the transcribed
region of active genes.

PKN2 (Protein kinase N2)

Protein kinase C-related kinase-2 (PRK2) as an HDAC5-interacting protein.
Evidence suggests that the unique phospho-acceptor cooperates with the 14-3-3
target sites to impair HDAC nuclear import.

SLC12A1 (Solute carrier
family 12)

This gene encodes a kidney-specific sodium-potassium-chloride cotransporter.

16

PTGS2 (prostaglandin
synthase 2, COX 2)

0.2487205

Encodes myocardin-related transcription factor B in a megakaryoblastic leukemia
gene family, shown to be involved in cancer cell invasion and motility.

Thought to regulate formation of clathrin-coated vesicles and function in the
induction of T cell receptor endocytosis.

CASC5 (Cancer
susceptibility candidate 5)

0.2420173

0.2635655

ITSN2 (Human Intersectin
2)

15

0.2407181

Thought to facilitate formation of heterotrimetric or multiprotein complexes.
Involved in variety of processes, including cell cycle progression, signal
transduction, apoptosis and gene regulation.

11

14

0.2339526

0.2579169

PCM1 (Pericentriolar
material 1)

13

0.2184341

Thought to function in the regulation of epithelial growth differentiation and in
tumor development.

10

12

0.2018486

Involved in chromosomal translocations that subsequently form chimeric
oncoproteins BCR-ABL, TEL-ABL and MLL-AF15q14 in human leukaemia.
Interact with the tumor suppressor pRb protein.Expressed in various human tumour
cell lines and primary tumours.

Linked to promotion of a variety of cancers via increased production of
inflammatory eicosanoid prostaglandin E2. Known target of NF B.

0.3140698

0.3235345

0.3310252

0.3414733

0.4050415

Table 2.4. Differential mRNA Expression in Lymphocytes in Patients with Higher Initial NF B
Activation. Differentially regulated genes were identified by SAM analysis (false discovery rate = 10%, fold
difference at least 1.5). Shown are results of repeated analyses of mRNA from 5 patients at highest omega-3
dose verses baseline (no omega 3 supplement). A fold change of less than 1 indicates that omega-3 consumption
decreased expression of the gene to the indicated fraction compared to baseline expression of the gene.
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DISCUSSION
Chronic lymphocytic leukemia is a disease that usually occurs in older people and in
early stages, CLL does not require treatment. If the time to progression could be extended or if
therapy were more effective then clinical benefit would be realized. Evidence has suggested that
NF B may play a key role in controlling apoptosis and disease progression in CLL (Braun et al.,
2006; Cilloni et al., 2007; Endo et al., 2007) . NF B is currently considered an important target
for the treatment of hematological malignancies, especially CLL (Braun et al., 2006; Cilloni et
al., 2007; Cilloni et al., 2006; Endo et al., 2007; Hewamana et al., 2009). In our animal studies
with other types of cancers, we have shown that omega-3 suppressed the activation of NF B
(Hardman, 2002) and increased the effectiveness of several chemotherapies including
doxorubicin (Hardman, Avula, Fernandes, & Cameron, 2001; Hardman, Moyer, & Cameron,
2000) . It was not known if this benefit would translate to humans. This pilot study was primarily
designed to determine whether omega-3 would reduce NF B activation in the lymphocytes of
patients with early (RAI stage 0-1) CLL. Secondary objectives were to 1) evaluate the safety of
consuming an omega-3 supplement, 2) determine circulating fatty acid concentrations in the
plasma, 3) determine if omega-3 could increase the sensitivity of patient‟s lymphocytes to
doxorubicin in vitro and 4) whether omega-3 might modify gene expression in the tumor cells
(lymphocytes) of humans.
Our patient characteristics indicated a range of prognoses from good to poor based on
differences in patient staging, cytogenetics, and phenotypes. For example, deletion of 13q14.3 is
associated with good prognosis; trisomy 12 is associated with intermediate prognosis; CD38
positive lymphocytes, high levels of ß2-microglublin (mg/L) > 2, and/or deletion of 17p13.1 are
associated with poor prognosis (Doubek et al., 2011; Mougalian & O'Brien, 2011) . Mutation
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status of the IgVH chain was not evaluated as this is not performed during routine clinical
practice at this institution.
Chronic lymphocytic leukemia cells have been demonstrated to have high NF B activity.
Our results appeared to indicate two populations of patients, those with higher initial NF B
activation (greater than the median) and those with lower initial NF B activation (lower than the
median). Hewamana et al. indicated that increased WBC counts significantly correlated with
increased Rel A, a subunit of NF B which contains the transcription activation domains, DNA
binding (Hewamana et al., 2008). Similarly, we found a positive correlation between WBC
counts and NF B activation (r2: 0.309, p: 0.0476, Appendix, Supplementary Figure 2.2). Data on
absolute lymphocyte counts indicated that the „lower initial activation‟ patients had significantly
lower absolute lymphocyte counts than patients exhibiting „higher initial activation‟ of NF B at
baseline. Patient staging indicated that 3 of 7 patients with higher initial NF B activity had a Rai
Stage of 1 (remainder had Rai Stage 0), whereas only 1 of 6 patients with lower initial NF B
activity had a Rai Stage of 1 (remainder had Rai Stage 0). The trend in patient staging,
correlation between WBC count and NF B activation, statistical differences observed at baseline
for absolute lymphocyte counts, and differences in initial NF B activity suggest that NF B
activation may be related to progression of the disease. Further studies will be needed to
determine if NF B activation correlates with progression of the disease and if suppressing NF B
activation will slow further progression.
Our results indicate that consumption of an n-3 supplement, predominantly composed of
EPA and DHA, increased the amount of n-3 in the plasma of subjects. Although the subjects had
early stage CLL (Rai Stages 0-1), we could not determine a reason, a priori, that would indicate
that the fatty acid concentrations in their plasma should be different from that of persons without
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CLL. Interestingly, despite plasma concentrations of EPA and DHA being highest following
consumption of 7.2 g of n-3/per day for a month of more, these concentration did not differ
statistically from that following consumption of 4.8 g of n-3/day (Mean [µM] ± SEM: 352.0 ±
15.98 vs 302.5 ± 14.95; p: 0.192 and 202.2 ± 14.43 vs 205.2 ± 13.34; p:1.00 , respectively (Table
2.3)). This suggests that plasma concentrations of EPA and DHA reached a steady state and that
a steady state plasma concentration of EPA or DHA can be achieved at a lower dose that is more
easily consumed. This is an important consideration for future clinical trials. A lower dose of
supplement would increase compliance rates and decrease side effects associated with n-3
consumption.
Discontinuation of n-3 consumption resulted in a reduction of EPA toward values
observed at baseline. Although DHA displayed a similar tendency for reduction toward baseline
values, levels of DHA 3 months after discontinuation n-3 consumption remained significantly
higher than baseline values (Mean [µM] ± SEM: 149.2 ± 6.54 vs 69.4 ± 9.41;p: <0.001 (Table
2.3)). This indicates that the retention time of DHA in the plasma of patients consuming n-3 is
greater than EPA. It is important to note that plasma levels of AA decreased following n-3
consumption and subsequently increased toward values observed at baseline after
discontinuation of n-3. It is not known if this is due to changes in the diet or if the increase in AA
is as a result of reduced bioavailability of n-3.
These data demonstrate that in patients with early stage CLL, consumption of an omega-3
fatty acid supplement had minimal side effects and strongly suppressed highly activated NF B.
A dose of 7.2 g of n-3/day suppressed NF B activity to nearly normal levels in all patients. This
biomarker would be expected to correlate with clinical benefit, perhaps extending the time to
requiring therapy. A longer randomized trial will be needed to determine if our intervention
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slows disease progression. In patients unable or unwilling to take 7.2 g of n-3 per day, over time
either 4.8 g or 2.4 g of n-3 per day also suppressed NF B to nearly normal levels. This suggests
that a maximum possible dose may not be required to achieve benefit from omega-3 but that a
lower dose, with time, could provide benefit. This idea is further supported by the fact that
plasma levels of n-3 after 7.2 g of n-3 per day did not differ statistically from 4.8 g of n-3 per day
(Table 2.3).
These data also demonstrate that patients with lower initial NF B activity did not have
NF B activity decreased below baseline levels while being supplemented with omega-3. A
normal level of NF B activation is needed for normal immune response and cellular responses to
other stress.
Based on our data, it can be concluded that consumption of omega-3 fatty acids
decreased the activity of NF B, a key target for slowing cancer progression, and would
potentially slow the progression of the disease. A larger randomized clinical trial will be needed
to determine if consumption of omega-3 fatty acids can slow progression of the disease.
Omega-3 fatty acids have consistently been shown to enhance the sensitivity of various
cancers to doxorubicin in vitro and in vivo (Bougnoux et al., 1999; Hardman, 2002; Hardman et
al., 2000). Doxorubicin is a previously used treatment option for CLL (Keating, 2010) and is an
active drug in this disease as part of the CHOP (cyclophosphamide, doxorubicin, oncovin and
prednisone) regimen (Leporrier et al., 2001). Although doxorubicin has been replaced as the
standard by other drugs such as bendamustine and fludarabine, we wanted to test the chemosensitivity of isolated lymphocytes to doxorubicin following inhibition of NF B activation as
this system was already in place. Omega-3 consumption was shown to increase sensitivity of
malignant lymphocytes to doxorubicin while discontinued consumption of omega-3 resulted in
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decreased sensitivity to doxorubicin. Our data illustrates that increased sensitivity of malignant
lymphocytes to doxorubicin following n-3 consumption was most profound in patients with
higher initial NF B activity. Little effect on chemo-sensitivity following n-3 consumption was
observed in patients with lower initial NF B activity. Increased sensitivity of malignant
lymphocytes from patients with higher initial NF B activity to doxorubicin suggests that high
NF B activity is associated with chemoresistance. Numerous preclinical studies have shown that
increased NF B activity increases chemoresistance (Li & Sethi, 2010). We are currently
preparing to conduct an additional clinical study aimed to determine if n-3 can increase the
sensitivity of lymphocytes from patients with CLL to anti-cancer drugs fludarabine,
chlorambucil or vincristine in vitro and whether enhanced sensitivity is through the inhibition of
NF B activation. Increasing the efficacy of the chemotherapeutic agent would be clinically
beneficial if patients progress to requiring therapy.
In patients with higher initial NF B activation, consumption of the omega-3 supplement
significantly suppressed expression of 31 identified genes. In this small population, no genes had
increased expression due to omega 3 consumption. The list of altered genes that have a known
function is included in Table 2.4. Of these 31 genes, JMJD1C, ZNF644 and PTGS2 are known to
be regulated by NF B. Functions of some of these genes of particular interest are discussed
below. (Numbers in brackets refer to number in first column of Table 2.4.)
Several chromatin conformation related proteins were identified including: JMJD1C [1]
which contains histone demethylation protein 2C (Katoh & Katoh, 2007). CHD9 [4] is a
chromatin remodeling protein (Marom, Shur, Hager, & Benayahu, 2006; Shur, Socher, &
Benayahu, 2006). ASH1L [12] is a histone methyl transferase (An, Yeo, Jeon, & Song, 2011)
and PKN2 [13] impairs histone deacetylase import (Harrison et al., 2010). Chromatin remodeling
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is being recognized as an important mechanism by which dietary components may alter gene
expression and influence cancer growth or progression.
Several down-regulatated genes were identified as important in cancer development.
RIF1 [2] is an embryonic stem cell marker. Inhibition of RIF1 has been shown to sensitize
cancer cells to some chemotherapies (Park et al., 2010). KIAA1109 [7] is thought to function in
epithelial growth and differentiation and in tumor development (Zhernakova et al., 2007).
BRWD1 [8] is an Oct4 (stem cell marker) interacting protein, its family members are involved in
cell cycle progression, signal transduction, apoptosis and gene regulation (Pardo et al., 2010).
Chromosomal aberrations involving PCM1 [10] are associated with thyroid carcinomas and a
variety of hematological malignancies (Hoeller, Walz, Reiter, Dirnhofer, & Tzankov, 2011).
CASC5 (15q14) is involved in chromosomal translocations that form oncoproteins in human
leukemias (Kuefer et al., 2003) and in increased cell proliferation of some cancers (Bogdanov &
Takimoto, 2008; Takimoto et al., 2002).
PTGS2 (prostaglandin synthase 2, COX-2 [16]), a known target of NF B, has been
linked to promotion of a variety of cancers possibly via increasing the production of
inflammation producing prostaglandin E2 (Hardman, 2002; Prueitt et al., 2007). Suppression of
COX-2 activity has been proposed as a mechanism to reduce cancer growth and resistance to
chemotherapy.
In conclusion, omega-3 consumption increased circulating plasma levels of n-3 while
decreasing n-6, suppressed NF B activation in patients with early stage (Rai Stage 0-1) CLL to
near normal levels and increased chemo-sensitivity of malignant lymphocytes to doxorubicin in
vitro. Suppression of NF B activity has been proposed as a drug development target to slow
progression of cancers. The mRNA expression of multiple genes related to cancer promotion or
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cancer aggressiveness were reduced in malignant lymphocytes following consumption of omega
-3. Much work should be done to validate that reduced mRNA correlates with decreased
expression of the protein and the clinical relevance. Since omega-3 was safe to consume and did
not have detrimental side effects, a definitive randomized clinical trial should be initiated to
determine whether there is clinical benefit for consumption of omega-3 to slowing progression of
chronic lymphocytic leukemia. In agreement with animal studies, in vitro doxorubicin sensitivity
assays suggest that when used in combination with chemotherapeutics, omega-3 fatty acids may
increase the efficacy of some chemotherapeutic drugs for patients who require therapy. Current
studies are underway to determine if omega-3 can enhance the sensitivity of lymphocytes from
patients with CLL to anti-cancer drugs fludarabine, chlorambucil or vincristine. Plasma
concentrations of fatty acids analyzed following consumption of n-3 and discontinued
consumption of n-3 provides insight into doses of n-3 which can be used in future clinical trials.
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APPENDIX
Baseline-Month 0
Blood Draws
Month #1: 3 capsules of n-3 per day
(2.4 g of n-3/day)
Blood Draws
Month #2:
6 capsules of n-3 per day
(4.8 g of n-3/day)
Blood Draws
Month #3:
9 capsules of n-3 per day
(7.2 g of n-3/day)
Blood Draws
Months #4-12:
Highest Tolerable Dose
Discontinue Consumption Post Month #12
Blood Draws
Month #15:
Follow-Up
0 g of n-3/day
Blood Draws

Supplementary Figure 2. 1. Omega-3 Dosing Schedule.
Each capsule of omega-3 contained 400mg EPA, 300mg DHA and 100-150mg other omega-3. Thus,
consumption of 3, 6, or 9 capsules/day yielded 2.4 g, 4.8 g, or 7.2 g/day of n-3, respectively
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Supplementary Figure 2. 2. Effects of Omega-3 on Blood Coagulation.
Blood coagulation times for collagen/ADP and collagen/EPI (ephinephrine) on omega-3
intervention are shown. No difference was observed in collagen/ADP, a measure of platelet
function, coagulation when omega-3 was introduced. A slight increase was observed in
collagen/EPI, a measure of clotting time, when omega-3 was introduced but this increase was not
statistically significant and was within normal parameters.
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Supplementary Figure 2. 3. Correlation Between WBC Counts and NF B Activation.
Correlation between WBC counts and NF B activation is shown. A significant positive
correlation was found between WBC counts and NF B activation. Correlation coefficients
were calculated by least squares linear regression.
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ABSTRACT
B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the
United States. Clinical treatment of CLL is often limited due to drug resistance and severe
therapy-induced toxicities. We hypothesized that the omega-3 (n-3) fatty acids, eicosapentaenoic
acid (EPA) and/or docosahexaenoic acid (DHA), would increase the sensitivity of malignant Blymphocytes to anti-cancer drugs doxorubicin, vincristine and/or fludarabine in vitro and that
increased sensitivity is achieved by alterations in cell-cycle progression leading to growth
inhibition and/or enhanced cell death. We further postulate that enhanced sensitivity is dependent
on the formation of lipid peroxides and to the generation of reactive oxygen species (ROS).
In the present study, B-CLL-derived leukemic cell lines EHEB and MEC-2 and the BProlymphocytic leukemic-derived (PLL) cell line JVM-2 were tested for in vitro sensitivity
against doxorubicin, vincristine or fludarabine in the presence or absence of vehicle, arachidonic
acid (omega 6), EPA or DHA. Cell cycle analysis and Annexin-V assays were performed to
determine cell cycle progression and % apoptotic cells, respectively. Assays for
malondialdehyde, a measure of lipid peroxidation, and DCF fluorescence assays, a measure of
intracellular ROS, were performed to determine if enhanced sensitivity of cells to the drugs by n3 was dependent on the formation of ROS.
Our results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell
lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone
and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific
manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid
peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3
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increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase
in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA.
N-3‟s are promising chemo-sensitizing agents for the treatment of CLL. Selective
enhancement of chemo-sensitivity of EHEB, JVM-2 and MEC-2 to drugs by n-3 that is not
dependent on increased lipid peroxidation and ROS generation indicates alternative mechanisms
by which n-3 enhances chemo-sensitivity.
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INTRODUCTION
B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the
United States (Riches, Ramsay, & Gribben, 2011). CLL is a disease of the elderly with two
thirds of patients being over 65 years of age at time of diagnosis (Riches et al., 2011). CLL
remains largely incurable outside of allogeneic transplantation (Riches et al., 2011). Despite the
success of current treatments such as fludarabine, many patients develop drug resistance and
disease relapse (Silber et al., 1994). As such, clinical treatment of CLL is often hindered by drug
resistance and the non-selectivity of most drugs (Schriever & Huhn, 2003). Additionally,
treatment options for CLL patients who require aggressive treatment are limited due to
significant side-effect profiles which are often too toxic for the elderly or those with
comorbidities (Riches et al., 2011). Given the age group of patients diagnosed with CLL, a
therapeutic intervention that can increase the sensitivity of CLL cells to chemotherapy without
causing additional adverse effects would be clinically beneficial.
Omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) are essential fatty acids
(FAs) which must be obtained from diet. Long chain omega-3 fatty acids (eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA)) are primarily found in fish oils (Simopoulos, 1991).
The omega-6 fatty acid, arachidonic acid (AA), is primarily found in the meat of animals that
consumed corn or soybeans. The ratio of omega-3 FAs to omega-6 FAs in the average western
diet is heavily weighted in favor of omega-6 (Simopoulos, 2000, 2003). Omega-3 fatty acids
have consistently been shown to enhance sensitivity of various solid tumor cells to chemotherapy
in vitro (Germain, Chajes, Cognault, Lhuillery, & Bougnoux, 1998; Kinsella & Black, 1993) and
in vivo (Borgeson, Pardini, Pardini, & Reitz, 1989; Hardman, Avula, Fernandes, & Cameron,
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2001; Shao, Pardini, & Pardini, 1997). However, it has not been shown whether n-3 can enhance
the sensitivity of CLL to anti-cancer drugs.
Previous studies performed by our group have shown that consumption of an omega-3
supplement, predominantly composed of EPA and DHA, increased the sensitivity of malignant B
lymphocytes isolated from patients with early CLL (RAI stages 0, 1) to doxorubicin in an in
vitro assay (Fahrmann et al., 2013). These findings prompted us to further evaluate the potential
use of omega-3 as a chemo-sensitizing agent for the treatment of CLL. The primary objective of
this study was to determine whether EPA and/or DHA could increase the sensitivity of malignant
B-lymphocytes to doxorubicin, vincristine and/or fludarabine in vitro. Secondary objectives were
to elucidate potential mechanism(s) by which n-3 enhance chemo-sensitivity. We hypothesized
that EPA and/or DHA would increase the sensitivity of malignant B-lymphocytes to
doxorubicin, vincristine and fludarabine in vitro and that enhanced sensitivity is mediated by
alterations in cell cycle progression leading to enhanced growth inhibition and/or enhanced cell
death. We further postulate that increased chemo-sensitivity is dependent, in part, on the
formation of lipid peroxides, and the generation of reactive oxygen species (ROS).
In this study we assayed for: 1) fatty acid lipid composition, 2) in vitro sensitivity of BCLL-derived cell lines EHEB, and MEC-2 and B-Prolymphocytic-derived (PLL) cell line JVM-2
against doxorubicin, vincristine and fludarabine in the presence of vehicle (no added FA), AA,
EPA or DHA, 3) % of apoptotic cells, 4) cell cycle distribution, 5) generation of intracellular
reactive oxygen species (ROS), and 6) levels of lipid peroxidation.
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METHODS
Chemicals
Ninety-five percent pure doxorubicin hydrochloride (Fisher Scientific), and 2fluoroadenine-9-β-D-arabinofuranoside (Sigma Aldrich) were dissolved in dimethyl sulfoxide
(DMSO) to stock solutions and diluted to the working concentrations in cell type specific culture
media. Vincristine sulfate salt (Sigma Aldrich) was dissolved in ddH2O to stock solutions and
diluted to the working concentrations in cell type specific culture media. Vitamin E (αtocopherol) (Sigma Aldrich) was dissolved in ethanol to stock solutions and diluted to working
concentrations in the cell type specific media.

Cell Lines
EHEB (B-CLL), JVM-2 and MEC-2 (B-Prolymphocytic Leukemia) were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). Cells were grown in 1640
RPMI (ATCC) (EHEB and JVM-2) or Iscove‟s Modified Dulbecco‟s Medium (HyClone,
Thermo Scientific) (MEC-2) supplemented with 10% Fetal Bovine Serum (HyClone, Thermo
Scientific), 100 units/mL penicillin and 0.1 mg/mL streptomycin. All cell lines were grown in
humidified incubator at 370C and 5% CO2.

Fatty Acid Treatments
Stock solutions of 100 mM eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)
or arachidonic acid (AA) (Cayman Chemical) in ethanol were made and diluted to the working
concentrations in cell type specific culture media. Fatty acid concentrations used represent the
concentration of each fatty acid that alone did not induce significant cytotoxicity. One million
five hundred thousand (1.5x106) cells per well were seeded in a 6 well plate (Santa Cruz
Biotechnology, Inc) and treated with vehicle (ethanol only), AA, EPA or DHA at the stated
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concentration for 72 hours. Cells were treated for 72 hours with FA to allow adequate time for
FA incorporation and to allow for any FA-dependent changes in cellular function. Chosen
concentrations of FA are clinically achievable (Fahrmann et al., 2013). Post 72 hours, cells were
counted with a hemocytometer and prepared for the assays below.

Lipid Composition
Fatty acid composition was assessed by gas chromatography according to our routine
techniques (Witte, Salazar, Ballester, & Hardman, 2010). Post 72 hours, cells were washed twice
with 1X PBS. Cells were subsequently homogenized in distilled water with 0.1% BHT to prevent
fatty acid oxidation. Lipids were extracted with chloroform/methanol, and then methylated.
Methylated lipids were separated and identified using gas chromatography as previously
published (Witte et al., 2010). Fatty acid methyl ester standards (Nu-Chek-Prep, Elysian, MN)
were used for peak identification.

Sensitivity Trials
Cell counts were performed and viability was determined by Trypan Blue Exclusion
assay following 72 hour fatty acid treatments (FA). Approximately 1x105 living cells/well were
seeded in triplicate into a round bottom 96 well plate (CELLSTAR, Greiner Bio One
International AG). Cells were subsequently treated with culture media containing DMSO, H2O
(solvent controls), doxorubicin (0–7.5μM), vincristine (0-250nM) or fludarabine (0-50μM)
without FA for 20 hours (doxorubicin) or 24 hours (vincristine, fludarabine). Cells were treated
in the presence or absence of 50μM vitamin E alone and in combination with doxorubicin
(1.5μM) after 72 hour FA pre-treatment for Vitamin E rescue trials. Cell viability was
determined using colorimetric MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (CALBIOCHEM, EMD MILLIPORE) assay. Cell viability was assessed by measuring
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the intensity of precipitate formed, relative to control specimens. Absorption was measured using
a SpectraMax M2 (Molecular Devices, Sunnyvale, CA) spectrophotometer at 570 nm. All
measurements obtained from the MTT assay following treatment with the anti-cancer drugs in
the presence of vehicle, AA, EPA or DHA were compared to cells treated with the vehicle or FA
alone. MTT assays were performed in technical and biological triplicate.

Measurement of Apoptosis by Annexin-V/Propidium Iodide Duel Stain
Apoptosis was measured by duel stain immunofluorescence flow cytometry. Briefly, post
72 hour FA treatments, cell counts were performed and approximately 5 x 105 cells were treated
in the presence of DMSO, H2O (solvent controls), doxorubicin (1.5μM), vincristine (100nM) or
fludarabine (40μM) as previously described under sensitivity trials. Cells were washed twice
with cold 1X PBS and subsequently incubated for 15 minutes in the dark in 100μL of Annexin-V
binding buffer (0.01 M HEPES, 0.14 M NaCl, 2.5 mM CaCl2), 1μL Annexin-V Alexa Fluor 488Conjugate (Invitrogen), and 10 μg/mL propidium iodide (Sigma Aldrich). Cells were analyzed
using an Accuri Flow Cytometer. „Early‟ Apoptosis was defined as cells positive for Annexin-VFITC only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and Propidium
Iodide (PI). „Necrotic‟ was defined as cells positive for PI only (Equation 2). Total% cell death
was defined as the sum population of cells in early apoptosis, late apoptosis and necrosis.
Annexin-V assays were performed in biological triplicate.

Necrotic

Late
Apoptosis

Equation 2: Total % Cell Death
Propidium Iodide

Total % Cell Death = (% Necrotic) + (% Late Apoptosis) + (% Early Apoptosis)
Early
Apoptosis

Annexin-V-FITC
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Cell Cycle Analysis
Post 72 hour FA treatments, cells were counted and approximately 1 x 106 cells were
treated in the presence of DMSO, H2O (solvent controls), doxorubicin (1.5μM), vincristine
(100nM) or fludarabine (40μM) as previously described under sensitivity trials. Cells were
subsequently washed twice with cold 1X PBS and resuspended in DNA staining buffer
containing 0.2% Triton X-100, 0.2% Na3-Citrate, 30 μg/mL RNase and 20 μg/mL propidium
iodide (Sigma Aldrich) or DNA staining buffer without propidium iodide to serve as negative
controls. Cells were incubated for 30 minutes in the dark at room temperature and subsequently
analyzed using an Accuri Flow Cytometer. Cell cycle analyses were performed in biological
triplicate. Calculation of G1/G2 ratio is described in Equation 3.

G1
(G0 + G1)

Events

Equation 3: G1/G2 Ratio
G1/G2 Ratio = (# of events in G0 + G1)/ (# of events in G2 + M)
G2
(G2 + M)
S

Lipid Peroxidation
Lipid peroxidation was measured by means of thiobarbituric acid reactive substances
(TBARS) assay. Briefly, approximately 1 to 1.5 x 106 cells were collected in 600μL 1X PBS
post 72 hour fatty acid treatments as described under fatty acid treatments and after doxorubicin
(1.5μM) or vincristine (100nM) or fludarabine (40μM)alone or in combination with 50μM
vitamin E (doxorubicin only). Cells were sonicated 2X on 10 second intervals at 40 V setting
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over ice using a Fisher Scientific Sonic Dismembrator. TBARS assay (Cayman Chemical), in
biological triplicate, was performed according to protocol and reported as ng of
malondialdehyde/μg of protein.

Intracellular ROS Generation
Levels of intracellular ROS were determined using 5-(and-6-)chloromethyl-2‟,7‟dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen). Briefly, post
72 hour fatty acid treatments, one hundred thousand (105) live cells were seeded in triplicate into
a round bottom 96 well plate (CELLSTAR, Greiner Bio One International AG). Cells were
washed twice with 1X Dulbecco‟s PBS (DPBS) (GIBCO, Invitrogen) and incubated for 60
minutes in the presence or absence of 10μM CM-H2DCFDA in Dulbecco‟s Modified Eagles
Medium (DMEM, Thermo Scientific) (SIGMA) without FBS containing 100 units/mL pencillin,
0.1 mg/mL streptomycin. Post 60 minute incubation, cells were washed 2X with 1X DPBS and
treated in the presence or absence of DMSO, doxorubicin (1.5μM), or fludarabine (40μM) where
after cell suspensions were transferred to a 96 well flat bottom black well plate (VWR
International, LLC). Fluorescence was measured every 10 minutes for 2 hours using SpectraMax
M2 spectrophotometer (Molecular Devices, Sunnyvale, CA) at 480 nm excitation 530 nm
emission. Assays for intracellular ROS generation were performed in technical triplicates and
biological duplicates.

Statistical Analysis
Prism© software (Graphpad, Inc., La Jolla, CA) was used for statistical analysis of
numeric data by Multiple Comparison using appropriate Post-Hoc Test and for linear regression
analyses. Prism© software (Graphpad, Inc., La Jolla, CA) was used for preparation of graphs.
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Statistical significance on Annexin-V assays is based on total% cell death as described in
Equation 2.

RESULTS
N-3 and N-6 fatty Acids Induce Cell Death
Figures 3.1A-C illustrates the % alive cells ± SEM of EHEB, JVM-2 and MEC-2
following treatment with vehicle, or increasing concentrations of AA, EPA and DHA. Cell
viability was assessed by Trypan Blue Exclusion assay following treatment for 72 hours.
Treatment with AA, EPA or DHA induced dose-responsive reductions in cell viability as
compared to vehicle in all three cell lines. We wanted to determine the chemo-sensitizing effects
of FA following treatment with concentrations of FA that alone did not induce significant
cytotoxicity. Thus, we chose to use concentrations of AA at 25µM, 35µM and 25µM, EPA at
50µM (all cell lines) and DHA at 75µM, 50µM and 50µM for EHEB, JVM-2 and MEC-2,
respectively. The chosen FA concentrations used in this study are clinically achievable
(Fahrmann et al., 2013). Gas chromatography post 72 hour of FA treatment validated FA
incorporation in all cells (Figure 3.2).
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Figure 3. 1. Determination of optimal FA concentrations.
Figures 3.1A-C illustrates the mean % live cells ± SEM of EHEB, JVM-2 and MEC-2 following 72 hour treatment with vehicle, or increasing
concentrations of AA, EPA or DHA. Percent (%) live cells was determined after 72 hour treatments by trypan blue exclusion assay. Figure 3.1A illustrates
the mean % live cells ± SEM of EHEB following treatment with vehicle, or increasing concentrations of AA, EPA or DHA. Significant reductions in % live
cells were observed at 55µM AA, 75µM and 100µM EPA, and 100µM DHA as compared to vehicle. Although not statistically significant, concentrations of
AA35µM and AA45µM indicated viabilities of 57% and 54%. FA concentrations of AA25µM, EPA50µM and DHA75µM were chosen for the remainder of
the study. Figure 3.1B illustrates the mean % live cells ± SEM of JVM-2 following treatment with vehicle, or increasing concentrations of AA, EPA or
DHA. Significant reductions in % live cells were observed at 45µM and 55µM AA, and 75µM and 100µM EPA as compared to vehicle. Although not
statistically significant, concentrations of DHA75µM and DHA100µM indicated cell viabilities of 65% and 55%. FA concentrations of AA35µM,
EPA50µM and DHA50µM were chosen for the remainder of the study. Figure 3.1C illustrates the mean % live cells ± SEM of MEC-2 following treatment
with vehicle, or increasing concentrations of AA, EPA or DHA. Significant reductions in % live cells were observed at 45µM AA, 75µM and 100µM EPA
and 75µM and 100µM DHA as compared to vehicle. FA concentrations of AA25µM, EPA50µM and DHA50µM were chosen for the remainder of the
study. Statistical significant was determined by Multiple Comparison Test using Tukey‟s correction. Abbreviations: AA- arachidonic acid, EPAeicosapentaenoic acid, DHA- docosahexaenoic acid, α= 0.05, * <0.05, **<0.01, ***< 0.001
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Figure 3. 2. Validation of FA incorporation.
Figure 3.2 illustrates the percentage (%) ± SEM of analyzed fatty acids in MEC-2 following 72 hour treatments
with vehicle, 25µM AA, 50µM EPA or 50µM DHA. Ten (10) fatty acids were analyzed, only % of AA, EPA,
DPA and DHA are shown. B-Leukemic cell lines EHEB and JVM-2 indicated similar results (data not shown).
Abbreviations: AA-arachidonic acid; EPA- eicosapentaenoic acid; DPA- docosapentaenoic acid; DHAdocosahexaenoic acid; (X:Yn-3/6): X denotes number of carbon atoms, Y denotes number of unsaturations, n-3:
omega 3, n-6: omega 6.
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EPA and DHA Differentially Sensitize Malignant B-lymphocytes to
Doxorubicin, Vincristine and Fludarabine In Vitro
In our study, we wanted to determine whether FA pre-treatment would synergistically
increase the cytotoxic effects (greater effect than the sum effect due to FA and drug individually)
of anti-cancer drugs doxorubicin, vincristine or fludarabine on three different B-leukemic cells.
Thus, all measurements obtained from the MTT assay following treatment with the anti-cancer
drug in the presence of vehicle, or FA were compared to cells treated with vehicle or FA only.
Figure 3.3A illustrates the in vitro sensitivity of EHEB to doxorubicin (0–7.5 μM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, cell viability was
significantly reduced in cells pre-treated with either EPA or DHA but not with AA when treated
with doxorubicin.
Figure 3.3B illustrates the in vitro sensitivity of EHEB to fludarabine (0-50μM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, cell viability was
significantly reduced in cells pre-treated with EPA when treated with fludarabine (30μM and
40μM). However, there was no difference in the sensitivity of EHEB to fludarabine when cells
were pre-treated with either AA or DHA. It is interesting to note that AA pretreatment had a nonsignificant slightly protective effect on EHEB cells treated with fludarabine.
Compared to vehicle, pre-treatment with AA, EPA or DHA did not significantly change
the sensitivity of EHEB to vincristine (Appendix, Supplementary Figure 3.1).
In our model, an increase in chemo-sensitivity of cells to the drug by FA can be mediated
by both enhanced cell death and/or enhanced growth-inhibition. To determine whether the
decreases in cell viability seen in the MTT assays were a result of enhanced cell death or of
growth-inhibition we performed an Annexin-V assay.
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Figure 3.3C illustrates the % dead EHEB cells (± SEM) in the presence or absence of
vehicle, AA, EPA, or DHA alone and after treatment with doxorubicin (1.5μM) or fludarabine
(40μM). The concentration of doxorubicin (1.5μM) was chosen as this concentration induced a
significant difference in cell viability between FA and vehicle pre-treated cells and because this
concentration is clinically achievable (Muller et al., 1993). The concentration of fludarabine
(40μM) was chosen as this concentration induced the greatest significant difference in cell
viability between EPA and vehicle pre-treated cells (Figure 3.3B); however, this concentration is
~5-10 times greater than the peak plasma concentration of fludarabine (Foran et al., 1999).
Compared to vehicle, cells pre-treated with DHA, but without drug, had significantly higher cell
death. The addition of doxorubicin or fludarabine to DHA pre-treated cells significantly
increased cell death as compared to vehicle and drug treatment. Cell death was mediated
predominately through apoptosis (Figure 3.3C). In cells treated with doxorubicin or fludarabine,
pre-treatment with either AA or EPA did not increase cell death as compared to vehicle. Figure
3.3D displays a graphical 2D representation of Annexin-V/PI plots of EHEB cells pre-treated
with either vehicle or DHA and following treatment with doxorubicin or fludarabine.
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Figure 3. 3. In vitro sensitivity of EHEB following treatment with doxorubicin or fludarabine in the
presence and absence vehicle, AA, EPA or DHA.
Figure 3.3A illustrates the % cell viability ± SEM of EHEB to doxorubicin (0-7.5µM) in the presence or
absence of vehicle, AA25µM, EPA50µM or DHA75µM. Cells pre-treated with either EPA or DHA had
significantly greater decreases in cell viability as compared to vehicle when treatment with doxorubicin. Figure
3.3B illustrates the % cell viability ± SEM of EHEB to fludarabine (0-50µM) in the presence or absence of
vehicle, AA25µM, EPA50µM or DHA75µM. Pre-treatment of cells with EPA had significantly greater
reductions in cell viability as compared to vehicle when treated with 30µM and 40µM fludarabine. Figure 3.3C
illustrates the % dead cells ± SEM of EHEB following pre-treatment with vehicle, AA25µM, EPA50µM or
DHA75µM alone and following treatment with 1.5µM doxorubicin or 40µM fludarabine. The % cell death was
determined by annexin-V/propidium iodide duel stain with flow cytometry. Pre-treatment with DHA alone
induced significantly greater cell death as compared to vehicle. Compared to vehicle, cells pre-treated with DHA
had significantly higher cell death when treated with doxorubicin or fludarabine. Figure 3.3D provides 2D
graphical representations of Annexin-V/PI Plots. „Early‟ Apoptosis was defined as cells positive for Annexin-VFITC only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. „Necrotic‟ was defined
as cells positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet‟s
correction (Figures 3.3A and B) or Tukey‟s correction (Figure 3.3C). α = 0.05, * <0.05, **<0.01, ***< 0.001.
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Figure 3.4A illustrates the in vitro sensitivity of JVM-2 to doxorubicin (0–7.5μM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, all FA pre-treatment
significantly decreased cell viability due to doxorubicin treatment.
Figure 3.4B illustrates the in vitro sensitivity of JVM-2 to vincristine (0-250nM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, only DHA pretreatment significantly decreased cell viability due to vincristine treatment.
Pre-treatment with AA, EPA or DHA did not induce any significant differences in the
sensitivity of JVM-2 cells to fludarabine (Appendix, Supplementary Figure 3.2).
Figure 3.4C illustrates the % dead JVM-2 cells (± SEM) in the presence or absence of
vehicle, AA, EPA, or DHA alone and following treatment with doxorubicin (1.5μM) or
vincristine (100nM). The concentration of vincristine (100nM) was chosen as this concentration
induced a significant difference in cell viability between DHA and vehicle pre-treated cells and
because this concentration is clinically achievable (Guilhaumou et al., 2011). Compared to
vehicle, pre-treatment with DHA alone induced significant cell death. Pre-treatment with DHA
significantly increased cell death due to either doxorubicin or vincristine treatment. Figure 3.4D
displays a graphical 2D representation of Annexin-V/PI plots of JVM-2 cells pre-treated with
either vehicle or DHA and following treatment with doxorubicin or vincristine.
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Figure 3. 4.In vitro sensitivity of JVM-2 following treatment with doxorubicin or vincristine in the
presence and absence vehicle, AA, EPA or DHA.
Figure 3.4A illustrates the % cell viability ± SEM of JVM-2 to doxorubicin (0-7.5µM) in the presence or
absence of vehicle, AA35µM, EPA50µM or DHA50µM. Cells pre-treated with AA, EPA or DHA induced
significantly greater decreases in cell viability as compared to vehicle when treated with doxorubicin. Figure
3.4B illustrates the % cell viability ± SEM of JVM-2 to vincristine (0-250nM) in the presence or absence of
vehicle, AA35µM, EPA50µM or DHA50µM. Compared to vehicle, only cells pre-treated with DHA had
significantly greater reductions in cell viability when treatment with vincristine. Figure 3.4C illustrates the %
dead cells ± SEM of JVM-2 following pre-treatment with vehicle, AA35µM, EPA50µM or DHA75µM alone
and following treatment with 1.5µM doxorubicin or 100nM vincristine. Pre-treatment with DHA alone induced
significantly greater cell death as compared to vehicle. Compared to vehicle, Cells pre-treated with DHA had
significantly greater cell death when treated with doxorubicin or vincristine. Figure 3.4D provides 2D graphical
representations of Annexin-V/PI Plots. „Early‟ Apoptosis was defined as cells positive for Annexin-V-FITC
only. „Late‟ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. „Necrotic‟ was defined as cells
positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet‟s
correction (Figures 3.4A and B) or Tukey‟s correction (Figure 3.4C). α = 0.05, * <0.05, **<0.01, ***< 0.001.
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Figure 3.5A illustrates the in vitro sensitivity of MEC-2 to doxorubicin (0–7.5μM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, pre-treatment with
either EPA or DHA significantly decreased cell viability due to doxorubicin treatment.
Figure 3.5B illustrates the in vitro sensitivity of MEC-2 to vincristine (0-250nM) in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, pre-treatment with
either EPA or DHA significantly decreased viability of cells treated with vincristine.
Pre-treatment of cells with AA, EPA or DHA did not increase the sensitivity of MEC-2 to
fludarabine (Appendix, Supplementary Figure 3.3).
Figure 3.5C illustrates the % dead cells ± SEM of MEC-2 in the presence or absence of
vehicle, AA, EPA, or DHA alone and following treatment with doxorubicin (1.5μM) or
vincristine (100nM). Compared to vehicle, cells pre-treated with DHA alone had significantly
higher cell death; whereas cells pre-treated with either AA or EPA had significantly less cell
death. The addition of doxorubicin or vincristine to DHA pre-treated cells induced higher cell
death as compared to vehicle; however, this was only significant when compared to AA pretreated cells. Figure 3.5D displays a graphical 2D representation of Annexin-V/PI plots of MEC2 cells pre-treated with either vehicle or DHA and following treatment with doxorubicin or
vincristine.
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Figure 3. 5. In vitro sensitivity of MEC-2 following treatment with doxorubicin or vincristine in the
presence and absence vehicle, AA, EPA or DHA.
Figure 3.5A illustrates the % cell viability ± SEM of MEC-2 to doxorubicin (0-7.5µM) in the presence or
absence of vehicle, AA25µM, EPA50µM or DHA50µM. Cells pre-treated with either EPA or DHA had
significantly greater decreases in cell viability as compared to vehicle when treated with doxorubicin. Figure
3.5B illustrates the % cell viability ± SEM of MEC-2 to vincristine (0-250nM) in the presence or absence of
vehicle, AA25µM, EPA50µM or DHA50µM. Cells pre-treated with either EPA or DHA had significantly
greater decreases in cell viability as compared to vehicle following treatment with vincristine. Figure 3.5C
illustrates the % dead cells ± SEM of MEC-2 following pre-treatment with vehicle, AA25µM, EPA50µM or
DHA50µM alone and following treatment with 1.5µM doxorubicin or 100nM vincristine. Compared to vehicle,
pre-treatment DHA alone induced significantly greater cell death; whereas pre-treatment with either AA or EPA
induced significantly lower cell death. Cells pre-treated with DHA had higher cell death, as compared to vehicle,
when treated with doxorubicin or vincristine; however, this was only significant when compared against AA pretreated cells. Figure 3.5D provides 2D graphical representations of Annexin-V/PI Plots. „Early‟ Apoptosis was
defined as cells positive for Annexin-V-FITC only. „Late‟ Apoptosis was defined as cells positive for AnnexinV-FITC and PI. „Necrotic‟ was defined as cells positive for PI only. Statistical significance was determined by
Multiple Comparison Test with Dunnet‟s correction (Figures 3.5A and B) or Tukey‟s correction (Figure 3.5C).
α = 0.05, * <0.05, **<0.01, ***< 0.001.
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N-3 Alone and in Combination with Anti-cancer Drugs Induce G2/M Arrest
We wanted to determine whether increased chemo-sensitivity by FA was also associated
with enhanced growth-inhibition; thus, we performed a cell-cycle analysis. Inhibition of cellcycle progression leads to growth-inhibition (reduced proliferation).
Table 3.1 illustrates the mean G1/G2 ratio ± SEM of all three cell lines in the presence of
vehicle, AA, EPA or DHA alone and following treatment with 1.5μM doxorubicin (EHEB,
JVM-2, MEC-2), 40μM fludarabine (EHEB), or 100nM vincristine (JVM-2, MEC-2). Cell cycle
analysis was not performed on EHEB following treatment with vincristine or on JVM-2 and
MEC-2 following treatment with fludarabine as there were no significant differences in the in
vitro sensitivity of these cell lines to these drugs in the presence AA, EPA or DHA as compared
to vehicle.
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Table 3. 1. Cell Cycle Analysis: G1/G2 Ratio
EHEB

(-) Drugs
(+) 1.5µM Dox
(+) 40µM Flud
JVM-2

(-) Drugs
(+) 1.5µM Dox
(+) 100nM Vin
MEC-2

(-) Drugs
(+) 1.5µM Dox
(+) 100nM Vin

Control ±
SEM
4.1 ± 0.09
9.2 ± 0.21
13.3 ± 0.21

Vehicle ±
SEM
4.3 ± 0.04
9.0 ± 0.27
15.5 ± 0.04

p-value

Control ±
SEM
2.4 ± 0.14
2.9 ± 0.16
1.2 ± 0.00

Vehicle ±
SEM
2.4 ± 0.04
3.1 ± 0.18
1.2 ± 0.02

p-value

Control ±
SEM
5.2 ± 0.29
3.0 ± 0.11
1.2 ± 0.07

Vehicle ±
SEM
4.8 ± 0.10
2.8 ± 0.23
1.4 ± 0.19

p-value

NS
NS
NS

NS
NS
NS

NS
NS
NS

AA25µM ±
SEM
3.7 ± 0.8
9.5 ± 0.32
13.5 ± 0.19

p-value

AA35µM ±
SEM
2.2 ± 0.06
2.6 ±0.00
0.9 ±0.00

p-value

AA25µM ±
SEM
4.9 ± 0.37
1.5 ± 0.08
0.7 ± 0.06

p-value

NS
NS
NS

NS
NS
<0.05

NS
<0.001
<0.05

EPA50µM ±
SEM
4.0 ± 0.50
8.9 ± 0.72
11.6 ± 2.08

p-value

EPA50µM ±
SEM
1.8 ±0.12
2.6 ± 0.07
0.8 ±0.01

p-value

EPA50µM ±
SEM
3.6 ± 0.14
1.12 ± 0.10
0.6 ± 0.04

p-value

NS
NS
NS

NS
NS
<0.01

<0.05
<0.001
<0.01

DHA75µM ±
SEM
4.2 ± 0.20
5.8 ± 0.77
4.9 ± 0.22

p-value

DHA50µM ±
SEM
1.8 ± 0.09
2.18 ± 0.23
0.9 ±0.06

p-value

DHA50µM ±
SEM
2.8 ± 0.28
1.1 ±0.15
0.9 ± 0.18

p-value

NS
<0.05
<0.01

<0.05
<0.05
<0.05

< 0.001
<0.001
NS

Table 3.1. Pre-treatment with FAs alone and following treatment with doxorubicin, vincristine or fludarabine induce G2/M arrest. Table 3.1
illustrates the G1/G2 ratios ± SEM of EHEB, JVM-2 and MEC-2 following treatment with 1.5µM doxorubicin, 100nM vincristine or 40µM fludarabine in
the presence or absence of vehicle, AA, EPA or DHA. Treatment with DHA alone indicated significantly lower ratios of G1/G2, indicative of G2/M arrest, as
compared to vehicle in all three cell lines. Treatment with EPA indicated a significantly lower G1/G2 ratio as compared to vehicle in MEC-2. Pre-treatment
with AA, EPA or DHA indicated significantly lower G1/G2 ratios as compared to vehicle following treatment with doxorubicin or vincristine. Only pretreatment with DHA indicated a significantly lower G1/G2 ratio as compared to vehicle following treatment with fludarabine in EHEB. Statistical
significance was determined by Multiple Comparison Test using Tukey‟s correction. Abbreviations: Dox: doxorubicin, Vin: Vincristine, Flud: Fludarabine. α
= 0.05, * <0.05, **<0.01, ***< 0.001.
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FA treatment alone: A significantly lower G1/G2 ratio indicates G2/M arrest. Treatment
with EPA alone induced a significantly lower G1/G2 ratio, as compared to vehicle in MEC-2 (p:
<0.05). Treatment with DHA alone induced a significantly lower G1/G2 ratio as compared to
vehicle in JVM-2 and MEC-2 (p: <0.05 and <0.001; respectively). Treatment with AA alone did
not induce any significant differences in the G1/G2 ratio as compared to vehicle in EHEB, JVM2 or MEC-2.
FA plus drug treatment: Cells pre-treated with AA had significantly lower G1/G2 ratios
as compared to vehicle when treated with doxorubicin (p: <0.001 in MEC-2) or vincristine (p:
<0.05 and <0.05 in JVM-2 and MEC-2, respectively).
Cells pre-treated with EPA had significantly lower G1/G2 ratios as compared to vehicle
when treated with doxorubicin (p:<0.001 in MEC-2) or vincristine (p:<0.01 in JVM-2 and MEC2). Cells pre-treated with DHA had significantly lower G1/G2 ratios as compared to vehicle
when treated with doxorubicin (p: <0.05, <0.05, and <0.001 in EHEB, JVM-2 and MEC-2,
respectively), fludarabine (p:<0.01 in EHEB), or vincristine (p:<0.05 and <0.001 in JVM-2 and
MEC-2, respectively).

N-3 Increases Generation of Intracellular ROS
To investigate ROS production in response to AA, EPA or DHA alone and following
treatment with doxorubicin or fludarabine we used a CM-H2DCFDA probe.
Figure 3.6A illustrates mean relative fluorescence units (RFU) ± SEM across time for
MEC-2. Of the 3 cell types, ROS were increased only in MEC-2 cells due to pre-treatment with
either EPA or DHA. Linear regression analysis indicated that the rate of increase in ROS was
significantly greater in DHA pre-treated MEC-2 cells than in vehicle pre-treated cells (Mean
slope (RFU)/min: 0.683 versus 0.267, p: <0.01). Similarly, the rate of increase in ROS was
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greater in the presence of EPA than in vehicle treated MEC-2 cells (Mean slope (RFU)/min:
0.483 versus 0.267, p: 0.08); however this was not statistically significant. Pre-treatment with
AA did not induce any differences in the levels of ROS as compared to vehicle.

N-3 Increases Lipid Peroxidation
To investigate the formation of lipid peroxides in response to AA, EPA or DHA
treatment alone and with doxorubicin, fludarabine or vincristine, levels of thiobarbituric acid
reactive substances (TBARS, byproducts of lipid peroxidation) were evaluated and compared to
a malondialdehyde (MDA, (a TBARS)) standard curve. Figure 3.6B illustrates the mean ng
MDA/μg of protein ± SEM of MEC-2 treated in the presence of vehicle, AA, EPA or DHA alone
and following treatment with 1.5μM doxorubicin or 100nM vincristine. Pre-treatment of MEC-2
cells with DHA alone induced significantly higher levels of TBARs than did vehicle. Only DHA
pre-treatment induced significantly higher levels of TBARs in doxorubicin treated cells. Cells
pre-treated with either EPA or DHA had significantly lower levels of TBARs when treated with
vincristine as compared to the FA alone. Analysis of TBARs levels following treatment with
fludarabine were not performed as no statistical differences were found in the in vitro sensitivity
trials. EHEB and JVM-2 had similar trends in levels of TBARs following n-3 pre-treatment as
observed in MEC-2; however, the drug treatment did not induce any significant differences as
compared to vehicle or n-3 alone (Appendix, Supplementary Figure 3.4).
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Figure 3. 6. Chemo-sensitizing capability of DHA is mediated through generation of intracellular ROS
and formation of lipid peroxides.
Figure 3.6A illustrates mean relative fluorescence units ± SEM of MEC-2 over the course of 2 hours following
72 hour pre-treatment with vehicle, AA25µM, EPA50µM or DHA50µM. Intracellular ROS was determined
using 5-(and-6-)chloromethyl-2‟,7‟-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) dye.
Treatment with either EPA or DHA alone induced significant increases in ROS generation. Linear regression
analysis indicated a greater slope following treatment with EPA or DHA versus vehicle (0.483 and 0.683 versus
0.267) indicating an increased generation of ROS across time. The addition of doxorubicin did not significantly
alter levels of ROS as compared to vehicle or FA alone (Appendix, Supplementary Figure 3.5). Figure 3.6B
illustrates the mean ng MDA/µg protein ± SEM in the presence or absence of vehicle, AA25µM, EPA50µM or
DHA50µM alone and following treatment with doxorubicin (1.5µM) or vincristine (100nM). Pre-treatment with
DHA alone induced significantly higher levels of MDA as compared to vehicle. The addition of doxorubicin to
DHA pre-treated cells induced significantly higher levels of MDA versus either alone. The addition of
vincristine to either EPA or DHA pre-treated cells induced significantly lower levels of MDA as compared to n3 or drug alone. Figure 3.6C illustrates the % cell viability ± SEM of MEC-2 following treatment with 1.5µM
doxorubicin and 50µM vitamin E alone and in combination in the presence or absence of vehicle, AA25µM,
EPA50µM or DHA50µM. Compared to vehicle, cells pre-treated with DHA had significantly greater reductions
in cell viability when treated with doxorubicin. Co-treatment of DHA pre-treated cells with doxorubicin and
vitamin E abrogated the enhanced sensitivity of MEC-2 to doxorubicin by DHA. Figure 3.6D illustrates the
mean ng MDA/µg protein ± SEM of MEC-2 following pre-treatment with DHA alone and after treatment with
1.5µM doxorubicin alone and in combination with 50µM vitamin E. Co-treatment with doxorubicin and vitamin
E in DHA pre-treated cells indicated significantly lower levels of MDA versus doxorubicin alone. Statistical
significance was determined by Multiple Comparison Test with Tukey‟s correction. Abbreviations: MDA:
malondialdehyde, α = 0.05, * <0.05, **<0.01, ***< 0.001.
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Vitamin E Abrogates Enhanced Sensitization of MEC-2 to Doxorubicin by
DHA
To validate that the ability of n-3 to sensitize malignant B-lymphocytes to doxorubicin is
dependent on the formation of toxic lipid peroxides, we tested the in vitro sensitivity of MEC-2
in the presence of vehicle, AA, EPA or DHA alone and following treatment with 1.5μM
doxorubicin alone or in combination with 50μM vitamin E. Figure 3.6C illustrates the in vitro
sensitivity of MEC-2 to 1.5μM doxorubicin and 50μM vitamin E alone and in combination in the
presence or absence of vehicle, AA, EPA or DHA. Compared to vehicle, DHA pre-treated cells
had significantly greater reductions in viability when treated with doxorubicin. The addition of
vitamin E abrogated the enhanced sensitization of MEC-2 to doxorubicin by DHA. In agreement
with the in vitro sensitivity trial, co-treatment of DHA pre-treated cells with doxorubicin and
vitamin E induced significant reductions in the levels of TBARs as compared to doxorubicin
alone (Figure 3.6D).

DISCUSSION
Chronic lymphocytic leukemia is the most common form of adult leukemia in the
western world (Riches et al., 2011). Clinical treatment of CLL is often limited due to drug
resistance and severe toxicities associated with chemotherapy (Riches et al., 2011; Schriever &
Huhn, 2003; Silber et al., 1994). A therapeutic intervention that could enhance the sensitivity of
CLL cells to anti-cancer drugs without causing additional adverse effects would be clinically
beneficial.
Omega-3 fatty acids have consistently been shown to enhance the sensitivity of various
solid tumor cells to chemotherapy in vitro (Germain et al., 1998; Kinsella & Black, 1993) and in
vivo (Borgeson et al., 1989; Hardman et al., 2001; Shao et al., 1997). However, this has not been
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shown in CLL. Previous results from our group indicated that consumption of an n-3 supplement
enhanced the sensitivity of lymphocytes isolated from patients with early stage (Rai 0,1) CLL to
doxorubicin in an in vitro assay (Fahrmann et al., 2013). These findings prompted us to further
evaluate the potential use of n-3 as chemo-sensitizing agents for the treatment of CLL.
The primary purpose of this study was to illustrate that pre-treatment of B-CLL-and BPLL-derived cells with n-3 increases the sensitivity of cells to actively used chemotherapeutic
drugs: doxorubicin and vincristine, components of the CHOP (cyclophosphamide, doxorubicin,
vincristine and prednisone) regimen (Leporrier et al., 2001; Van der Jagt et al., 2012), or
fludarabine, a commonly used first-line treatment option for CLL (Riches et al., 2011; Silber et
al., 1994). Rather than testing combination therapies, we evaluated the ability of n-3 to enhance
the sensitivity of malignant B-lymphocytes to single-arm treatments. Secondary objectives were
to elucidate potential mechanism(s) by which n-3 enhanced chemo-sensitivity.
Although designated as a single disease, CLL is characterized by biological and clinical
heterogeneity. For these reasons, we particularly wanted to demonstrate that the chemosensitizing effects of n-3 were not limited to one specific cell sub-type (cell line). Rather we
wanted to demonstrate that the chemo-sensitizing effects of n-3 would be seen in multiple celltypes. Thus, each cell line could be viewed as a distinct case of CLL.
For the purposes of this study, we used the highest concentrations FAs that alone did not
induce significant cytotoxicity (Figures 3.1A-C). Our results indicated that clinically achievable
concentrations of EPA and DHA generally, but not equally, sensitized the B-leukemic cells to
the drugs. Only JVM-2 cells were sensitized to doxorubicin (1.5μM) when cells were pre-treated
with AA (Figure 3.4A), indicating that the chemo-sensitizing capabilities of FAs are more likely
to be found amongst n-3 fatty acids than n-6 fatty acids. This is an important consideration. The
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western diet is heavily favored towards n-6 FA with little to no n-3 FA intake (Simopoulos,
2000, 2002). Omega-3 and n-6 FAs compete with each other for incorporation into the cell
(Simopoulos, 2000, 2002). The addition of n-3 as an augment to therapy may, therefore, provide
clinical benefit to the patient receiving therapy. We are currently conducting a clinical trial to
determine if we will see the same chemo-sensitizing capabilities of n-3 on lymphocytes isolated
from patients with CLL.
We have illustrated that pre-treatment with n-3 increased the sensitivity of B-CLL- and
B-PLL-derived cells to three actively used chemo-therapeutic drugs. While doxorubicin,
vincristine and fludarabine have different mechanisms by which they exert their cytotoxic
effects, all three drugs can induce cell death and/or growth-inhibition. Thus, increasing the
sensitivity of cells to the drug is not a function limited to increased cell death, but can also be
mediated through increased growth-inhibition (reduced proliferation). Both cell death and/or
growth-inhibition leads to a decrease in numbers of viable cells in culture. For these reasons, we
performed Annexin-V assays, as a measure of cellular death, and cell cycle analyses, as an
indirect measure of growth (proliferation). Increased cell death and/or increased growthinhibition are clinically relevant and would provide benefit to the patient.
Collectively, our results indicated that pre-treatment with DHA, as compared to vehicle,
enhanced cell death due to doxorubicin in all three cell lines, vincristine in two (JVM-2 and
MEC-2) of the three cell lines, and fludarabine in one (EHEB) of the three cell lines. Increased
cell death is clinically beneficial and would improve the outcome of the patient receiving
therapy.
Noteworthy, MEC-2, which harbors a p53 mutation, showed enhanced cell death due to
vincristine or doxorubicin when pre-treated with DHA as compared to vehicle. This is an
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important observation. The loss of short arm p13 of chromosome 17, which disrupts the p53
tumor suppressor gene, is found in approximately 5-10% of all CLL patients and is associated
with particularly poor prognosis and chemorefractoriness (Gaidano, Foa, & Dalla-Favera, 2012).
N-3 may provide a beneficial augment to the treatment of chemorefractory CLL patients.
We performed cell-cycle analyses to determine whether increased chemo-sensitivity by
FA was associated with enhanced growth-inhibition. Previous studies have demonstrated that n-3
treatment alone can induce cell cycle arrest at the G2/M phase (Dekoj et al., 2007). Vincristine is
a mitotic inhibitor known to induce cell cycle arrest at the M phase (Casado et al., 2009).
Similarly, studies have indicated that malignant cells in G2/M arrest are more sensitive to
doxorubicin than normal cells (Ling, el-Naggar, Priebe, & Perez-Soler, 1996; Tyagi, Singh,
Agarwal, Chan, & Agarwal, 2002). For these reasons, we were particularly interested in the ratio
of cells in G1 (G0 + G1) and G2 (G2 + M) phases. An increase in the population of cells in the
G2 (G2 + M) phase is indicative of G2/M arrest. Thus, an increase in G2 (G2 + M) would result
in a lower population of cells in G1 (G0 + G1) and a lower G1/G2 ratio. A decrease in the G1/G2
ratio (indicative of G2/M arrest) would be expected to result in growth-inhibition (reduced
proliferation).
Our results illustrate that cells pre-treated with n-3, but without drug, had significantly
greater G2/M arrest, indicated by a lower G1/G2 ratio, as compared to vehicle pre-treated cells
(Table 3.1). This demonstrates that n-3 by themselves can potentially slow the growth of
malignant B-lymphocytes. This is of considerable interest as we had previously shown that
consumption of n-3 decreased the activity of nuclear factor kappa B (NFκB) in isolated
lymphocytes of patients with early stage CLL and would be expected to slow the progression of
the disease (Fahrmann et al., 2013). Studies have shown that inhibition of NFκB activation leads
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to cell cycle arrest at the G2/M phase aiding to both growth-inhibition and cell death (Zhang,
Ruan, et al., 2012; Zhang, Tao, et al., 2012). Future studies will be aimed in determining if n-3
can slow the progression and growth of CLL and whether growth-inhibition is mediated through
suppression of NFκB activation and G2/M arrest. Slowing the progression of CLL by n-3 FAs
could be a therapeutic choice in patients for whom standard chemotherapy is not an option.
The addition of doxorubicin to FA pre-treated cells induced significantly greater G2/M
arrest than when cells were not treated with n-3 prior to doxorubicin (Table 3.1). It is interesting
to note that cells pre-treated with either EPA (MEC-2) or DHA (EHEB, JVM-2 and MEC-2)
which had significantly greater G2/M arrest due to doxorubicin also showed increased chemosensitivity to doxorubicin than did cells pre-treated with vehicle (Figures 3.3A, 3.4A and 3.5A).
This suggests that n-3 plus doxorubicin induced greater growth-inhibition than doxorubicin
alone. This notion is supported by other investigators who have shown that cells in G2/M arrest
are more sensitive to doxorubicin as compared to normal cells (Ling et al., 1996; Tyagi et al.,
2002) and, importantly, that enhanced sensitivity of cells in G2/M arrest to doxorubicin was
mediated through both growth-inhibition and apoptosis (Tyagi et al., 2002).
Similarly, the addition of vincristine (JVM-2 and MEC-2) or fludarabine (EHEB) to cells
pre-treated with certain FAs (all FAs in JVM-2, AA and EPA in MEC-2, DHA in EHEB) had
significantly greater G2/M arrest as compared to vehicle pre-treated cells (Table 3.1). However,
there was no association between the increase in chemo-sensitivity of cells to vincristine (JVM-2
and MEC-2) or fludarabine (EHEB) by FA and the increase in G2/M arrest.
Numerous pre-clinical studies have demonstrated that enhanced chemo-sensitization by
n-3, particularly DHA, was dependent on the formation of toxic lipid peroxides and generation of
ROS (Begin, Ells, Das, & Horrobin, 1986; Begin, Ells, & Horrobin, 1988; Das & Madhavi,
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2011; Germain et al., 1998; Hardman et al., 2001; Kang et al., 2010). We wanted to determine
whether the increase in chemo-sensitivity of cells to the anti-cancer drugs by FA was dependent
on the induction of oxidative stress. Our results illustrate that n-3 induced significantly higher
levels of intracellular ROS than did vehicle in MEC-2 cells (Figure 3.6A). Linear regression
analysis indicated an increased rate of ROS generation in the presence of either EPA or DHA as
compared to vehicle. However, this effect was not enhanced by the addition of any of the anticancer drugs. Results also illustrate that treatment with n-3 alone induced higher levels of
TBARS, (products of lipid peroxidation), as compared to vehicle in all three cell lines (only
MEC-2 is shown, Figure 3.6B). Only MEC-2 had significantly higher levels of TBARs following
treatment with doxorubicin in cells pre-treated with DHA as compared to cells treated with DHA
or doxorubicin alone (Figure 3.6B). The addition of vitamin E, a fat soluble anti-oxidant,
abrogated the enhanced sensitivity of MEC-2 to doxorubicin by DHA (Figure 3.6C) and
decreased the levels of TBARS (Figure 3.6D). The fact that enhanced sensitivity of MEC-2 to
doxorubicin by DHA and increased formation of TBARs was abrogated by vitamin E supports
the notion that enhanced chemo-sensitivity by DHA is, in part, dependent on the formation of
lipid peroxides.
In conclusion, EPA and DHA differentially sensitized B-leukemic cell lines EHEB,
JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro. Enhanced chemosensitivity is likely mediated through both increased cellular death as well as growth-inhibition.
Our results have shown that enhanced sensitivity is also, in part, dependent on the formation of
toxic lipid peroxides. Additional work should be done to elucidate the mechanisms by which n-3
increase chemo-sensitivity. Supplementation of the diet with n-3 fatty acids provides a promising
non-toxic approach to not only sensitize CLL cells to anti-cancer drugs but may have
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independent therapeutic benefit. Importantly, the chemo-sensitizing effects of n-3 do not appear
to be limited to a specific cell-type or a specific drug. Increased chemo-sensitivity is clinically
beneficial and would be expected to increase drug efficacy, and potentially reduce drug dosage
resulting in decreased drug-induced toxicities.
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APPENDIX
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Supplementary Figure 3. 1. In Vitro sensitivity of EHEB following treatment with vincristine in the presence or
absence of vehicle, AA, EPA or DHA.
The % cell viability ± SEM of EHEB to vincristine (0-250nM) in the presence or absence of vehicle, AA25µM,
EPA50µM or DHA75µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences
in the sensitivity of EHEB cells to vincristine.
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Supplementary Figure 3. 2. In Vitro sensitivity of JVM-2 following treatment with fludarabine in the presence
or absence of vehicle, AA, EPA or DHA.
The % cell viability ± SEM of JVM-2 to fludarabine (0-40µM) in the presence or absence of vehicle, AA35µM,
EPA50µM or DHA50µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences
in the sensitivity of JVM-2 cells to fludarabine.
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MEC-2
Live Cell Fraction (compared to no Fludarabine)
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Supplementary Figure 3. 3. In Vitro sensitivity of MEC-2 following treatment with fludarabine in the presence or
absence of vehicle, AA, EPA or DHA.
The % cell viability ± SEM of MEC-2 to fludarabine (0-40µM) in the presence or absence of vehicle, AA25µM,
EPA50µM or DHA50µM is shown. Pre-treatment with AA, EPA or DHA did not induce any significant differences in the
sensitivity of MEC-2 cells to fludarabine.
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Supplementary Figure 3. 4. Effects of FA pre-treatment alone and follwed by treatment with anti-cancer drugs on the
formation of lipid peroxides and generation of ROS in EHEB and JVM-2.
Supplementary Figure 3.4A illustrates mean relative fluorescence units ± SEM of EHEB over the course of 2 hours
following 72 hour pre-treatment with vehicle, AA25µM, EPA50µM or DHA75µM. Intracellular ROS was determined using
5-(and-6-)chloromethyl-2‟,7‟-dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H2DCFDA) dye. Compared to vehicle,
pre-treatment with FA did not induce any significant changes in the levels or generation of ROS. Supplementary Figure
3.4B illustrates the mean ng MDA/µg protein ± SEM of EHEB in the presence or absence of vehicle, AA25µM, EPA50µM or
DHA75µM alone and following treatment with doxorubicin (1.5µM) or fludarabine (40µM). Pre-treatment with either EPA
or DHA alone induced significantly higher levels of MDA as compared to vehicle. The addition of doxorubicin to FA pretreated cells did not induced any significantly changes in the levels of MDA versus either alone. The addition of fludarabine
to DHA pre-treated cells induced significantly lower levels of MDA as compared to DHA or drug alone. Supplementary
Figure 3.4C illustrates mean relative fluorescence units ± SEM of JVM-2 over the course of 2 hours following 72 hour pretreatment with vehicle, AA35µM, EPA50µM or DHA50µM. Compared to vehicle, pre-treatment with FA did not induce any
significant changes in the levels or generation of ROS. Supplementary Figure 3.4D illustrates the mean ng MDA/µg protein
± SEM of JVM-2 in the presence or absence of vehicle, AA35µM, EPA50µM or DHA50µM alone and following treatment
with doxorubicin (1.5µM) or vincristine (100nM). Pre-treatment with DHA alone induced significantly higher levels of MDA
as compared to vehicle. The addition of either doxorubicin or vincristine to FA pre-treated cells did not induce any significant
differences in levels of MDA as compared to FA alone. Statistical significance was determined by Multiple Comparison Test
with Dunnet‟s correction. Abbreviations: MDA: malondialdehyde, α = 0.05, * <0.05, **<0.01, ***< 0.001.; N.D.: no detect.
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Supplementary Figure 3. 5. The addition of doxorubicin to FA pre-treated MEC-2 cells does not increase
the generation of ROS versus either alone.
Mean relative fluorescence units ± SEM of MEC-2 in the presence or absence of AA25µM, EPA50µM or
DHA50µM alone and following treatment with 1.5µM doxorubicin is shown. The addition of doxorubicin to FA
pre-treated cells did not increase the levels or generation of ROS versus FA alone. Abbrev. Dox: doxorubicin.
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CHAPTER 4: DISCUSSIONS AND CONCLUSIONS
The body of work performed and compiled in the previous chapters highlights the
potential applications of n-3 as therapeutic options (both as adjuvants and individual treatments)
for the treatment of CLL. In this context, it is important to remember the over-arching goal of
these projects. It should be recalled that CLL is the most common form of adult leukemia in the
western world (Gaidano, Foa, & Dalla-Favera, 2012). CLL is a disease of the elderly with a
median age range of 60-68 years (Shanafelt & Call, 2004). CLL is typically diagnosed in the
asymptomatic stages where “watchful waiting” remains the primary course of treatment
(Shanafelt & Call, 2004). However, approximately 50% of these patients will progress to
symptomatic stage and require therapy (Shanafelt & Call, 2004). Although numerous therapies
exist for CLL, most are undermined due to progressive drug resistance which can manifest
during the course of treatment and severe drug-induced toxicities which are often too toxic for
the elderly or those with co-morbidities (Shanafelt & Call, 2004). Therefore, a non-toxic
therapeutic intervention which could slow the progression of the disease or enhance the chemosensitivity of malignant cells to chemotherapy would be clinically beneficial. Slowing
progression of the early stages of the disease would provide improved quality of life and clinical
benefit. Increased chemo-sensitivity for individuals who require therapy would increase drug
efficacy and potentially reduce drug dosage, thereby reducing drug-induced toxicities. Similarly,
increased tolerability of therapy regimens may also increase the number of chemotherapy cycles
a patient can tolerate, thereby increasing the likelihood of receiving a response.
Several studies have demonstrated that NF B can promote oncogenesis by virtue of its
ability to regulate the expression of a wide array of genes that modulate apoptosis, proliferation,
inflammation, tumor metastasis, and angiogenesis (Clevers, 2004). Constitutively active NF B
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has been observed in various solid tumors as well as hematological malignancies (Braun et al.,
2006; Darnell, 2002; Ditsworth & Zong, 2004) and has been linked to aggressive tumor growth
and resistance to both chemotherapy and radiotherapy (Li & Sethi, 2010). Consistent with these
thoughts, NF B has been found to be constitutively active in CLL cells (Hewamana, Alghazal, et
al., 2008; Hewamana, Lin, et al., 2008; Hewamana et al., 2009). Studies by Hewamana et al.
indicated that increased binding of Rel A, a subunit of NF B which contains the transactivation
domain, was positively correlated with WBC counts, a measure of tumor burden, and
lymphocyte doubling time, a measure of tumor kinetics (Hewamana, Alghazal, et al., 2008).
Furthermore, Hewamana et al. also demonstrated that Rel A DNA binding was strongly
associated with Binet staging, predictive of time to initial treatment and subsequent treatment,
and predictive of overall survival (Hewamana et al., 2009). Similarly, we found that NF B
activation was positively correlated with WBC counts (Appendix, Supplementary Figure 2.2).
Additionally, we found that patients who displayed „lower initial NF B activation‟ had
significantly lower absolute lymphocyte counts (Mean ± SEM: 11.9 ± 3.2 x 103 lymphocytes/µl
vs 28.8 ± 4.0 x 103 lymphocytes/µl; p: 0.009; Table 2.2) and tended to be at lower Rai stage
(stage 0, 84% vs 58%, not statistically different by Fisher exact test) than patients exhibiting
„higher initial NF B activation‟ at baseline. Collectively, our results support the observations of
Hewamana et al. and indicate the prognostic value of NF B activity.
Rel A DNA binding has also been shown to be negatively correlated with induction of
spontaneous apoptosis in vitro suggesting that NF B is an important mediator of survival
(Hewamana, Alghazal, et al., 2008). This is supported by the fact that inhibition of NF B
activation, through the use of an irreversible-IKK inhibitor (LC-1), induced dose-responsive
increases in apoptosis (Hewamana, Lin, et al., 2008). The addition of LC-1 was also able to
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overcome the cytoprotective effects of CD40L and IL-4, upstream agonists of NF B activation,
providing further support of the importance of NF B in CLL (Hewamana, Lin, et al., 2008).
Inhibition of NF B activation by LC-1 was also shown to exhibit strong synergy with
fludarabine, a commonly used first-line treatment in CLL (Riches, Ramsay, & Gribben, 2011;
Silber et al., 1994), in both good prognostic CLL patients who were fludarabine-sensitive and
poor prognostic CLL patients who displayed chemorefractoriness toward fludarabine
(Hewamana, Lin, et al., 2008). Given the ability of NF B to promote survival of CLL cells in
vitro and aid in various biological processes such as proliferation, migration, inhibition of
apoptosis and chemo-resistance, a therapeutic interventions which target NF B would be of
considerable interest and clinically relevant.
In our initial study, we demonstrated that consumption of an n-3 supplement,
predominately composed of EPA and DHA, suppressed activation of NF B in lymphocytes
isolated from patients in the early stages of CLL (Figures 2.2. and 2.3). Gene expression profiles
indicated that consumption of n-3 decreased the expression of 31 genes including genes known
to be regulated by NF B (JMJD1C, ZNF644 and PTGS2; Table 2.4). Suppression of genes
known to be regulated by NF B supports our findings that n-3 suppressed NF B activation. We
also found that, in patients who were unwilling to take 7.2 g of n-3 per day, over time either 4.8 g
or 2.4 g of n-3 per day also suppressed NF B to nearly normal levels. This provides an important
piece of information as it indicates that a lower consumption of n-3 can provide equal benefit as
a higher dose over a period of time. A lower dose would aid in study design allowing for
increased compliancy rates and a decreased likelihood of adverse effects associated with n-3
consumption.
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In line with this thought, despite plasma concentrations of EPA and DHA being highest
following consumption of 7.2 g of n-3/per day for a month of more, these concentration did not
differ statistically from that following consumption of 4.8 g (6 capsules; composition: 2.4 g of
EPA, 1.8 g of DHA, 0.6 g of other n-3) of n-3/day (Table 2.3). This suggests that plasma
concentrations of EPA and DHA reached a state of saturation and that saturated concentrations
of EPA or DHA can be achieved at lower concentrations. Our findings are supported by Yee et
al. who indicated that a dose of ~2.5g/day EPA+DHA achieved the maximum possible elevation
of concentrations in mammary tissue and blood in a supplementation study (Yee et al., 2010).
Similarly, Arterburn et al. indicated that supplementation with 2g/day DHA resulted in plasma
saturation (Arterburn, Hall, & Oken, 2006). Thus, consumption of a lower concentration of n-3
over time could achieve similar effects as those observed at higher concentrations supporting our
findings that either 2.4 g or 4.8 g of n-3 per day can also suppressed NF B activation.
Evidence by our group and others (Hewamana, Alghazal, et al., 2008; Hewamana, Lin, et
al., 2008; Hewamana et al., 2009) suggest that activated NF B correlates with disease
progression. Therefore, inhibition of NF B activation would be expected to slow the progression
of CLL. Our results justify expansion into a definitive randomized clinical trial aimed to
determine whether consumption of n-3 will slow the progression of early stage CLL to
symptomatic CLL and whether clinical benefit is correlated with suppression of NF B
activation. Given that CLL is a heterogeneous disease with a highly variable course of
progression (Eichhorst, Dreyling, Robak, Montserrat, & Hallek, 2011; Gaidano et al., 2012); aim
should be taken to target patients who are at risk of progressing quickly. This would allow for
identification of potential clinical benefit in a short period of time, thereby preventing the use of
long multi-year studies.
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Although we have demonstrated that n-3 suppressed NF B activation in lymphocytes
from our patient population, potential benefit from n-3 is likely multi-factorial, a trait provided
by the diversity of the various n-3 metabolites. In this sense, the application of metabolomics
coupled with lipidomics and genomic studies should be explored. The application of these types
of profiling studies may provide key insight into the functionality and potential benefits of n-3
consumption.
Increasing evidence suggests that leukaemogenesis can be explained by epigenetic
alterations (Chen, Odenike, & Rowley, 2010; Galm, Herman, & Baylin, 2006). Epigenetic
changes, which include DNA methylation, histone modifications and microRNAs, alter gene
expression without changing DNA sequences. Histone modifications alter gene expression
through changes in chromatin composition and conformation. Our results indicated that
consumption of n-3 reduced mRNA abundance of multiple genes associated with chromatin
remodeling (Table 2.3). These genes are JMJD1C (JmjC domain-containing histone
demthylation protein 2C) (Katoh & Katoh, 2007), CHD9 (a chromatin remodeling transcription
regulator) (Marom, Shur, Hager, & Benayahu, 2006; Shur, Socher, & Benayahu, 2006), ASH1L
(a histone methyltransferase) (An, Yeo, Jeon, & Song, 2011) and PKN2 (a histone deacetylase 5
interacting protein) (Harrison et al., 2010). Current studies are underway to determine whether n3, EPA, induces changes in histone post-translational modifications (PTMs) in lymphocytes
isolated from patients with CLL and how changes in PTMs correlate to changes in mRNA levels.
The intent of this study is to provide novel insight into specific epigenetic changes induced by n3 consumption and the genes that are influences by those changes. Future studies will be aimed
at determining whether epigenetic changes induced by n-3 in CLL cells will correlate with
increased clinical benefit.
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Our results also indicated that consumption of n-3 increased the sensitivity of
lymphocytes from patients with early stage CLL to doxorubicin in an in vitro assay. These
findings prompted us to further explore the chemo-sensitizing capabilities of n-3. In our second
study, we evaluated whether n-3, EPA and/or DHA, would enhance the chemo-sensitivity of
CLL-derived cell lines EHEB and MEC-2 and PLL-derived cell line JVM-2 to actively used
chemo-therapeutic drugs doxorubicin, vincristine and/or fludarabine in vitro.
Results from these studies indicated that EPA and DHA generally, but not equally,
sensitized B-leukemic cells to actively used chemotherapeutic drugs: doxorubicin and
vincristine, components of the CHOP regime (Leporrier et al., 2001; Van der Jagt et al., 2012),
or fludarabine, a commonly used first-line treatment option for CLL (Riches et al., 2011; Silber
et al., 1994). Importantly, we demonstrated that the chemo-sensitizing capabilities of n-3 were
not specific towards one specific cell sub-type, but rather, multiple sub-types. This is a desirable
trait given the vast heterogeneity that exists amongst CLL patients (Gaidano et al., 2012; Riches
et al., 2011). Similarly, the fact that n-3 enhanced the chemo-sensitivity of B-leukemic cells to
three different anti-cancer drugs, whose cytotoxic effects are mediated through different
mechanisms of action, highlights the versatility and potential applicability of n-3 as adjuvant
therapies.
Even though n-3 generally increased the chemo-sensitivity of B-leukemic cells to anticancer drugs, cells pre-treated with AA generally indicated no difference in chemo-sensitivity as
compared to vehicle. Inversely, in EHEB, pre-treatment with AA appeared to protect against the
cytotoxic effects of fludarabine; however, this was not statistically significant (Figure 3.3B).
Collectively, this indicates that the sensitizing capacities of FAs are more likely to be found
amongst the n-3 FA rather than the n-6 FA. This is an important consideration as the western diet
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is heavily favored towards n-6 with little to no n-3 consumption (Simopoulos, 2008). N-3 and n6 compete with each other for incorporation and metabolism, often times having antagonistic
actions (Simopoulos, 2002). The addition of n-3 as an adjuvant to therapy may, therefore,
provide clinical benefit to patients receiving therapy.
Results from our second study also indicated that enhanced chemo-sensitivity of Bleukemic cells to anti-cancer drugs by n-3, particularly DHA, was associated with an increase in
G2/M arrest (indicative of growth-inhibition) (Table 3.1) and increased cell death (Figures 3.3C,
3.4C and 3.5C). Slowing the growth and/or increasing cell death of malignant cells is highly
desirable and would provide clinical benefit.
Notably, MEC-2, which harbors a p53 mutation, showed enhanced cell death due to
vincristine or doxorubicin when pre-treated with DHA as compared to vehicle. The loss of short
arm p13 of chromosome 17, which disrupts the p53 tumor suppressor gene, is found in
approximately 5-10% of all CLL patients and is associated with particularly poor prognosis and
chemo-refractoriness (Gaidano et al., 2012). N-3 may provide a beneficial augment to the
treatment of chemo-refractory CLL patients.
We have also demonstrated that enhanced chemo-sensitivity of MEC-2 cells to
doxorubicin by DHA was, in part, mediated through generation of ROS and formation of lipid
peroxides (Figure 3.6). Selective enhancement of chemo-sensitivity of EHEB, MEC-2 and JVM2 to anti-cancer drugs by n-3 that was not dependent on increased lipid peroxidation and
generation of ROS indicates alternative mechanism(s) through which n-3 enhance chemosensitivity.
Collectively, results from our initial study and subsequent study highlight the potential
application of n-3 as therapeutic options for the treatment of CLL and provided key data to
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support expansion into our current clinical trial. The primary aim of our current study is to
determine whether n-3 EPA and/or DHA increase the chemo-sensitivity of lymphocytes isolated
from patients with CLL who 1) have a WBC count ≥ 17 (103/µL) or have progressed to the point
of requiring therapy but have not received therapy or 2) have relapsed post standard first line
therapy and require second-line therapy but have not received second-line therapy to anti-cancer
drugs fludarabine, vincristine or chlorambucil in vitro. Secondary objectives of this study are to
1) evaluate whether increased chemo-sensitivity of cells to anti-cancer drugs by n-3 is mediate,
in part, through suppression of NF B activation and 2) demonstrate that increased chemosensitivity is selective against the malignant cells and not healthy cells. While the data obtained
thus far is limited, the results are encouraging. The primary goal of this study is to provide the
final data necessary for expansion into a definitive clinical trial aimed to determine whether
consumption of n-3 will improve the efficacy of chemo-therapy in CLL patients who require
treatment. Future studies will also be aimed at evaluating the safety of n-3 as an adjuvant
therapy.
Whereas transitions to clinical studies are the primary focus of the studies highlighted in
this thesis, further studies evaluating the mechanism(s) of actions through which n-3 induce
growth-inhibitory effects, increased cell death and/or enhanced chemo-sensitivity are also areas
of importance. Mechanistic studies will provide a further understanding of how n-3 function as
therapeutic options. In this sense the following areas of research are of particular interest:
Studies have indicated that malignant cells in G2/M arrest are more sensitive to
doxorubicin than normal cells (Ling, el-Naggar, Priebe, & Perez-Soler, 1996; Tyagi, Singh,
Agarwal, Chan, & Agarwal, 2002). Similarly, vincristine is a mitotic inhibitor known to induce
cell cycle arrest at the M phase (Casado et al., 2009). Studies have demonstrated that inhibition

152

of NFκB activation leads to cell cycle arrest at the G2/M phase aiding to both growth-inhibition
and cell death (Zhang, Ruan, et al., 2012; Zhang, Tao, et al., 2012). Our initial study
demonstrated that consumption of n-3 reduced activation of NF B in lymphocytes of early stage
CLL patients. In our second study, we demonstrated that n-3, particularly DHA, induced G2/M
arrest alone and indicated greater G2/M arrest when used with anti-cancer drugs versus anticancer drugs alone. Future studies should be conducted to determine whether the ability of n-3 to
induce arrest at G2/M is mediated through suppression of NF B activation and how this
proposed mechanism influences the chemo-sensitizing capabilities of n-3.
Multi-drug resistance remains one of the primary causes of suboptimal outcomes in
cancer therapy and is a major target of intervention (Gottesman, Fojo, & Bates, 2002). Pglycoprotein (Pgp), encoded by MDR1 (ABCB1) gene, is an ABC transporter shown to confer
resistance to certain chemotherapeutic drugs including anthracyclines and alkaloids (Gottesman
et al., 2002; Leonard, Fojo, & Bates, 2003; Sonneveld et al., 1992). MDR1 has been shown to be
overexpressed in CLL and correlate with increased Pgp activity (Consoli et al., 2002; Hoellein et
al., 2010; Sparrow, Hall, Siregar, & Van der Weyden, 1993; Szendrei et al., 2008). Additionally,
MDR1 was particularly found to be elevated in patients with advanced stages of the disease and
correlated with clinical drug resistance (Hoellein et al., 2010; Sparrow et al., 1993; Szendrei et
al., 2008). Similarly, multidrug-resistance-associated protein 1 (MRP1), another type of ABC
transporter, has been shown to be increased in CLL (Hoellein et al., 2010) and confer drug
resistance in vitro (Gottesman et al., 2002). MRP1 (ABCC1) expression, like MDR1, has also
been negatively correlated with response to therapy and survival in clinical settings (Gottesman
et al., 2002). MRP1‟s mode of action is primarily by transporting glutathione and glutathioneconjugated anti-cancer drugs (Gottesman et al., 2002; Keppler, 1999). MDR1 expression is
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known to be regulated through COX-2 (Liu, Qu, & Tao, 2010; Sorokin, 2004) and NF B (Wang,
Liu, Zhang, Yu, & Wang, 2007; Zatelli et al., 2009). MRP1 expression has also been shown to
be strongly correlated with COX-2 expression (Szczuraszek et al., 2009). Studies have illustrated
that inhibition of COX-2 and NF B lead to decreased expression of MDR1 mRNA and Pgp
resulting in increased sensitivity of solid tumors and hematologic malignancies to
chemotherapeutic drugs in vitro (Wang et al., 2007; Zatelli et al., 2009). Similarly, studies
utilizing COX-2 inhibitors indicated decreased expression of MRP1 and enhanced cytotoxicity
of anticancer drugs in vitro (Liu et al., 2010). We have demonstrated that consumption of n-3
suppressed activation of NF B and reduced mRNA abundance of COX-2 in lymphocytes
isolated from early stage CLL patients (Table 2.4). Future studies evaluating whether n-3 can
suppress the expression and/or the efflux capabilities of MDR1/MRP1 and whether this is
through suppression of NF B activation and/or COX-2 are of considerable interest. Additionally,
studies have demonstrated that n-3 can deplete glutathione pools (Merendino et al., 2003).
Glutathione is a key component for the functional activity of MRP-mediated efflux (Gottesman
et al., 2002; Keppler, 1999). Therefore, depletion of glutathione pools by n-3 may inhibit the
efflux capabilities of MRPs, thereby increasing the efficacy of certain anti-cancer drugs. Future
studies should be performed to explore whether n-3 can deplete glutathione pools and whether
this will reduce the functional capabilities of MRPs and aid to increased anti-cancer drug
efficacy. The potential application of n-3 to combat multi-drug resistance remains of
considerable importance and warrants investigation.
In conclusion, the application of n-3 as therapeutic options for the treatment of CLL is
very promising and presents several advantages over conventional therapy. N-3 are non-toxic
(dose-dependent) and have the potential of slowing the growth of cancer, increasing the chemo-
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sensitivity of malignant cells to chemo- and radio-therapy and reducing toxicities. Slowing the
growth of cancer would prolong the time before treatment is required and improve the quality of
life for the individual. Increased chemo-sensitivity would lead to increased drug efficacy and
potential decreases in drug dosage thereby leading to reduced drug-induced toxicities. Similarly,
reducing therapy-induced toxicities by n-3 can lead to potential increases in the amount of cycles
a patient can tolerate, thereby increasing the likelihood of receiving a response. Therefore, the
use of n-3 as therapeutic options for CLL warrants further attention and presents a novel
therapeutic approach.
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